An Investigation into predictors of risk-associated injecting behaviours in a sample of injecting drug users by Antel, Elizabeth
An Investigation into Predictors of Risk-Associated Injecting Behaviours in a 
Sample of Injecting Drug Users 
Elizabeth Antel 
BA (Hons) 
A report submitted in partial requirement for the degree of Master of Psychology 
(Clin) at the University of Tasmania 
I declare that this thesis is my own work and that, to the best of my knowledge and 
belief, it does not contain material from published sources without proper 
acknowledgement, nor does it contain material which has been accepted for the 
award of any other higher degree or graduate diploma in any university. 
Signature: Date: ZO CD . f 1  
  
iii 
Acknowledgements 
Firstly I would like to thank my supervisor, Dr Raimondo Bruno, for his ongoing 
support, guidance and patience throughout the course of this research project. I 
would also like to acknowledge the Australian Government Department of Health 
and Aging and the Illicit Drug Reporting System project, and the participants of the 
BDRS which enabled the current thesis to proceed. Finally, I am especially grateful to 
my family and friends, whose support was unwavering and whose encour- agement 
and belief in me assisted me immensely in striving to complete my goals. 
iv 
Contents  
Literature Review 	 0 
Blood-borne viruses 	 2 
Risk Factors 	 9 
Sex 	 9 
Age 	 15 
Duration of Injecting 	 20 
Frequency of Injecting 	 25 
Drug Choice 	 28 
Sexual Orientation 	 32 
Treatment 	 35 
Accommodation 	 38 
Education 	 41 
Ethnicity 	 44 
Prison History 	 49 
Impulsivity 	 54 
Pharmacological effects of drug use 	 68 
Psychological distress 	 77 
Conclusion 	 82 
References 	 87 
Empirical Study 	 111 
Empirical Study Abstract 	 112 
Introduction 	 114 
Blood-borne viruses 	 114 
Risk Factors 	 116 
Impulsivity 	 119 
Psychological Distress 	 120 
Pharmacological Effects of Drug Use 	 121 
Rationale for Current Study 	 124 
Hypotheses 	 125 
V 
Method 	 126 
Participants 	 126 
Materials and Instruments 	 127 
Procedure 	 133 
Results 	 135 
BBV-TRAQ-SV 	 135 
Measurement Models 	 136 
Linear Regression Analyses 	 140 
Discussion 	 158 
References 179 
Appendix A: BBV-TRAQ-SV 	 207 
Literature Review 
A Review of Predictors for Injecting Risk-Taking amongst Injecting Drug Users: 
Implications for the Reduction of Blood-Borne Virus Transmission 
1 
Literature Review Abstract 
The sharing and lending of injecting equipment amongst the injecting drug 
user (IDU) population has been identified as a leading cause of the transmission of 
blood-borne viruses such as hepatitis B (HBV), hepatitis C (HCV), and human 
immunodeficiency virus (HIV). A large body of research exists which has attempted 
to identify those IDU who are at elevated risk for engaging in behaviours known to 
be associated with BBV transmission. Primary amongst these identified factors are 
those relating to impulsivity traits, psychological distress including anxiety and 
depression, and pharmacological effects of drug use. Also, a number of demographic 
and drug use variables also are routinely investigated in the literatures as possible 
risk factors, and typically include factors of sex, age, duration of injecting history, 
frequency of injecting, preferred drug of choice, sexual orientation, drug treatment 
status, accommodation status, education level, ethnicity, and the presence or absence 
of prison history. 
The following literature review describes the existing research into each of 
these key variables, elucidating those which present as the clear risk factors for BBV 
transmission risk behaviours, and those which are somewhat ambivalent in the 
prediction of risk behaviours and BBV transmission rates. Further, the review 
discusses the need for comprehensive research to be conducted, identifying the 
variables that are most predictive of BBV risk behaviours amongst this population. 
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Blood-borne viruses 
The term 'blood-borne virus'(BBV) refers to a virus which is spread by 
inoculation of contaminated blood through a breach in the skin or mucosal lining 
(Farrell, 2002). Some of the most common BBVs include the hepatitis B virus 
(HBV), hepatitis C virus (HCV), and the human immunodeficiency virus (HIV). 
Cases of each of these viruses have been noted worldwide, and in some locations the 
prevalence of these viruses has become particularly problematic. 
Hepatitis B is a virus which may cause such symptoms as fatigue, rashes, 
joint pain, and fever (Kumar & Clark, 2005). These symptoms are usually only 
present for a few weeks, and some people who are infected with the virus report no 
symptoms. While most people recover completely from hepatitis B infection, a 
minority will go on to develop conditions such as chronic hepatitis or liver cancer 
(hepatocellular carcinoma) as a result of the initial infection, or become 
asymptomatic carriers of the virus (Kumar & Clark, 2005). A vaccine is now 
available to protect against the hepatitis B virus. 
The human immunodeficiency virus (HIV) has received much public 
attention in Australia since the early 1980s when prevention campaigns were 
introduced in a bid to limit the spread of the virus. Like HBV, many people infected 
with this virus may be asymptomatic for some time before signs of infection become 
apparent, however others exhibit symptoms shortly after becoming infected. 
Infection with this virus may lead to the development of acquired immunodeficiency 
syndrome (AIDS), with subsequent high risk of mortality as a result of a lowered 
immune system. While rates of HIV infection initially decreased in response to 
prevention efforts, recent research reveals that there has been a substantial increase in 
new HIV diagnoses in Australia whereby rates increased by 41% in the period 2000 
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to 2005 (National Centre in HIV Epidemiology and Clinical Research, 2006b). At 
the end of 2005, there were estimated to be 15,310 people living with HIV/AIDS in 
Australia. The notable recent increase in new HIV cases indicates that the provision 
of prevention campaigns and education is vitally important to ensure that 
transmission rates are curbed. 
The hepatitis C virus was first identified in 1988 and is now estimated to 
affect millions of people worldwide. At the end of 2005, there were approximately 
264,000 people living with HCV antibodies in Australia alone (Ministerial Advisory 
Committee on AIDS, 2006) and it is now the most common communicable disease in 
Australia (Dore, Law, MacDonald, & Kaldor, 2003). Epidemiological studies of 
hepatitis C reveal that there was a 45 per cent increase in new hepatitis C infections 
in Australia between 1997 and 2001, from 11,000 per annum in 1997 to 16,000 per 
annum in 2001, and the prevalence of hepatitis C is expected to more than triple by 
2020 unless changes are implemented (Law et al., 2003). 
Of those who develop HCV antibodies following exposure to the virus, 
around 25% are expected to clear the virus within 2 to 6 months of becoming 
infected (Australian Institute for Primary Care, 2001). However, the remaining 75% 
will develop chronic infection and remain at risk of developing long term health 
consequences. Indeed, around 7% of those with chronic infection will develop 
cirrhosis of the liver after 20 years following exposure, 2% will develop 
hepatocellular carcinoma, and 4% will develop liver failure (Ministerial Advisory 
Committee on AIDS, 2006). The economic cost of this virus is huge. For the year 
1996/97, the direct cost associated with the HCV in Australia was conservatively 
estimated to be $75 million, while costs associated with loss of productivity resulting 
from premature death or absenteeism were estimated for this period to be $32.5 
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million (Lowe & Cotton, 1999), notwithstanding the substantial personal cost to 
quality of life of those affected (Southgate et al., 2003). These figures are likely to 
underestimate current healthcare costs associated with the virus. 
During chronic HCV infection, common symptoms include lethargy and 
fatigue, fever, nausea, muscle aches, and poor appetite and can affect the individual 
so much that participation in various areas of their lives, such as family, social 
relationships, and work, becomes difficult to sustain (Community Affairs References 
Committee, 2004; Parliament of NSW, 1998). In some cases, this then may lead to 
the breakdown of relationships including divorce, reduced income as a result of 
being unable to work, and social isolation. The psychological impact that hepatitis C 
has on the infected individual is also well documented. Feelings of fear, 
apprehension, anxiety, uncertainty about the future, mood swings, loss of self-
esteem, stress, and depression are commonly reported by those affected by hepatitis 
C (Community Affairs References Committee, 2004; Parliament of NSW, 1998). 
Stigmatisation and discrimination by health care professionals, friends, and the 
general community are also common themes recognised by those experiencing HCV 
(Parliament of NSW, 1998). Diagnosis with HCV clearly can have a devastating 
impact on the individual, both psychologically and physically. 
Because blood-borne viruses are spread through blood-to-blood contact, any 
activity where this is likely to occur creates a risk of virus transmission. In the case 
of HCV, identified transmission routes include vertical (mother-to-child) 
transmission, occupational needle-stick injuries, tattooing, piercing, acupuncture and 
other forms of skin penetration when contaminated equipment is used (Australian 
Institute for Primary Care, 2001; Farrell, 2002). In Australia, recipients of blood 
products prior to 1990, when screening for HCV antibodies was not conducted, were 
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also at risk of becoming infected. While there is some controversy regarding 
transmission of the virus through sexual contact (Pancholi, 2007), it is likely that the 
risk of transmitting the virus by this method is low and is likely to be responsible for 
only a small minority of HCV transmissions where blood-to-blood contact is present 
during sexual contact (Australian Institute for Primary Care, 2001). 
While any of the abovementioned routes can transmit the virus, it has been 
shown that the vast majority of new cases of HCV infection are transmitted during 
the process of injecting illicit drugs. In fact, estimates are that just over 80% of 
prevalent HCV cases are transmitted in this way (Dore, Pritchard-Jones, Fisher, & 
Law, 1999; Ministerial Advisory Committee on AIDS, 2006). According to the 2007 
National Drug Strategy Household Survey, it is estimated that 328,100 Australians 
over the age of 14 had ever injected drugs (1.9%), and 82,400 people over 14 years 
had injected in the previous 12 months (0.5%) (Australian Institute of Health and 
Welfare, 2008). Amongst the injecting drug user (IDU) population, HCV prevalence 
falls in the range of 50% to 70% (Law et al., 2003), and incidence among this 
demographic has been estimated at 15% per year (Crofts, Jolley, Kaldor, Van Beek, 
& Wodak, 1997; Ministerial Advisory Committee on AIDS, 2006). In contrast, HCV 
rates within the general population are much smaller, at approximately 0.06% in 
2005 (National Centre in HIV Epidemiology and Clinical Research, 2006b). 
Virus transmission through injecting drug use has long been recognised as 
occurring through the sharing or re-using of needles and syringes. Within the 
literature, the term 'sharing' refers to both donating equipment to another (lending), 
or using another's equipment (borrowing). However, in addition to transmission 
occurring through needle sharing, evidence also reveals that other injecting 
paraphernalia such as swabs, spoons, water vials, tourniquets, and syringe barrels as 
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well as contact with contaminated hands or other body parts and mixing surfaces also 
provide opportunities for virus transmission (Crofts, Aitken, & Kaldor, 1999; Hagan 
et al., 2001; MacDonald & Wodak, 2003; Maher etal., 2006; Thorpe etal., 2002). 
Even small volumes of blood can transmit BBVs efficiently (Gerberding, 1995), and 
due to this, strict hygiene needs to be adhered throughout the injection process in 
order to reduce the transmission of blood-borne viruses such as HBV, HCV, and 
HIV. 
It is clear that due to the high rates of virus transmission occurring within the 
TDU population, intervention programs should primarily be targeted to this group. In 
response to the emergence of HIV, needle and syringe programs were introduced in 
the late 1980s to distribute sterile injecting equipment such as needles and syringes in 
an effort to encourage safe and clean injecting practices. As a consequence of this 
and other harm reduction strategies, rates of new HIV cases were shown to decline, 
and it is now generally recognised that Australia's speedy response to the emergence 
of this virus resulted in a largely successful prevention campaign (Commonwealth 
Department of Health and Aged Care, 2000). Several large Australian studies (eg. 
(Crofts & Aitken, 1997; Loxley, Carruthers, & Bevan, 1995; MacDonald et al., 
1997) indicate that while there has been variation in needle sharing rates over time, 
there has generally been a reduction in the sharing of needles and syringes in IDU 
populations since significant harm reduction measures were put in place in the early 
1990s. An annual survey of TDU participants attending needle and syringe program 
sites in Australia has provided evidence for this trend. In 1995 approximately 30% of 
participants reported the reuse of someone else's used syringe in the month prior to 
survey, while in 2007 this figure had dropped to 18% (National Centre in HIV 
Epidemiology and Clinical Research, 2003, 2008). It is estimated that as a result of 
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the introduction of needle and syringe programs alone, 25,000 cases of HIV had been 
avoided by the year 2000, and 4,500 deaths will have been averted by 2010 
(Commonwealth Department of Health and Ageing, 2002). In terms of treatment 
costs, this translates to a saving of an estimated $7,025 million. 
However, while the introduction of needle and syringe programs has been 
shown to be effective in reducing HIV incidence in IDU in both Australia and 
worldwide (Commonwealth Department of Health and Ageing, 2002; Hurley, Jolley, 
& Kaldor, 1997), the same cannot be said for the transmission of HCV. While there 
is some evidence of a slight reduction of HCV transmission rates during the 1980s in 
response to HIV prevention campaigns, incidence rates have since increased and are 
occurring at extremely high levels, even in primary health settings which emphasise 
the prevention of blood borne virus contamination (i.e. health centres which provide 
medical care, counselling, social welfare services, needle syringe exchange services 
to clients including youth, sex workers and 1DU) (Crofts et al., 1997; MacDonald et 
al., 2000; Van Beek, Dwyer, Dore, Luo, & Kaldor, 1998).The greater difficulty in 
controlling the spread of HCV is generally attributed to the higher viral infectivity 
content that HCV has compared with HIV, meaning that even extremely small 
volumes of blood can transmit the virus efficiently, even amounts so small as to be 
invisible to the naked eye (Gerberding, 1995). In addition, transmission rates are 
difficult to control as the high background prevalence rate means that even an 
occasional risky injection episode carries with it a considerable risk of infection 
(Crofts et al., 1999). The high frequency of injecting also contributes to the difficulty 
in controlling the spread of the virus. 
In Australia, transmission rates of HCV amongst IDU are even higher than 
previously thought. In a recent study, Maher and colleagues (Maher, Li, Jalaludin, 
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Chant, & Kaldor, 2007) recruited a group of new initiates into injecting drug use 
from needle and syringe programs, methadone clinics, and street-based outreach in 
south-western Sydney who were tested to be anti-HCV seronegative. Participants 
were followed up every 3 to 6 months until seroconversion or study completion. The 
results of this study revealed that seroconversion incidence rates were an alarming 
45.8 per 100 person years. For those who had been injecting for less than one year, 
the mean time to HCV seroconversion was just 0.31 years. This leaves a very small 
window of opportunity for intervention efforts to be implemented. The results from 
this study indicate that the rate of HCV transmission in Australia has now become 
one of the highest in the world. 
The above study highlights the severity of the issue of blood-borne virus 
transmission in Australia, and also the urgent need for implementation of effective 
interventions to curb these soaring transmission rates. It is clear that while current 
interventions have helped to reduce transmission, there is still great room for 
improvement in the delivery of intervention techniques. Currently, these 
interventions are generally delivered to all accessible IDU, regardless of their 
propensity to take risks in relation to the sharing of injecting equipment. Ideally, 
what is needed is the ability to distinguish those IDU who are likely to engage in risk 
behaviours from those who are unlikely to take these risks. By doing so, this allows 
additional high cost interventions to be more specifically targeted to those who are 
found to be most at risk of sharing or using unsterile injecting equipment, and hence 
be at risk of transmitting or spreading blood-borne viruses. The lack of an available 
vaccine for HCV also adds to the impetus to carry out this research. 
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Risk Factors 
Many studies have been conducted investigating the potential risk factors 
which differentiate those who are likely to share needles and other injecting 
paraphernalia from those who choose not to share equipment. Similarly, studies also 
indirectly examine the propensity to share by studying the seroepidemiology of the 
virus, and determining which factors are associated with seroconversion in cohort 
studies or prevalence of the virus in cross-sectional studies. With the current high 
rates of HCV transmission, recent studies tend to focus on this blood-borne virus as 
opposed to HIV. Presumably, this is because campaigns to reduce the rates of HIV 
transmission have been somewhat successful, however rates of HCV transmission 
remain high. As such, the risk factors associated with HCV transmission will be the 
primary topic of examination here. While the results of studies to date appear to 
show some clear trends in which certain factors contribute significantly to the 
sharing of needles and equipment and to the transmission of blood-borne viruses, 
there still remain some factors which do not lend to easy interpretation as distinct 
risk variables. This may indicate that there are some shared associations with latent 
variables. For example, the literature may indicate that females are at a greater risk 
for BBV transmission, however in reality this may be due to the fact that it is more 
common for female DU to be injected by others. The issue as to what factors 
contribute significantly to the transmission of viruses such as HCV is certainly a 
complex one. 
Sex 
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One factor most commonly investigated in these studies is whether males or 
females are most at risk for HCV acquisition. Australian studies examining needle 
sharing risk yield differing results, with some studies reporting a significant sex 
difference (Dwyer et al., 1994; Larson, Shannon, & Eldridge, 1999; Lucas & 
Easthope, 1996), while others note no such difference in needle sharing propensity 
between the genders (Darke, Hall, & Carless, 1990; Dwyer et al., 2002; Loxley et al., 
1995; MacDonald et al., 1997; Treloar et al., 2003). Others again report gender 
differences in some aspect of sharing, but not others. For example, Breen, Roxburgh, 
and Degenhardt (2005) found that female participants were more likely to lend 
needles, however there was no difference between males and females in their 
tendency to borrow needles or to share any injecting paraphernalia such as spoons, 
water, or filters. Overseas studies of gender differences in needle sharing tend to 
report higher rates of sharing amongst female participants (Booth, 1995; Evans et al., 
2003; Montgomery et al., 2002; Valente & Vlahov, 2001). A similar pattern of 
results is found amongst seroepidemiological studies both in Australia and overseas, 
where some report sex differences while others do not find any such difference. 
While the majority of studies show that females are more likely to participate in 
some aspect of sharing (either lending or borrowing), there are a minority of studies 
which found that males are significantly more likely to engage in this behaviour. For 
details of studies examining sex as a risk factor, please refer to Table 1. 
It appears then that there is considerable discrepancy in the literature 
regarding whether a sex difference exists in the sharing of injecting equipment and 
the seroepidemiology of HCV, particularly amongst Australian studies. Of the 
literature examined however, the results of these studies suggest a trend towards 
females being at higher risk for BBV acquisition than males. Indeed, Southgate et al. 
(2003) concurs that the literature suggests that females are more likely to share 
injecting equipment when compared with males. 
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Table 1 
Findings of Studies Investigating Sex as a predictor of FICV Transmission and Equipment Sharing 
Study 	HCV 	Sharing 	Group at Greater Risk 	 Study Characteristics 	 Origin 
n = 181. IDU recruited through NSP and 'snowballing'. Must have 	UK 
injected drugs in month preceding interview and speak English. 
Cross-sectional design. 
n = 593. Recruited using street-based outreach. Eligible if injected 	US 
drugs in the past 30 days and /or smoked crack cocaine in past 2 
days, not in drug treatment in the past 30 days, and over 18 years. 
Cross-sectional design. 
n = 154. Recruited through NSP and snowballing. Eligible if at least 	Aus 
monthly injecting in past 6 months and resided in Sydney over the 
past 12 months. Cross-sectional design. 
n = 303. IDU recruited by peer workers through social networks, 	Aus 
community agencies, and prisons. Prospective cohort study. 
n = 315. IDU recruited through social networks, community 	Aus 
agencies and prisons. Cohort design. 
n = 100. Opiate users in and out of treatment. Recruited through 
	
Aus 
advertisements in waiting rooms of methadone clinics and health 
centres. Cross-sectional design. 
n = 283. Incarcerated and community methadone maintenance 	Aus 
patients who have been in treatment for more than 6 months. Cross-
sectional design. 
n = 1,245. IDU from Sydney recruited by flyers around sites such as Aus 
NSPs and social security offices. Cross-sectional design. 
n = 416. Participants who had injected monthly for past 6 months. 	Aus 
Recruited via snowballing, posted advertisements, and NSP sites. 
Cross-sectional design. 
n = 844. Recruited by street outreach, eligible if injected drugs in the US 
past month, under 30 years old, and spoke English. Cross-sectional 
design. 
Bennett (2000) Males more likely to lend 
injecting equipment, females 
more likely to borrow injecting 
equipment 
Booth (1995) 	
• 	
Female 
Breen (2005) 	
 
Females more likely to lend 
needles 
No difference between genders 
in borrowing needles 
No difference between genders 
in sharing ancillary injecting 
equipment 
Crofts (1993)* 	 Male 
Crofts (1994)* 
Darke (1990) 
Darke (1998) 	 Females more likely to borrow 
injecting equipment 
No difference between genders 
in lending of equipment 
Dwyer (1994) 	 Female 
Dwyer (2002) 
Evans (2003) 	 Female 
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Loxley (1995) 	 n = 872. IDU from Adelaide, Melbourne, Sydney, and Perth 	Aus 
recruited by advertisements with agencies (e.g. NSPs, health 
centres) and snowballing. Cross-sectional design. 
Larson (1999) 	 Female 	 n = 77. Aboriginal and Torres Strait Islander IDU who had 	Aus 
injected in past 12 months. Cross-sectional design. 
Lucas (1996) 	 Female 	 n = 215. IDU from Hobart, Tasmania. Cohort study over 4 years. 	Aus 
MacDonald (2000) 	 Female n = 4,141. IDU who had attended selected NSP sites around 	Aus 
Australia 1995 — 1997. Repeated cross-sectional surveys. 
MacDonald (1997) 	 = 	 n = 1,005. All IDUs who had attended 21 NSPs across Australia in Aus 
one week in March 1995. Cross-sectional survey. 
Maher (2004) 	 Male 	 n = 372. IDU in South-West Sydney with history of IDU in last 6 	Aus 
months and HCV serostatus not known to be positive. Recruited 
using word-of-mouth and snowballing methods. Cross-sectional 
design. 
Maher (2006)* 	 Female 	 n = 368. HCV negative IDU who had injected drugs in the past 6 	Aus 
months. Recruited through direct approaches, outreach, NSPs, 
methadone and sexual health clinics. Prospective cohort study. 
Maher (2007)* 	 Female 	 n = 215. IDU who had injected drugs in the past 6 months and 	Aus 
were seronegative or had unknown HCV serostatus. Recruited 
through outreach, methadone clinics, and NSPs. Prospective 
cohort study. 
Montgomery (2002) 	 Female 	 n = 320. IDU and referred members of their social networks. 	US 
Cross-sectional design. 
Treloar (2003) 	 = 	 n = 336. IDU aged between 16 — 25 years who had been injecting 	Aus 
for 4 years or less from urban Sydney, urban Brisbane, or rural 
NSW. Recruited by advertisements in NSPs, treatment centres, 
health clinics, local press etc. Cross-sectional design. 
Valente (2001)* 	 Female 	 n = 1,184. IDU who had attended a Baltimore NSP. Cohort study. 	US 
Van Beek (1994) = 	 n = 201. All IDU who had attended a primary health care facility 	Aus 
in central Sydney and had undertaken HCV testing. Retrospective 
cross-sectional study.  
Key: 
denotes male sex is a significant positive predictor of risk 
denotes female sex is a significant positive predictor of risk 
= denotes sex is a non-significant factor 
*indicates studies of particularly high quality due to design or power 
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Studies examining this gender difference assert that this tendency can at least 
in part be explained due to status factors and norms amongst IDU circles. That is, 
within the culture of injecting drug use, it has been reported that, within some 
subgroups, it is normal injecting etiquette for women to borrow used needles from 
their sexual partner if there is insufficient clean injecting equipment available at a 
group injecting session (Klee, Faugier, Hayes, Boulton, & Morris, 1990b). In 
accordance with this, Bennett, Velleman, Barter and Bradbury (2000) found in their 
study that men generally were more likely to pass on equipment, and women were 
more likely to receive. Other studies (Booth, 1995; Dwyer et al., 1994; Evans et al., 
2003; Lenton & Tan-Quigley, 1997; Loxley et al., 1995) also find that females are 
more likely to share injecting equipment with sex partners more so than men. Miller 
and Neaigus (2001) report that male sex partners are often older than the female, and 
are more likely to have been exposed to BBV such as HCV, HIV, and HBV, further 
adding to transmission risk. It has also been reported that sharing needles and 
injecting paraphernalia with one's partner is also viewed as a sign of trust, solidarity, 
and intimacy within that partnership (Dwyer et al., 1994; Klee et al., 1990b) so the 
tendency to decline an offer of used needles carries with it connotations of distrust 
and therefore would not be a preferable course of action to take. In their study of 
gender differences in sexual and injection risk behaviours amongst DU in San 
Francisco, Evans et al. (2003) found that a further factor explaining females' greater 
risk for contracting BBV is that they were more likely to be injected by someone 
else, thereby increasing the opportunities for BBV transmission. Bruno (2006) found 
similar trends in a sample of Tasmanian IDU, such that females were more likely 
than males to be injected by others. 
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Age 
A further demographic variable that has received considerable attention in the 
BBV risk literature is the age of the IDU and the impact this has on the sharing of 
injecting equipment and on HCV seroprevalence. Studies specifically examining 
needle sharing reveal a clear trend that those IDU who are younger in age are more 
likely to share needles than those who are older (Dwyer et al., 2002; Larson et al., 
1999; Lenton & Tan-Quigley, 1997; Southgate et al., 2003; Valente & Vlahov, 
2001). This trend is apparent both in Australian studies and in international research. 
Most of these studies label younger IDU as those who are under the age of 25, while 
older 1DU are categorised as those older than 25 years. Naturally, there remains some 
discrepancy in these findings which should be noted, with a few studies reporting no 
effect of age on needle sharing (Darke et al., 1990; Evans et al., 2003; Treloar et al., 
2003) and one study reporting that older study participants were more likely to share 
equipment (Loxley et al., 1995); however the overall trend is clearly that younger 
1DU are more likely to engage in risky injection practices in terms of the sharing of 
needles and related injecting equipment (see Table 2 for a summary of research 
findings). 
When examining the seroepidemiological studies, these can be divided into 
those which examine HCV prevalence rates and those which examine HCV 
incidence rates. The benefit of incidence studies is that information can be obtained 
regarding at what age and when 1DU are becoming infected with the virus, whereas 
prevalence studies can only provide information as to the cumulative impact of HCV 
infection. By looking at these two groups of studies separately, the literature clearly 
reveals that prevalence among IDU is high and that prevalence rates increase the 
older the person is. For example, Crofts et al. (1994) found that the prevalence of 
16 
HCV in IDU under the age of 25 was 46%, while in those participants aged over 25, 
this figure jumps to 80%. Similarly, Van Beek, Buckley, Stewart, MacDonald, and 
Kaldor (1994) found that in IDU aged under 20 years, the prevalence rate was 17%, 
while in those over 35 years of age the rate was an alarming 93%. Similar findings 
are found in international studies (Chang, Ko, & Liu, 1998; Diaz et al., 2001; 
Guadagnino et al., 1995; Lamden et al., 1998; Patti et al., 1993; Stark et al., 1995; 
Thomas et al., 1995). When looking more specifically at incidence studies, this 
research reveals that those TDU who are younger in age are contracting the virus at a 
faster rate than those [DU who are older (Crofts et al., 1995; Hagan et al., 1999; Van 
Beek et al., 1998). In a study by Van Beek and colleagues, (Van Beek et al., 1998) 
incidence rates were found to be 75.6 per 100 person years for those IDU under 20 
years of age, however in those 30 years and older the rate was only 6.6 per 100 
person years. Together, these studies reveal that the greatest risk period for 
contracting HCV is in younger IDU, but the likelihood of having contracted the 
disease rises with age, most likely due to the cumulative risk that each injection 
episode brings. However, it should also be noted that some studies no not detect an 
effect of age on HCV incidence or prevalence (e.g. Garfein et al., 1998; Hagan et al., 
2001; Maher et al., 2006; Maher et al., 2007). Despite this, the clear majority of 
studies indicate a significant effect of age. 
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Table 2 
Findings of Studies Investigating Age as a predictor of HCV Transmission and Equipment Sharing 
Study 	HCV 	Sharing 	Group at Greater Risk 	 Study Characteristics 	 Origin 
n = 934. Participants were drug users (injecting and non-injecting) 	Taiwan 
recruited from a drug treatment centre and a prison. Cross-sectional 
design. 
n = 303. IDU recruited by peer workers through social networks, 	Aus 
community agencies, and prisons. Prospective cohort study. 
n = 315. IDU recruited through social networks, community 	Aus 
agencies and prisons. Cohort design. 
n = 3,629. Victorian prison entrants (not all IDU). Cross-sectional 	Aus 
design. 
n = 100. Opiate users in and out of treatment. Recruited by 	Aus 
advertising in waiting rooms of methadone clinics and health 
centres. Cross-sectional design. 
n = 557. IDU aged 18 —29 who had injected in last 6 months and 
	
US 
been injecting for less than 3 years. Street recruited. Cross-sectional 
design. 
n = 416. Participants must have injected monthly for past 6 months. 	Aus 
Recruited via snowballing, posted advertisements, NSP sites. Cross-
sectional design. 
n = 844. Recruited by street outreach, eligible if injected drugs in the US 
past month, under 30 years old, and spoke English. Cross-sectional 
design. 
n = 229. IDU aged 18 — 29 years. Recruited through community 	US 
outreach. Prospective cohort study. 
n = 146. Male heterosexual IDU (injected in the past 12 months) 	Italy 
who had attended a methadone maintenance clinic. Cross-sectional 
design. 
n = 28 (case patients), n = 38 (control patients). Participants were 	US 
IDU who had attended a health department. Case-control design. 
n = 647. IDU recruited from drug treatment, corrections, and social 
	
US 
service agencies. Eligible if had injected in previous year, were over 
14 years old, and were English or Spanish speaking. Prospective 
cohort study. 
Chang (1998) >30 years greater risk than those 
29 and under 
Crofts (1993)* 	 >25 years at greater risk 
compared with those <25 years 
Crofts (1994)* 	 >25 years at greater risk 
compared with those <25 years 
Crofts (1995) Those who seroconverted were 
younger (mean 22.2 years) than 
those who did not seroconvert 
(mean 26.2 years) 
Darke (1990) 
Diaz (2001) 	 25 — 29 years at greater risk 
compared with those 18 —24 
years 
Dwyer (2002) 	 <25 years at greater risk 
compared with those > 25 years 
Evans (2003) 
Garfein (1998) 
Guadagnino (1995) 	 Those > 27 years old at greater 
risk than those 26 years and 
younger 
Hagan (1995) 	 <25 years at greater risk than 
those 25 — 34 years old 
Hagan (1999)* 	 Age groups <24 years and 25 — 
34 higher rates of HCV than 
those > 35 
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n = 317. Clients who had injected in the past year, were over 14 
years old, and English or Spanish speaking were eligible. Recruited 
from drug treatment and correction centres. Follow up 1 year later. 
Prospective cohort study. 
n = 773. Drug users (injecting & non-injecting) who had hepatitis 
serology testing between 1992 and 1996 at public health facilities. 
Retrospective cross-sectional design. 
n = 77. Aboriginal and Torres Strait Islander IDU (injected in past 
12 months). Cross-sectional design. 
n = 511. Questionnaires were included in Fitpacks over a 6 week 
period in 183 community pharmacies in WA to be mailed back 
anonymously. Cross-sectional study. 
n = 872. IDU from Adelaide, Melbourne, Sydney, and Perth 
recruited by advertising with agencies (e.g. NSPs, health centres) 
and snowballing. Cross-sectional design. 
n = 11,229. IDU who had attended NSP sites across Australia. 
Cross-sectional survey. 
n = 4,141. IDU who had attended selected NSP sites around 
Australia 1995 — 1997. Repeated cross-sectional surveys. 
n = 368. HCV negative IDU who had injected drugs in the past 6 
months. Recruited through direct approaches, outreach, NSPs, 
methadone and sexual health clinics. Prospective cohort study. 
n = 215. IDU who had injected drugs in the past 6 months and were 
seronegative or had unknown HCV serostatus. Recruited through 
outreach, methadone clinics, and NSPs. Prospective cohort study. 
n = 645. Regular IV heroin users who had attended methadone 
maintenance centres in Rome. Cross-sectional design. 
n = 746. IDU who had attended a drug treatment centre. Case-
control study. 
n = 110. IDU who had attended a drug dependency clinic. Records 
of these clients at initial assessment were examined over a 2 year 
period. Retrospective cross-sectional design. 
n = 2,738. Clients who had attended NSP sites over a week period in 
October 2001. Cross-sectional study. 
n = 405. Clients of drug abuse treatment centres, a hospital, and 
BBV prevention centre who had injected drugs in the last 3 months. 
Cross sectional design. 
Hagan (2001)* 
Lamden (1998) 
	
1' 	 > 25 years at greater risk 
compared with those <25 years 
Larson (1999) 	 <20 years at greater risk 
compared with those > 20 years 
Lenton (1997) 	 <26 years at greater risk 
compared with those > 26 years 
Loxley (1995) 	 >25 years at greater risk 
compared with those <25 years 
NCHECR (2006a) 	 <20 years at greater risk 
compared with those > 20 years 
MacDonald (2000) 
	
'1' 	 > 25 years at greater risk 
compared with those < years 
Maher (2006)* 
Maher (2007)* 
Patti (1993) 	 Prevalence increases from <25 
to 35 years. No further increase 
after 35 years 
Rezza (1996) 	 > 28 years at greater risk 
compared with those <28 years 
Robinson (1995) 
Southgate (2003) 	 <25 years at greater risk 
compared with those > 25 years 
Stark (1995) 	 Older age associated with 
greater risk 30 years at 
greatest risk) 
US 
UK 
Aus 
Aus 
Aus 
Aus 
Aus 
Aus 
Aus 
Italy 
Italy 
NZ 
Aus 
Germany 
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n = 1,356. Clients with history of IDU in last 10 years recruited from US 
health centres and probation offices. Cohort study. 
n = 336. IDU aged between 16 — 25 years who had been injecting for Aus 
4 years or less from urban Sydney, urban Brisbane, or rural NSW. 
Recruited by advertisements in NSPs, treatment centres, health 
clinics, local press etc. Cross-sectional design. 
n = 1,184. IDU who had attended a Baltimore NSP. Cohort study. 	US 
n = 201. All IDU who had attended a primary health care facility in 	Aus 
central Sydney and who had undertaken HCV testing. Retrospective 
cross-sectional study. 
n = 1,078. Clients of BBV prevention centre with history of IDU. 	Aus 
Retrospective cohort study. 
n = 346. IDU and non-IDU recruited at methadone dispensary sites 	Netherlan 
and STD clinic. Prospective cohort design. 	 ds 
n = 1,593. Sample had history of IDU in last 10 years. Cohort study. US 
Mean follow up 6.5 years  
Thomas (1995)* 
Treloar (2003) 
Valente (2001)* 
Van Beek (1994) 
Van Beek (1998)* 
Van den Hoek 
(1990) 
Villano (1997)* 
<25 years at greater risk 
compared with those > 25 years 
< 39 years at greater risk 
compared with those > 39 years 
Risk increases with age 35 at 
greatest risk) 
<20 years at greater risk 
compared with those >20 years 
Key: 
denotes older age is a significant predictor of increased risk 
denotes younger age is a significant predictor of increased risk (alternatively, older age predicts less risk) 
= denotes age is a non-significant factor 
*indicates studies of particularly high quality due to design or power 
Duration of Injecting 
Somewhat more specific than a simple assessment of age, duration of 
injecting drug use is a further variable often identified in the literature as predictive 
of greater risk for HCV transmission and the sharing of injecting equipment. Indeed, 
the vast majority of studies reveal that this variable is a significant predictor of the 
presence of HCV in univariate analyses, and is often found to be an independent 
predictive factor in multivariate analyses. Only a small minority find that this 
variable does not contribute to HCV risk (Dwyer et al., 2002; Van Beek et al., 1998; 
Villano et al., 1997). Prevalence studies both in Australia and overseas clearly 
indicate that the longer a person has used drugs intravenously the higher the 
likelihood that they have contracted the virus (Bell et al., 1990; Chang et al., 1998; 
Chetwynd, Brunton, Blank, Plumridge, & Baldwin, 1995; Crofts et al., 1993; Diaz et 
al., 2001; Donahue et al., 1991; Garfein, Vlahov, Galai, Doherty, & Nelson, 1996; 
Girardi et al., 1990; Lamden et al., 1998; Loxley et al., 1995; MacDonald et al., 
2000; Maher et al., 2004; Patti et al., 1993; Robinson et al., 1995; Smyth, Keenan, 
Dorman, & O'Connor, 1995; Stark et al., 1995; Thomas et al., 1995; Van Beek et al., 
1994; Zeldis et al., 1992). The increase in risk as a function of length of injecting 
drug use is likely due to the effect of cumulative exposure. Incidence studies reveal 
that the greatest risk period for seroconversion is in the initial years of injecting 
(Garfein et al., 1998; Hagan et al., 1999; Hagan et al., 2001; Maher et al., 2006; 
Maher et al., 2007). In a recent study examining the incidence of HCV in Australia, 
Maher et al. (2007) found that incidence rates in those who had injected for less than 
one year was 98.2 per 100 person years, 52.2 per 100 person years in those who had 
injected for one to three years, and 31.4 per 100 person years in those who had 
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injected for three to six years. In percentage terms, this equates to 29.9% of the total 
sample having undertaken seroconversion, with 43.6% of the total seroconversions 
occurring in participants who have been injecting for one year or less, 32.8% of those 
injecting for one to three years, and 23.4% in those who have been injecting for over 
three years. In considering results of incidence research such as that cited above, the 
most risky time for contracting HCV would appear to be shortly following initiating 
into injecting drugs. This factor is clearly an important one to consider in 
determining HCV risk. Details of research examining this variable are outlined 
below in Table 3. 
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Table 3 
Findings of Studies Investigating Duration of Injecting as a predictor of HCV Transmission and Equipment Sharing 
Study 	 HCV 	Sharing 	 Notes 	 Study Characteristics 	 Origin 
Increases with duration (anti-
HCV positive group = mean 
duration 63 months, anti-HCV 
negative group = mean duration 
37 months) 
Those injecting for > 5 years at 
greater risk than those injecting 
5 years 
Increases with duration. 1-5 
years injecting history = 73.5% 
anti-HCV positive, 11 or more 
years, 92.5% positive. 
Those injecting > 8 years at 
greater risk than those injecting 
<8 years 
Those injecting > 3 years at 
greater risk than those injecting 
<3 years 
Increases with duration. (71.4% 
of those injecting for less than 1 
year had HCV-antibodies 
present, 91.7% of those injecting 
for over 10 years had HCV-
antibodies) 
Those injecting more than 6 
months at greater risk than those 
injecting less than 6 months 
Those injecting for at least 2 
years at greater risk 
n = 172. IV heroin users who had presented to a drug treatment 	Aus 
centre seeking entry to a methadone program. Cross-sectional 
design. 
n = 934. Participants were drug users (injecting and non-injecting) Taiwan 
recruited from a drug treatment centre and a prison. Cross- 
sectional design. 
n = 116. IDU who had attended a methadone treatment clinic in 	NZ 
Christchurch. Cross-sectional design. 
n = 303. IDU recruited by peer workers through social networks, 	Aus 
community agencies, and prisons. Prospective cohort study. 
n = 557. IDU aged 18 —29 who had injected in past 6 months and US 
had injected for less than 3 years. Street recruited. Cross-sectional 
design. 
n = 225. IDU from Baltimore area enrolled in another study of 
	
US 
HIV infection. Prospective cohort study. 
n = 416. Participants had injected monthly for past 6 months. 	Aus 
Recruited via snowballing, posted advertisements, NSP sites. 
Cross-sectional design. 
n = 844. Recruited by street outreach, eligible if injected drugs in 	US 
the past month, under 30 years old, and spoke English. Cross-
sectional design. 
n = 716. Clients with history of IDU in last 10 years recruited 
	
US 
from health centres and probation offices. Cohort study. 
n = 229. IDU aged 18 —29 years. Recruited through community 	US 
outreach. Prospective cohort study. 
Bell (1990) 
Chang (1998) 
Chetwynd (1995) 
Crofts (1993)* 
Diaz (2001) 
Donohue (1991)* 
Dwyer (2002) 
Evans (2003) 
Garfein (1996)* 
Garfein (1998) 
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n = 80. IDU who had attended a methadone treatment program in 	Italy 
Rome. Cross-sectional design. 
n = 28 (case patients), n = 38 (control patients). Participants were 	US 
IDU who had attended a health department. Case-control design. 
n = 647. IDU recruited from drug treatment, corrections, and 	US 
social service agencies. Eligible if had injected in previous year, 
over 14 years old, and spoke English or Spanish. Prospective 
cohort study. 
n = 317. Clients who had injected in the past year, were over 14 	US 
years old, and spoke English or Spanish were eligible. Recruited 
from drug treatment and correction centres. Follow up 1 year later. 
Prospective cohort study. 
n = 773. Drug users (injecting & non-injecting) who had hepatitis 	UK 
serology testing between 1992 and 1996 at public health facilities. 
Retrospective cross-sectional design. 
n = 872. IDU from Adelaide, Melbourne, Sydney, and Perth 
	
Aus 
recruited by advertising with agencies (e.g. NSPs, health centres) 
and snowballing. Cross-sectional design. 
n = 4,141. IDU who had attended selected NSP sites around 
	
Aus 
Australia 1995 — 1997. Repeated cross-sectional surveys. 
n = 372. IDU in South-West Sydney with history of IDU in last 6 
	
Aus 
months and had HCV serostatus not known to be positive. 
Recruited using word-of-mouth and snowballing methods. Cross-
sectional design. 
n = 368. FICV negative IDU who had injected drugs in the past 6 
	
Aus 
months. Recruited through direct approaches, outreach, NSPs, 
methadone and sexual health clinics. Prospective cohort study. 
n = 215. IDU who had injected drugs in the past 6 months and 
	
Aus 
were seronegative or had unknown HCV serostatus. Recruited 
through outreach, methadone clinics, and NSPs. Prospective 
cohort study. 
n = 645. Regular IV heroin users who had attended a methadone 	Italy 
maintenance centre in Rome. Cross-sectional design. 
n = 746. IDU who had attended a drug treatment centre. Case- 	Italy 
control study. 
Girardi (1990) 
	
Risk increases with duration of 
injecting (1-5 years = 33.3% 
HCV positive, > 10 years = 
84.3% positive) 
Hagan (1995) 
	
Those injecting for more than 5 
years are at greater risk 
Hagan (1999)* 
	
Those injecting for more than 1 
year at greater risk 
Hagan (2001)* 
	
Those injecting for more than 2 
years at greater risk 
Lamden (1998) 
	
Increases with longer duration 
(OR = 8.9 in those > 10 years 
compared with < 3 years 
injecting) 
Loxley (1995) 
	
Increases with longer duration 
MacDonald (2000) 
	
Those injecting for more than 5 
years at greater risk 
Maher (2004) 	 Those injecting for more than 3 
years at greater risk compared 
with those injecting less than 3 
years 
Maher (2006)* 
	
Those injecting for more than 1 
year at greater risk 
Maher (2007)* 
	
Those injecting for more than 1 
year at greater risk 
Patti (1993) 	 > 5 years at greater risk than 
those < 5 years IV use 
Rezza (1996) 	 >2.5 years at greater risk 
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Robinson (1995) 
Smyth (1995) 
Stark (1995) 
Thomas (1995)* 
Treloar (2003) 
Van Beek (1994) 
Van Beek (1998) 
Villano (1997)* 
Zeldis (1992) 
Longer duration of IV drug use 
(anti-HCV negative group mean 
8.1 years, anti-HCV positive 
group mean 11.8 years) 
Longer duration of IV drug use. 
(>2 years = seroprevalence 
95%, duration < 2 years 
seroprevalence 70%) 
<5 years (66.1% HCV 
antibodies present) 15 years 
(94.5% HCV antibodies present) 
Those injecting for more than 5 
years at greater risk (risk 
increases with duration) 
Those injecting for more than 2 
years at greater risk than those 
injecting less than 2 years 
Increases with longer duration (< 
3 years OR = 1, 10+ years OR = 
19.3) 
Increases with longer duration 
(odds increase by 1.5 for each 5 
years IV use)  
n = 110. IDU who had attended drug dependency clinic. Records 	NZ 
of these clients at initial assessment were examined over a 2 year 
period. Retrospective cross-sectional design. 
n = 272. IDU who had attened drug treatment centre during a one- Ireland 
year period. Cross-sectional design. 
n = 405. Clients of drug abuse treatment centres, a hospital, and 
	
Germany 
BBV prevention centre who had injected drugs in the last 3 
months. Cross sectional design. 
n = 1,356. Clients with history of IDU in last 10 years recruited 
	
US 
from health centres and probation offices. Cohort study. 
n = 336. IDU aged between 16 — 25 years who had injected for 4 	Aus 
years or less from urban Sydney, urban Brisbane, or rural NSW. 
Recruited by advertisements in NSPs, treatment centres, health 
clinics, local press etc. Cross-sectional design. 
n = 201. All IDU who had attended a primary health care facility 	Aus 
in central Sydney who had undertaken HCV testing. Retrospective 
cross-sectional study. 
n = 1,078. Clients of BBV prevention centre with history of IDU. 	Aus 
Retrospective cohort study. 
n = 1,593. Sample had history of IDU in last 10 years. Cohort 	US 
study. Mean follow up 6.5 years 
n = 585. IDU enrolled in drug treatment programs. Cohort study. 	US 
Key: 
is denotes longer duration of injecting is a significant predictor 
I. denotes shorter duration of injecting is a significant predictor 
= denotes Duration of Injecting non-significant factor 
*indicates studies of particularly high quality due to design or power 
Frequency of Injecting 
Another variable covarying with years of injection is the frequency of 
injecting which has also been found to be a significant risk factor, for both needle 
sharing and for the risk of HCV infection. Generally, studies examining this variable 
report that those IDU who inject on a daily basis or more frequently have a greater 
propensity to share injecting equipment and are more likely to contract blood borne 
viruses (see Table 4). Very few studies have found this factor not to be predictive of 
needle sharing or HCV transmission risk (Diaz et al., 2001; Hagan et al., 1999; 
Maher et al., 2007). The reason for the consistent significance of this variable is 
likely again due to the cumulative risk of injecting, such that the more often an 
individual engages in an injecting episode, the number of opportunities for 
contracting blood borne viruses is increased. Alternatively, this finding may also 
reflect a reduction in hygiene standards when injecting illicit drugs such that the 
injecting episode carries with it more risk for BBV transmission (Darke et al., 1990). 
A lowered adherence to strict hygiene procedures when injecting drugs which can be 
seen in those who inject on a more frequent basis can be indicative of the desire to 
remove withdrawal symptoms. In users who have developed dependence to a drug, 
the presence of withdrawal symptoms (e.g. tremors, muscle cramps, nausea, chills, 
irritability) is an unpleasant experience which occurs as a result of the abrupt 
cessation of the use of the drug. The experience of withdrawal symptoms therefore 
creates a strong drive to remove the symptoms, and of course this can be achieved by 
further use of the drug. The drive to do this can lead to IDU becoming more risky in 
their injection practices during the rush to remove symptoms as quickly as possible. 
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Table 4 
Findings of Studies Investigating Frequency of Injecting as a predictor of HCV Transmission and Equipment Sharing 
Study 	 HCV 	Sharing 	Group at Greater Risk 	 Study Characteristics 	 Origin 
n = 557. IDU aged 18 —29 who had injected in the last 6 months 	US 
and had been injecting for less than 3 years. Street recruited. 
Cross-sectional design. 
n = 416. Participants who had injected monthly for past 6 months. 	Aus 
Recruited via snowballing, posted advertisements, NSP sites. 
Cross-sectional design. 
n = 716. Clients with history of IDU in last 10 years recruited 	US 
from health centres and probation offices. Cohort study. 
n = 229. IDU aged 18 —29 years. Recruited through community 	US 
outreach. Prospective cohort study. 
n = 647. IDU recruited from drug treatment, corrections, and 	US 
social service agencies. Eligible if had injected in previous year, 
were over 14 years old, and spoke English or Spanish. Prospective 
cohort study. 
n = 317. Clients who had injected in the past year, were over 14 	US 
years old, and spoke English or Spanish were eligible. Recruited 
from drug treatment and correction centres. Follow up 1 year later. 
Prospective cohort study. 
n = 511. Questionnaires included in Fitpacks over a 6 week period Aus 
in 183 community pharmacies in WA to be mailed back 
anonymously. Cross-sectional study. 
n = 1,005. All IDUs who had attended 21 NSPs across Australia in Aus 
a one week period in March 1995. Cross-sectional survey. 
n = 4,141. IDU who had attended selected NSP sites around 	Aus 
Australia 1995 — 1997. Repeated cross-sectional surveys. 
n = 372. IDU in South-West Sydney with history of IDU in last 6 	Aus 
months and HCV serostatus not known to be positive. Recruited 
using word-of-mouth and snowballing methods. Cross-sectional 
design. 
n = 368. HCV negative IDU who had injected drugs in the past 6 	Aus 
months. Recruited through direct approaches, outreach, NSPs, 
methadone and sexual health clinics. Prospective cohort study. 
Diaz (2001) 
Dwyer (2002) 
	
Those who inject at least once 
daily 
Garfein (1996)* 
	
Those who inject at least once 
daily 
Garfein (1998) 
	
Those who inject at least once 
daily 
Hagan (1999)* 
Hagan (2001)* 
	
Those who inject at least once 
daily 
Lenton (1997) 
	
Those who inject at least once 
daily 
MacDonald (1997) 
	
Those who inject at least daily, 
and more than once a week 
compared with those who inject 
once a week or less 
MacDonald (2000) 
	
Those who inject at least once 
daily 
Maher (2004) 
	
Those who inject at least once 
daily 
Maher (2006)* 
	
Those who inject at least once 
daily 
NCHECR (2006a) 
Southgate (2003) 
Thomas (1995)* 
Treloar (2003) 
Those who inject at least once 
daily 
Those who inject at least once 
daily 
Those who inject at least once 
daily 
Those who inject at least once 
daily 
once per week at greater risk 
than those who inject < once per 
week 
Those who inject at least once 
daily 
Those who inject > once a 
month at greater risk than those 
who inject < once a month 
Those who inject at least once 
daily 
Those who inject at least once 
daily 
Valente (2001)* 
Van Ameijden 
(1993) 
Van Beek (1994) 
Van den Hoek 
(1990) 
Villano (1997)* 
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Maher (2007)* n = 215. IDU who had injected drugs in the past 6 months and 	Aus 
were seronegative or had unknown HCV serostatus. Recruited 
through outreach, methadone clinics, and NSPs. Prospective 
cohort study. 
n = 11,229. IDU who had attended NSP sites across Australia. 	Aus 
Cross-sectional survey. 
n = 2,738. Clients who had attended NSP sites over a one week 	Aus 
period in October 2001. Cross-sectional study. 
n = 1,356. Clients with history of IDU in last 10 years recruited 	US 
from health centres and probation offices. Cohort study. 
n = 336. IDU aged between 16 — 25 years who had injected for 4 	Aus 
years or less from urban Sydney, urban Brisbane, or rural NSW. 
Recruited by advertisements in NSPs, treatment centres, health 
clinics, local press etc. Cross-sectional design. 
n = 1,184. IDU who had attended a Baltimore NSP. Cohort study. 	US 
n = 305. Drug users (injecting and non-injecting) recruited from a 	Netherlands 
methadone program clinic and STD clinic. Prospective cohort 
study. 
n = 201. All IDU who attended a primary health care facility in 	Aus 
central Sydney who had undertaken HCV testing. Retrospective 
cross-sectional study. 
n = 346. IDU and non-IDU recruited at methadone dispensary 	Netherlands 
sites and STD clinic. Prospective cohort design. 
n = 1,593. Sample had history of IDU in last 10 years. Cohort 	US 
study. Mean follow up 6.5 years  
Key: 
T denotes Frequency of Injecting is a significant predictor of increased risk 
= denotes Frequency of Injecting non-significant factor 
*indicates studies of particularly high quality due to design or power 
Drug Choice 
A further factor which is routinely examined in this literature is whether the 
type of drug injected has an effect on the transmission of BBVs or the tendency to 
share equipment. This may reflect the acute cognitive effects of the drug and/or the 
dependence potential for the drug (discussed in subsequent sections). The literature 
indicates that those [DU who use stimulants tend to be marginally more at risk as 
opposed to those IDU who use opiates (see Table 5 for details of research examining 
drug choice as a risk factor for sharing and HCV transmission). 
The reason for this difference is unclear, however the type of drug primarily 
used may influence possible BBV transmission due to the frequency with which the 
drug is injected. Therefore, users who inject drugs with a shorter active period may 
be more likely to increase their use of the drug because the time at which they are 
'high' is not long. As noted above, the more a person injects the more at risk they are 
for transmitting BBVs. 
Drug choice is also a factor which is worthy of investigation due to the 
pharmacological effect which the drug can have on the user. Briefly, the 
pharmacological action of the drug can result in cognitive changes leading to 
disinhibited behaviour and an increase in risk-taking. This is discussed in detail 
below. 
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Table 5 
Findings of Studies Investigating Drug Choice as a predictor of HCV Transmission and Equipment Sharing  
Study 	HCV 	Sharing 	Studies Showing 	Group at Greater Risk 	 Study Characteristics 	 Origin 
Stimulant 
Preference 
Associated with 
HCV 
Transmission 
Opioids 
Chetwynd (1995) 
Crofts (1993)* 
Crofts (1994)* 
Darke (1990) 
Donohue (1991) 
Dwyer (2002) 
Hagan (1999)* 
Men who use opiates at greater 
risk than men who don't use 
opiates. 
Opiate users at greater risk than 
amphetamine users 
Polydrug users and those using 
higher levels of heroin at greater 
risk than those using higher levels 
of cocaine 
Injection of cocaine versus non-
injection of cocaine 
Sharing: Those at greater risk are 
those who last injected and 
injected most over the last month 
drugs other than amphetamines or 
heroin 
HCV: Those at greater risk are 
those who last injected drugs other 
than amphetamines or heroin, and 
injected 2 or more drug types the 
last time they injected 
Heroin/speedball users at greater 
risk than stimulant users 
n = 116. IDU who had attended a methadone 
treatment clinic in Christchurch. Cross-sectional 
design. 
n = 303. IDU recruited by peer workers through 
social networks, community agencies, and prisons. 
Prospective cohort study. 
n = 315. IDU recruited through social networks, 
community agencies and prisons. Cohort design. 
n = 100. Opiate users in and out of treatment. 
Recruited by advertising in waiting rooms of 
methadone clinics and health centres. Cross-sectional 
design. 
n = 225. IDU from Baltimore area enrolled in another 
study of HIV infection. Prospective cohort study. 
n = 416. Participants who had injected monthly for 
the past 6 months. Recruited via snowballing, posted 
advertisements, NSP sites. Cross-sectional design. 
n = 647. IDU recruited from drug treatment, 
corrections, and social service agencies. Eligible if 
had injected in previous year, over 14 years old, and 
spoke English or Spanish. Prospective cohort study. 
NZ 
Aus 
Aus 
Aus 
US 
Aus 
US 
Loxley (1995) 
MacDonald 
(2000) 
NCHECR (2006a) 
Van Beek (1994) 
Zeldis (1992) 
Those who last injected opiates at 
greater risk than those who last 
injected amphetamines 
Methadone/heroin users at greater 
risk than amphetamine users 
Those who inject heroin had 
higher sharing rates than those 
who inject amphetamines 
Higher in opiate users than 
stimulant users 
Heroin users at greater risk than 
amphetamine users 
n = 872. IDU from Adelaide, Melbourne, Sydney, and Aus 
Perth recruited by advertising with agencies (e.g. 
NSPs, health centres) and snowballing. Cross- 
sectional design. 
n = 4,141. IDU who had attended selected NSP sites 	Aus 
around Australia 1995 — 1997. Repeated cross- 
sectional surveys. 
n = 11,229. IDU who had attended NSP sites across 	Aus 
Australia. Cross-sectional survey. 
n = 201. All IDU who had attended a primary health 	Aus 
care facility in central Sydney who had undertaken 
HCV testing. Retrospective cross-sectional study. 
n = 585. IDU enrolled in drug treatment programs. 	US 
Cohort study. 
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Cocaine and other Psychostimulants 
Diaz (2001) 
Garfein (1996)* 
Garfein (1998) 
Guadagnino 
(1995) 
Maher (2004) 
Those who inject cocaine or 
speedball at greater risk than those 
who inject heroin and crack 
Users of cocaine in the last 6 
months at greater risk than those 
who haven't used cocaine in the 
last 6 months 
Users of cocaine and speedball 
exclusively or with other drugs at 
greater risk than those who don't 
use cocaine or speedball. 
Cocaine users at greater risk than 
non-cocaine users 
Cocaine users at greater risk than 
n = 557. IDU aged 18 — 29 who had injected in last 6 	US 
months and had injected for less than 3 years. Street 
recruited. Cross-sectional design. 
n = 716. Clients with history of IDU in last 10 years 	US 
recruited from health centres and probation offices. 
Cohort study. 
n = 229. IDU aged 18 —29 years. Recruited through 	US 
community outreach. Prospective cohort study. 
n = 146. Male heterosexual IDU (injected in the past 	Italy 
12 months) attending methadone maintenance clinic. 
Cross-sectional design. 
n = 372. IDU in South-West Sydney with history of 	Aus 
amphetamine users 
Cocaine users at greater risk than 
heroin and 'other drug' users. 
Cocaine users at greater risk than 
heroin or 'other drug' users 
Study examined last drug injected: 
stimulants (cocaine or `speed'), 
heroin or opiates, methadone, 
polydrugs, 'other'/not reported. 
Those who inject cocaine at 
greater risk than those who do not 
inject cocaine 
IV cocaine users. No comparison 
group reported. 
Type of drug previously or 
currently injected. 
Benzodiazepines, methadone, 
cocaine, heroin. 
Polydrug users at greater risk than 
primarily opiate, primarily 
stimulant, steroids, and 'unknown' 
drug users. 
Polydrug users at greater risk than 
those who use one drug 
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IDU in last 6 months and HCV serostatus not known 
to be positive. Recruited using word-of-mouth and 
snowballing methods. Cross-sectional design. 
n = 368. HCV negative IDU who had injected drugs 	Aus 
in the past 6 months. Recruited through direct 
approaches, outreach, NSPs, methadone and sexual 
health clinics. Prospective cohort study. 
n = 215. IDU who had injected drugs in the past 6 	Aus 
months and were seronegative or had unknown HCV 
serostatus. Recruited through outreach, methadone 
clinics, and NSPs. Prospective cohort study. 
n = 1,005. All IDUs who had attended 21 NSPs 	Aus 
across Australia in a one week period in March 1995. 
Cross-sectional survey. 
n = 1,356. Clients with history of IDU in last 10 years US 
recruited from health centres and probation offices. 
Cohort study. 
n = 746. IDU who had attended a drug treatment 	Italy 
centre. Case-control study. 
n = 346. IDU and non-IDU recruited at methadone 	Netherlan 
dispensary sites and STD clinic. Prospective cohort 	ds 
design. 
n = 773. Drug users (injecting & non-injecting) who 	UK 
had hepatitis serology testing between 1992 and 1996 
at public health facilities. Retrospective cross- 
sectional design. 
n = 1,078. Clients of BBV prevention centre with 	Aus 
history of IDU. Retrospective cohort study. 
Maher (2006)* 
Maher (2007)* 
MacDonald 	 .= 
(1997) 
Thomas (1995)* 
Rezza (1996) 
Van den Hoek 
(1990) 
Polydrugs 
Lamden (1998) 
Van Beek (1998)* 
Key: 
T denotes Drug Choice is a significant predictor of increased risk 
= denotes Drug Choice non-significant factor 
*indicates studies of particularly high quality due to design or power 
Sexual Orientation 
Sexual orientation has also been examined within the literature as a possible 
demographic factor which impacts on HCV transmission or the likelihood of sharing 
injecting equipment. While there has been no specific mention as to why this 
variable is consistently examined within the existing literature, one would assume 
that this factor is of interest to researchers to determine whether some cultural 
difference which exists in this population may alter or contribute to the risk of BBV 
transmission or the sharing of injecting equipment. 
A thorough examination of the literature indicates that this factor does not 
reliably influence one's likelihood of either sharing injecting equipment or the 
transmission of BBVs such as HCV. By far the majority of studies report this 
finding, including those with strong methodology. For instance, Hagan et al. (1999) 
report that an 1DU's sexual orientation does not predict HCV seropositivity despite 
this study utilising sound methodological procedures including having an ample 
number of participants, and using a cohort design where the participants were 
followed up over time. In the review conducted, only a minority of studies report that 
heterosexuals are at an increased risk, and even fewer studies report that 
homosexuals or bisexuals are at a greater risk than other sexual identities. Please 
refer to table 6 below for details of the studies which examine this factor in BBV 
transmission and the sharing of injecting equipment. 
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Chetwynd (1995) 
Crofts (1994)* 
Diaz (2001) 
Donohue (1991) 
Garfein (1996)* 
Garfein (1998) 
Hagan (1999)* 
Loxley (1995) 
MacDonald (1997) 
Patti (1993) 
Thomas (1995)* 
Treloar (2003) 
Van Beek (1994) 
Van Beek (1998)* 
Higher in heterosexuals than 
homosexual and bisexual 
Higher in heterosexual than 
other orientations 
Higher in bisexual and 
homosexual than heterosexual 
Higher in heterosexual 
Higher in heterosexual than bi-
or homosexual 
Higher in heterosexual than 
homosexual 
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Table 6 
Findings of Studies Investigating Sexual Orientation as a predictor of HCV Transmission and Equipment Sharing 
Study 	HCV 	Sharing 	Group at Greater Risk 	 Study Characteristics 	 Origin 
n = 116. IDU had had attended a methadone treatment clinic in 	NZ 
Christchurch. Cross-sectional design. 
n = 315. IDU recruited through social networks, community 	Aus 
agencies and prisons. Cohort design. 
n = 557. IDU aged 18 —29 who had injected in last 6 months and 	US 
been injecting for less than 3 years. Street recruited. Cross-sectional 
design. 
n = 225. IDU from Baltimore area enrolled in another study of HIV 	US 
infection. Prospective cohort study. 
n = 716. Clients with history of IDU in last 10 years recruited from 	US 
health centres and probation offices. Cohort study. 
n = 229. IDU aged 18 —29 years. Recruited through community 	US 
outreach. Prospective cohort study. 
n = 647. IDU recruited from drug treatment, corrections, and social 	US 
service agencies. Eligible if had injected in previous year, over 14 
years old, and spoke English or Spanish. Prospective cohort study. 
n = 872. IDU from Adelaide, Melbourne, Sydney, and Perth 	Aus 
recruited by advertising with agencies (e.g. NSPs, health centres) 
and snowballing. Cross-sectional design. 
n = 1,005. All IDUs who had attended 21 NSPs across Australia in a Aus 
one week period in March 1995. Cross-sectional survey. 
n = 645. Regular IV heroin users who had attended methadone 	Italy 
maintenance centres in Rome. Cross-sectional design. 
n = 1,356. Clients with history of IDU in last 10 years recruited from US 
health centres and probation offices. Cohort study. 
n = 336. IDU aged between 16 — 25 years who had injected for 4 	Aus 
years or less from urban Sydney, urban Brisbane, or rural NSW. 
Recruited by advertisements in NSPs, treatment centres, health 
clinics, local press etc. Cross-sectional design. 
n = 201. All IDU who attended a primary health care facility in 	Aus 
central Sydney who had undertaken HCV testing. Retrospective 
cross-sectional study. 
n = 1,078. Clients of BBV prevention centre with history of IDU. 	Aus 
Retrospective cohort study. 
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Villano (1997)* 	= 	 n = 1,593. Sample had history of IDU in last 10 years. Cohort study. US 
Mean follow up 6.5 years  
Key: 
T denotes homosexuality found to increase risk 
denotes homosexuality found to decrease risk 
= denotes Sexual Orientation non-significant factor 
*indicates studies of particularly high quality due to design or power 
Treatment 
An rpu's current drug treatment status is also often considered as a 
contributing factor to BBV transmission. It would be hoped that being engaged in 
treatment or having had past treatment would be associated with safer injecting 
practices, and therefore not be associated with HCV transmission and equipment 
sharing, however this does not appear to be the case. Some studies report that having 
a history of being in treatment is a significant factor, however a substantial number 
report that one's treatment status or history of treatment has no impact on BBV 
transmission or the sharing of injection equipment (see Table 7 below). A review of 
the literature would seem to suggest that this factor is not consistently predictive of 
risky injecting practices. It should be noted however, that studies which demonstrate 
that treatment has a significant impact report varying treatment conditions. For 
instance, some report that a history of methadone treatment impacts on HCV 
transmission, while others report that current treatment is associated, and still others 
report that not being in drug treatment is related to HCV transmission. Taken as a 
whole then, it would appear that an IDU's treatment status cannot be said to be 
predictive of HCV transmission, nor of the sharing of injecting equipment largely 
due to contamination by these extraneous factors. 
The reason for this lack of significance as a predictor variable may be that it 
is not until IDU experience acute symptoms associated with unsafe injecting that 
treatment is sought. Once in treatment, risk behaviours may decrease for that period, 
but then increase once symptoms have resolved. This is, of course, hypothetical and 
has not been examined in detail in a systematic literature review to date. 
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Table 7 
Findings of Studies Investigating Treatment Status as a predictor of HCV Transmission and Equipment Sharing 
Study 	HCV 	Sharing 	 Notes 	 Study Characteristics 	 Origin 
n = 303. IDU recruited by peer workers through social networks, 	Aus 
community agencies, and prisons. Prospective cohort study. 
n = 100. Opiate users in and out of treatment. Recruited by 	Aus 
advertisements in waiting rooms of methadone clinics and health 
centres. Cross-sectional design. 
n = 557. IDU aged 18 —29 who had injected in last 6 months and 	US 
had been injecting for less than 3 years. Street recruited. Cross-
sectional design. 
n = 416. Participants had injected monthly for past 6 months. 	Aus 
Recruited via snowballing, posted advertisements, NSP sites. 
Cross-sectional design. 
n = 773. Drug users (injecting & non-injecting) who had hepatitis 	UK 
serology testing between 1992 and 1996 at public health facilities. 
Retrospective cross-sectional design. 
n = 872. IDU from Adelaide, Melbourne, Sydney, and Perth 	Aus 
recruited by advertising with agencies (e.g. NSPs, health centres) 
and snowballing. Cross-sectional design. 
n = 4,141. IDU who attended selected NSP sites around Australia 	Aus 
1995 — 1997. Repeated cross-sectional surveys. 
n = 372. IDU in South-West Sydney with history of IDU in last 6 	Aus 
months and HCV serostatus not known to be positive. Recruited 
using word-of-mouth and snowballing methods. Cross-sectional 
design. 
n = 368. HCV negative IDU who had injected drugs in the past 6 	Aus 
months. Recruited through direct approaches, outreach, NSPs, 
methadone and sexual health clinics. Prospective cohort study. 
n = 215. IDU who had injected drugs in the past 6 months and 	Aus 
were seronegative or had unknown HCV serostatus. Recruited 
through outreach, methadone clinics, and NSPs. Prospective 
cohort study. 
n = 746. IDU who had attended a drug treatment centre. Case- 	Italy 
control study. 
n = 1,356. Clients with history of IDU in last 10 years recruited 	US 
from health centres and probation offices. Cohort study. 
Crofts (1993)* Women with history of 
methadone treatment. 
Darke (1990) 	 Not being in current treatment 
associated with BBV risk 
behaviour 
Diaz (2001) 	 Being in treatment. 
Dwyer (2002) 	 Previous, but not current 
treatment 
Lamden (1998) 
Loxley (1995) 
MacDonald (2000) History of methadone treatment. 
Maher (2004) 	 Not in drug treatment over the last 
year associated with increased 
risk. 
Maher (2006)* 
Maher (2007)* 
Rezza (1996) 	 Methadone treatment in previous 
6 months 
Thomas (1995)* 	 History of drug treatment. 
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Van Beek (1998) 	= 	 n = 1,078. Clients of BBV prevention centre with history of IDU. 	Aus 
Retrospective cohort study.  
Key: 
T denotes treatment involvement increases risk 
1 denotes treatment involvement decreases risk (alternatively, not being in treatment increases risk) 
= denotes Treatment Status non-significant factor 
*indicates studies of particularly high quality due to design or power 
Accommodation 
Accommodation status is also examined as a possible predictive variable for 
the risk of transmission of HCV and the sharing of injecting equipment, however 
based on the literature reviewed it appears that whether one is in stable or unstable 
housing does not make a difference in this regard. Most studies report that this factor 
is not predictive of BBV transmission risk, and only one study found unstable 
housing to be a risk-factor. This study, conducted by Dwyer et al. (2002) was a 
cross-sectional design, and therefore deviates in the quality of methodology when 
compared with the other studies, all of which utilise longitudinal designs and can 
demonstrate changes over time. However, it should be noted that this study is the 
only study reviewed which was conducted in Australia, as opposed to the United 
States and the disparate findings may reflect geographical differences. 
The lack in finding accommodation status as a predictor for risk of BBV 
transmission and sharing of injecting equipment is somewhat surprising. It would not 
be unreasonable for one to assume that stable housing would produce more safe 
injecting practices when compared with unstable housing environments. Stable 
housing would presumably allow one to set up a sterile injecting environment which 
allows the IDU to inject in an unhurried manner, allowing safe injecting. Unstable 
housing, by contrast, may require the IDU to inject in an environment which 
necessitates hurried injecting and which is less sterile, such as is the case with street-
based injecting. Indeed, street-based injecting has been found to be associated with 
BBV transmission (Maher, Dixon, Lynskey, & Hall, 1998; Strathdee et al., 2001). 
When an IDU is injecting in these environments, a pressure exists to inject quickly so 
as not to be seen by the police, members of the public, and other users (Southgate et 
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al., 2003). Unfortunately, the literature reporting that unstable housing does not 
impact on the sharing of injecting equipment or on BBV transmission risk does not 
elaborate on this finding. At this stage, the reason for the result is unclear. 
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Table 8 
Findings of Studies Investigating Accommodation Status as a predictor of HCV Transmission and Equipment Sharing 
Study 	HCV 	Sharing 	 Notes 	 Study Characteristics 	 Origin 
Diaz (2001) = n = 557. IDU aged 18 —29 who had injected in last 6 months and 	US 
been injecting for less than 3 years. Street recruited. Cross-sectional 
design. 
Dwyer (2002) 	 Those with unstable 	n = 416. Participants had injected monthly for past 6 months. 	Aus 
accommodation at greater risk Recruited via snowballing, posted advertisements, NSP sites. Cross-
sectional design. 
Evans (2003) 	 = 	 n = 844. Recruited by street outreach, eligible if injected drugs in 	US 
the past month, under 30 years old, and spoke English. Cross- 
sectional design. 
Hagan (2001)* 	 = 	 n = 317. Clients who had injected in the past year, were over 14 	US 
years old, and spoke English or Spanish were eligible. Recruited 
from drug treatment and correction centres. Follow up 1 year later. 
Prospective cohort study. 
Thomas (1995)* 	 = 	 n = 1,356. Clients with history of IDU in last 10 years recruited 	US 
from health centres and probation offices. Cohort study. 
Villano (1997)* 	 = 	 n = 1,593. Sample had history of IDU in last 10 years. Cohort 	US 
study. Mean follow up 6.5 years  
Key: 
I denotes unstable accommodation increases risk 
denotes unstable accommodation decreases risk 
= denotes accommodation status non-significant factor 
*indicates studies of particularly high quality due to design or power 
Education 
Similarly, the amount of formal education that an 1DU has received has been 
found not to have an impact on whether they are at risk for BBV transmission or the 
sharing injecting equipment. As can be seen in Table 9 below, the majority of studies 
find that education level is not a predictive factor. Among the studies reviewed, only 
a minority found that a relationship existed. Atler et al. (1999) report that education 
is a significant factor for HCV transmission whereby those with lower education 
levels are at a greater risk. While this is so, this finding cannot be viewed with the 
same veracity as other studies which examine education as a risk factor as this 
sample comprised those from the general population rather than solely examining 
DU. 
The reason for education not impacting on the risk for the transmission of 
HCV or for the risk of sharing injecting equipment is not examined in the literature 
reviewed. However, it could be hypothesised that the participants in these studies 
generally have a lower education level than the general population. The population 
captured in studies such as those reviewed are limited to those presenting to public 
treatment facilities and Needle and Syringe Programs (NSPs), and therefore do not 
generally include the more high functioning IDU who are not enrolled in treatment 
programs or attend NSP facilities. Considering this, the population recruited for such 
studies is not representative of the actual 1DU population, instead reflecting those 
who are lower functioning. In this way, these studies may be inherently biased, 
reflecting those who are more likely to have lower education levels. If this is the 
case, the range of years in education may not be extensive enough to detect a 
difference in education level as it applies to risk in this context. Of course, the 
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observed result may simply reflect a real phenomenon where one's level of education 
simply does not have any predictive value to BBV transmission risk. 
43 
Table 9 
Findings of Studies Investigating Education as a predictor of HCV Transmission and Equipment Sharing 
Study 	HCV 	Sharing 	 Notes 	 Study Characteristics 	 Origin 
Atler (1999) Lower education levels 	12 	n = 21,241. Serology testing conducted on those 6 years and older 	US 
years) at greater risk than those 	who participated in a national health survey 1988 — 1994. Not all 
with higher education (> 12 	participants IDU. Cross-sectional study. 
years) 
Chang (1998) 
Dwyer (2002) 
Evans (2003) 
Garfein (1996)* 
Maher (2006)* 
Thomas (1995)* 
Treloar (2003) 	 1 	Lower education levels (< grade 
10) at greater risk than those 
with higher education (> grade 
10) 
Villano (1997)* 
n = 934. Participants were drug users (injecting and non-injecting) 	Taiwan 
recruited from a drug treatment centre and a prison. Cross-sectional 
design. 
n = 416. Participants had injected monthly for past 6 months. 	Aus 
Recruited via snowballing, posted advertisements, NSP sites. Cross-
sectional design. 
n = 844. Recruited by street outreach, eligible if injected drugs in 	US 
the past month, under 30 years old, and spoke English. Cross- 
sectional design. 
n = 716. Clients with history of IDU in last 10 years recruited from 	US 
health centres and probation offices. Cohort study. 
n = 368. HCV negative IDU who had injected drugs in the past 6 	Aus 
months. Recruited through direct approaches, outreach, NSPs, 
methadone and sexual health clinics. Prospective cohort study. 
n = 1,356. Clients with history of IDU in last 10 years recruited 	US 
from health centres and probation offices. Cohort study. 
n = 336. IDU aged between 16 — 25 years injecting for 4 years or 	Aus 
less from urban Sydney, urban Brisbane, or rural NSW. Recruited 
by advertisements in NSPs, treatment centres, health clinics, local 
press etc. Cross-sectional design. 
n = 1,593. Sample had history of IDU in last 10 years. Cohort 	US 
study. Mean follow up 6.5 years  
Key: 
T denotes higher education reduces risk 
denotes lower education increases risk 
= denotes education is a non-significant factor 
*indicates studies of particularly high quality due to design or power 
Ethnicity 
It is not clear whether one's ethnicity is a risk factor for HCV transmission or 
the sharing of injecting paraphernalia. Some studies report that this makes no 
difference, while others report that ethnicity does have an impact (see Table 10). 
Even amongst the more well-designed studies which utilise prospective cohort 
designs with large samples and serological testing (eg. Garfein et al., 1996; Thomas 
et al., 1995) discrepancy exists. While this is so, one study reports that the Afro-
American race is at more risk for HCV transmission, while the other concludes that 
there is no effect of ethnicity on one's propensity to be infected with HCV. 
In Australia, several studies from Maher and colleagues (Maher et al., 2006; 
Maher et al., 2007) with sound methodology suggest that ethnicity is a predictive 
factor. However, while some studies such as Maher's indicate that there is a 
significant effect of ethnicity, no one particular race has found to be consistently 
predictive and groups may be broad (eg. 'other' race in comparison to the dominant 
group in the population under study) and therefore provide limited information as to 
the ethnic backgrounds that are more at risk. Taking this literature as a whole then, it 
would appear that no particular race is more at risk than others in BBV transmission 
and equipment sharing. 
The reason for a lack of clear findings in studies examining ethnicity as a 
factor may be due to research investigating minority status in the majority cultural 
context, rather than about 'race' as such. This is problematic, as ethnic minorities can 
be disadvantaged when compared with the majority. For instance, the Indigenous 
population in Australia underperform when compared with the national population in 
areas such as literacy, numeracy, student attendance, retention into secondary 
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education (Commonwealth of Australia, 2001) and therefore relationships with BBV 
risk behaviours is more complicated than simply examining race. The factor of 
'ethnicity' in reality may comprise a number of other contributing factors, such as 
education as outlined above. While this is one possible explanation as to why 
ethnicity is not clearly identified within the current literature as a risk factor for BBV 
transmission and the sharing of injecting equipment among the IDU population, 
studies which examine this variable do not commonly provide an explanation as to 
why this variable is under examination as a possible factor, nor explain why it is not 
consistently reported as a risk factor in existing research. 
Table 10 
Findings of Studies Investigating Ethnicity as a predictor of HCV Transmission and Equipment Sharing 
Study 	HCV 	Sharing 	Studies Showing that 	Group at Greater 
Asian Ethnicity is Risk 
predictor of HCV 
transmission 
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Study Characteristics 	 Origin 
Australian Studies 
Dwyer (2002) 
Maher (2004) 
Maher (2006)* 
Maher (2007)* 
Southgate (2003) 
Treloar (2003) 
Asian greater 
risk than non-
Asian 
Prospective 
cohort study, (n 
= 368). Ethnic 
minority at 
greater risk than 
non-ethnic 
minority 
Culturally and 
Linguistically 
Diverse (CALD) 
background 
greater risk than 
Anglo- 
Australian. 
Asian and 
Indigenous at 
greater risk 
n = 416. Participants had injected monthly for past 6 	Aus 
months. Recruited via snowballing, posted 
advertisements, NSP sites. Cross-sectional design. 
n = 372. IDU in South-West Sydney with history of IDU Aus 
in last 6 months and HCV serostatus not known to be 
positive. Recruited using word-of-mouth and snowballing 
methods. Cross-sectional design. 
n = 368. HCV negative IDU who had injected drugs in 	Aus 
the past 6 months. Recruited through direct approaches, 
outreach, NSPs, methadone and sexual health clinics. 
Prospective cohort study. 
n = 215. IDU who had injected drugs in the past 6 months Aus 
and were seronegative or had unknown HCV serostatus. 
Recruited through outreach, methadone clinics, and 
NSPs. Prospective cohort study. 
n = 2,738. Clients who had attended NSP sites over a one Aus 
week period in October 2001. Cross-sectional study. 
n = 336. IDU aged between 16 — 25 years who had 	Aus 
injected for 4 years or less from urban Sydney, urban 
Brisbane, or rural NSW. Recruited by advertisements in 
NSPs, treatment centres, health clinics, local press etc. 
Cross-sectional design. 
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American Studies 
n = 21,241. Serology testing conducted on those 6 years 	US 
and older who participated in a national health survey 
1988 — 1994. Not all participants IDU. Cross-sectional 
study. 
n = 557. IDU aged 18 —29 who had injected in last 6 	US 
months and had been injecting for less than 3 years. 
Street recruited. Cross-sectional design. 
n = 28 (case patients), n = 38 (control patients). 	US 
Participants were IDU who had attended a health 
department. Case-control design. 
n = 716. Clients with history of IDU in last 10 years 	US 
recruited from health centres and probation offices. 
Cohort study. 
n = 1,356. Clients with history of IDU in last 10 years 	US 
recruited from health centres and probation offices. 
Cohort study. 
n = 1,184. IDU who attended a Baltimore NSP. Cohort 	US 
study. 
n = 585. IDU enrolled in drug treatment programs. 	US 
Cohort study. 
Atler (1999) 	 -= 
Diaz (2001) 	 = 
Hagan (1995) 
	 T 	 White race 
greater risk than 
non-white 
Garfein (1996)* 	= 
Thomas (1995)* 
	T 	 Afro-American 
race greater risk 
than non-Afro-
American. (n = 
1356) 
Valente (2001)* 
	T 	 'Other race' 
greater risk than 
African 
American. 
(n=1184) 
Zeldis (1992) 	 T 	 African 
American, 
Hispanic, and 
'other' greater 
risk than White 
race 
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European Studies 
Van Ameijden 	 n = 305. Drug users (injecting and non-injecting) were 	Netherlands 
(1993) 	 recruited from a methadone program clinic and STD 
clinic. Prospective cohort study. 
Key: 
is denotes Ethnicity is a significant predictor 
= denotes Ethnicity non-significant factor 
*indicates studies of particularly high quality due to design or power 
Prison History 
The high prevalence of HCV among the prison population has long been 
identified as a significant problem, both here in Australia and overseas. A national 
survey of the BBV status of Australian prison entrants in 2007 reported the 
prevalence of HIV in less than 1%, HCV in 35%, and core HBV anti-bodies in 21% 
of the sample (Butler & Papanastasiou, 2008). Of these prison entrants, 55% reported 
a history of IDU (Butler & Papanastasiou, 2008) and research indicates that a 
substantial portion of incarcerated offenders have had some exposure to illicit drugs. 
In 2001, the Australian Institute of Criminology conducted survey research with 
adult male offenders who were incarcerated. Of those surveyed, over 80% reported 
ever having used cannabis, heroin, amphetamines, or cocaine, and current regular use 
in the six months prior to imprisonment was reported by 62% of offenders (Makkai 
& Payne, 2003). A similar study conducted with female incarcerated offenders in 
2003 reports strikingly similar results, where over 80% reported ever having used 
drugs, and 62% reported being regular drug users in the six months prior to their 
arrest (Johnson, 2004). 
As Crofts et al. (1995) explains, a substantial number of prison entrants are 
injecting drug users and are in prison because of drug use and engagement in illegal 
activity in order to generate money for drugs. This relationship has been supported 
by both the female and male offenders reports cited above. While the progression of 
these offences appears to differ between the sexes, where in general criminal activity 
precedes illegal drug use in male offenders (Makkai & Payne, 2003), and in female 
offenders illegal drug use precedes criminal activity (Johnson, 2004), they are 
nevertheless clearly related. When these samples were asked as to whether they felt 
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that drug and alcohol abuse contributed to their offending, 41% of the female 
offenders (Johnson, 2004) and 51% of male offenders (Malckai & Payne, 2003) 
reported that there was a causal relationship. Attribution for this relationship was 
broadly categorised into economic compulsive effects, psychopharmacological 
effects of drugs, and that drugs and/or alcohol lead to crime. The male incarcerated 
offenders study also reports that while cash is the primary method to obtain illegal 
drugs, other methods include violence and trading stolen goods (Makkai & Payne, 
2003), again highlighting the link between illicit drug use and crime. 
As the above research highlights, there is a strong relationship between crime 
and drug use. Because injecting drug use is associated with the transmission of BBV, 
the prison population has a greater prevalence of BBV than the general population, 
leading to imprisonment logically being a risk factor for BBV transmission amongst 
TDUs. However, there is a double edged sword here, as IDU have a higher 
prevalence of BBVs due to their drug use and unsafe injecting practices, however 
once in prison there are further factors present which allow for the quick spread of 
viruses. In Australia, prisoners do not have access to sterile injecting equipment, 
which results in an increased likelihood of sharing, lending, and reuse amongst the 
prison population. Other prison practices such as tattooing and unprotected sexual 
intercourse contribute to the spread of viruses such as HIV, HCV, and HBV (Crofts 
et al., 1995). 
Indeed, the large majority of Australian studies find that having a prison 
history is a predictor of HCV infection, and evidence also suggests this is a risk 
factor for the sharing of injecting equipment (see Table 11). Some particularly well-
designed studies have been conducted showing this trend, and credence should be 
given to these studies. For instance, the study by Maher and colleagues (2006) 
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demonstrates strong methodology, where 368 1DU were followed up every three 
months until study completion at three years or until seroconversion. In terms of 
similar studies conducted overseas, the results of these indicate that prison history is 
not predictive of HCV transmission risk or of equipment sharing risk. Villano et al. 
(1997) demonstrates this in a study using strong longitudinal methods, where he 
followed up 1DU for a mean of 6.5 years. The reason for the differing results 
obtained in Australia compared with overseas studies is unclear. 
Chetwynd (1995) 
Crofts (1993)* 
Diaz (2001) 
Dwyer (2002) 
Lamden (1998) 
Maher (2004) 
Maher (2006)* 
MacDonald (2000) 
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Table 11 
Findings of Studies Investigating Prison History as a predictor of HCV Transmission and Equipment Sharing 
Study Characteristics 
n = 172. IV heroin users who presented to a drug treatment centre 
seeking entry to a methadone program. Cross-sectional design. 
n = 116. IDU who attended a methadone treatment clinic in 
Christchurch. Cross-sectional design. 
n = 303. IDU recruited by peer workers through social networks, 
community agencies, and prisons. Prospective cohort study. 
n = 557. IDU aged 18 —29 who had injected in last 6 months and 
had been injecting for less than 3 years. Street recruited. Cross-
sectional design. 
n = 416. Participants had injected monthly for past 6 months. 
Recruited via snowballing, posted advertisements, NSP sites. 
Cross-sectional design. 
n = 773. Drug users (injecting & non-injecting) who had hepatitis 
serology testing between 1992 and 1996 at public health facilities. 
Retrospective cross-sectional design. 
n = 372. IDU in South-West Sydney with history of IDU in last 6 
months and HCV serostatus not known to be positive. Recruited 
using word-of-mouth and snowballing methods. Cross-sectional 
design. 
n = 368. HCV negative IDU who had injected drugs in the past 6 
months. Recruited through direct approaches, outreach, NSPs, 
methadone and sexual health clinics. Prospective cohort study. 
n = 4,141. IDU who attended selected NSP sites around Australia 
1995 — 1997. Repeated cross-sectional surveys. 
n = 11,229. IDU who attended NSP sites across Australia. Cross-
sectional survey. 
n = 645. Regular IV heroin users who attended methadone 
maintenance centres in Rome. Cross-sectional design. 
n = 2,738. Clients who attended NSP sites over a week period in 
October 2001. Cross-sectional study. 
n = 405. Clients of drug abuse treatment centres, a hospital, and 
BBV prevention centre who had injected drugs in the last 3 
months. Cross-sectional design. 
n = 1,356. Clients with history of IDU in last 10 years recruited 
from health centres and probation offices. Cohort study. 
Origin  
Aus 
NZ 
Aus 
US 
Aus 
UK 
Aus 
Aus 
Aus 
Aus 
Italy 
Aus 
Germany 
US 
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Van Beek (1998)* 	T 	 History of imprisonment 	n = 1,078. Clients of BBV prevention centre with history of IDU. 	Aus 
Retrospective cohort study. 
Villano (1997)* 	= 	 n = 1,593. Sample had history of IDU in last 10 years. Cohort 	US 
study. Mean follow up 6.5 years.  
Key: 
t denotes prison history is a significant predictor of increased risk 
= denotes prison history non-significant factor 
*indicates studies of particularly high quality due to design or power 
Impulsivity 
The section above highlights that a variety of demographic variables have 
been implicated as being predictive of needle sharing. However, an area which has 
not been examined in detail within the existing literature, and which also may have 
an impact on needle sharing, is that of personality variables. In particular, the trait of 
impulsivity is one which logically would appear to influence one's decision 
regarding whether to share needles or not to share. One would expect that an 
individual impulsive in nature would not engage in a detailed and balanced decision 
making process, but rather would consider the immediate rewards of the situation 
and therefore choose to share, if placed in such a situation, in order to become 
intoxicated or to ameliorate withdrawal symptoms, disregarding the potential 
consequences of this behaviour. Since this factor has been little examined in the 
literature to date, it is one which is well worth investigation and therefore forms a 
substantial focus of the current study. The concept of impulsivity has received much 
attention in the personality literature over several decades, and the popular models 
and conceptualisations of impulsivity are reviewed briefly in the paragraphs which 
follow. 
Typically, impulsivity is conceptualised as a personality trait where 
behaviours involve rashness, a lack of foresight or planning, and a lack of reflection 
and deliberation (Dawe & Loxton, 2004). Within the psychological personality 
literature, much attention has been paid to this construct due to its obvious 
implications to risk-taking. However, the precise nature of this construct and the 
elements which comprise it has been the source of some contention among theorists. 
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While there have been many postulations as to the exact nature of this trait 
(e.g. Cloninger, 1987; Dawe & Loxton, 2004; Eysenck & Eysenck, 1978; Gray, 
1987; Zuckerman & Kuhlman, 2000), several key theories remain popular amongst 
the recent literature. Among these is Gray's behavioural inhibition and behavioural 
activation system (BIS/BAS) theory of personality (Gray, 1987). In his theory, Gray 
asserts that there are two key dimensions of personality which reflect the tendency 
for individuals to respond to environmental cues differently, depending on the 
sensitivity of two neurological systems. The first of these systems is the behavioural 
inhibition system (BIS). Neurologically, this system is thought to involve the 
septohippocampal system, which comprises the hippocampus proper, dentate gyrus, 
entorhinal cortex, subicular area, and the posterior cingulated cortex (Gray & 
McNaughton, 2000). The BIS is theorised to be responsible for controlling the 
experience of anxiety in response to environmental cues. Gray also contends that the 
activation of this system inhibits goal seeking behaviour due to the inhibition of 
behaviour which may result in negative outcomes. 
The second of Gray's dimensions is the behavioural activation system (BAS) 
which is believed to involve dopaminergic, particularly the mesolimbic 
dopaminergic pathways of the brain, as well as the catecholaminergic pathways 
(Dawe, Gullo, & Loxton, 2004; Stellar & Stellar, 1985). The activity of dopamine in 
these pathways is pivotal for reward and reinforcement and activates in response to 
reinforcers including food, sex, and drugs of abuse. The neural substrate of BAS has 
been found to share many similarities to the neural pathways which underlie the 
reinforcing effects of these experiences (Dawe et al., 2004), and therefore is also 
involved in the promotion of reinforcement and reward. It is postulated that those 
who have heightened BAS sensitivity are likely to engage in goal directed behaviour 
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and to experience pleasant emotions such as happiness when confronted with cues of 
possible reward. Gray asserts that the BAS system is analogous to impulsivity, in that 
those individuals who have a heightened BAS sensitivity are more sensitive to 
signals of reward and thus engage in behaviours to seek out these rewards while 
ignoring potential future punishment. In their development of a scale to assess BIS 
and BAS sensitivity, Carver and White (1994) further refined the BAS component 
into three subscales reflecting different aspects of behavioural activation. The 
'Reward Responsiveness' subscale focuses on positive responses to the occurrence 
of anticipation of a reward. The 'Drive' subscale comprises items relating to the 
persistent pursuit of desired goals. Finally, the Tun Seeking' subscale centres on the 
desire for new rewards as well as a willingness to approach a potentially rewarding 
event on the spur of the moment. 
Cloninger (1987) proposed that there are three main dimensions of 
personality, which he termed novelty seeking, harm avoidance, and reward 
sensitivity. He asserted that varying levels and combinations of these dimensions can 
explain individual differences in personality. The 'novelty seeking' dimension is 
most analogous to impulsivity, and Cloninger describes this personality dimension as 
"a heritable tendency toward intense exhilaration or excitement in response to novel 
stimuli or cues for potential rewards or exploratory activity in pursuit of potential 
rewards as well as active avoidance of monotony and potential punishment" (p. 575). 
He explains further that individuals who are high in the dimension of novelty seeking 
but lower in the other two dimensions are characterised as impulsive, exploratory, 
fickle, excitable, tempered, extravagant, and disorderly. Biologically, Cloninger 
(1987) explains that novelty-seeking traits reflect differences in the brian's 
'incentive' system, which is associated with changes in the modulation of dopamine 
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through nirgrostriatal, mesolimbic and mesofrontal projections. The author also notes 
that dopamine agonists such as amphetamines, cocaine, alcohol and opiates facilitate 
dopaminergic transmission and therefore behavioural activation. 
A further conceptualisation of impulsivity is Zuckerman's 'sensation seeking' 
construct. Initially Zuckerman examined sensation seeking in order to determine an 
individual's response to sensory deprivation (Zuckerman, 1971), however over time 
this has developed into determining the various components that lead to one 
behaving in an impulsive manner. Zuckerman's term 'sensation seeking' is 
synonymous with impulsivity and has recently been defined as "...a trait defined by 
the seeking of varied, novel, complex and intense sensations and experiences, and the 
willingness to take physical, social, legal, and financial risks for the sake of such 
experience" (cited in Zuckerman & Kuhlman, 2000). 
Eysenck's conceptualisation of personality is regarded as prominent work in 
this field. In particular, his concepts of impulsivity and venturesomeness are 
particularly significant. These concepts exist within Eysenck's Impulsiveness, 
Venturesomeness and Empathy (WE) questionnaire of the Eysenck Personality 
Scales (Eysenck & Eysenck, 1978). Within this theoretical framework, impulsivity 
refers to rash, unplanned impulsive behaviour without consideration of the 
consequences. On the other hand, venturesomeness refers to impulsive acts in which 
consequences have been weighed and considered to be acceptable risk. 
A number of scales have been developed to assess impulsivity in relation to 
each of these theoretical conceptualisations. Eysenck and colleagues (Eysenck & 
Eysenck, 1978) have developed the WE scale to assess their formulation of each of 
these constructs. The tri-dimensional personality questionnaire (TPQ) was developed 
by Cloninger (1987) as a measurement tool for his model of personality, which 
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includes the aspect of impulsivity which he termed novelty seeking. To assess Gray's 
notion of the existence of two motivational systems, Carver and White (1994) 
designed the BIS/BAS scales as a measure of one's dispositional sensitivity to each 
of these systems. Zuckerman (1978) has also developed a tool to assess sensation 
seeking, named the sensation seeking scale (SSS). 
In addition to the instruments mentioned above, an alternative measure of 
impulsivity is Arnett's (1994) Arnett Inventory of Sensation Seeking (AISS). This 
tool was developed as a result of dissatisfaction with other models of impulsivity, 
and in particular as a result of the limitations of the SSS which was then widely used. 
For instance, Arnett (1994) criticised the SSS on several grounds, including the fact 
that it used a forced choice format, used outdated language, referred to physical 
activities such as skiing and mountain climbing which may therefore elicit responses 
that reflect changes in age and physical ability rather than sensation seeking. Finally, 
Arnett (1994) highlighted that the scale was subject to a serious confounding factor — 
that it contains items on alcohol use, drug use, and sexual behaviour, which are the 
types of behaviour under examination in many studies which employ this scale. 
Arnett's (1994) AISS sought to address these flaws by providing a valid tool which 
uses a Likert-type response format, does not contain items that are intrinsically age-
related, and does not contain items that involve illegal or norm-breaking behaviour 
so as not to define sensation-seeking on the basis of rule breaking and to recognise 
that it can be expressed in a legal fashion. Arnett's scale also differed from 
alternative scales such as the SSS because it provided a focus not just on the novelty 
of stimulation, but also emphasised the role of the intensity of stimulation. In the 
conceptualisation of sensation seeking, novelty of stimulation refers to seeking out 
novel sensations while intensity of stimulation refers to seeking out sensations which 
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are intense in experience. For instance, items developed by Arnett (1994) to assess 
novelty include "I can see how it would be interesting to marry someone from a 
foreign country" and "I would have enjoyed being one of the first explorers of an 
unknown land", while items to assess intensity include "When I listen to music, I 
prefer it to be loud" and "I can see how it must be exciting to be in a battle during a 
war". Zuckerman's (1978) conceptualisation focussed on complexity of stimulation, 
however Arnett dropped this from the AISS due to research indicating that intensity 
was more of a defining quality of sensation seeking in comparison with complexity. 
Therefore, Arnett (1994) had addressed a number of limitations of the measurement 
of sensation seeking in the development of the AISS. 
While there have been a number of theories relating to the nature of 
impulsivity, there appears to be some overlap between the models, and accordingly 
many measures of impulsivity are correlated. For instance, Carver and White (1994) 
argue that Cloninger and Gray's models of impulsivity stem from essentially the 
same theoretical background and can be thought of as one and the same 
conceptualisation. While this must be recognised, the very existence of such a vast 
array of literature leads one to thinking that this is not a simple, unified, and 
unidimensional construct. Indeed, many researchers have subjected their theories and 
associated assessment tools to factor analyses, in an effort to more clearly define the 
impulsivity construct. As a result of such investigation, it is now generally accepted 
among theorists that impulsivity is in fact a multidimensional construct. 
So, if impulsivity is to be viewed as a multidimensional construct, how many 
factors are there and what are they? To attempt to answer this question and remove 
some of the ambiguity surrounding the different conceptualisations of impulsivity 
and the elements which comprise this construct, a series of factor analyses have been 
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conducted by a number of researchers. Even so, some of these studies reveal a two-
factor structure, while others conclude that impulsivity is comprised of three-factors. 
Still others propose that the structure of impulsivity is comprised of four factors (eg. 
(Jorm et al., 1998; Lynam & Miller, 2004; Whiteside, Lynam, Miller, & Reynolds, 
2005). These differing results may be explained by the fact that these researchers are 
utilising different measures of impulsivity (eg. the Urgency, Premeditation, 
Perseverence and Sensation Seeking (UPPS) impulsivity scale, the BIS/BAS scales) 
and applying factor analyses to different data sets. This then creates a differing 
structure which is less likely to produce the same number of factors. 
The existence of such different views of the number of factors of impulsivity 
meant that the answer to the initial question remained unanswered. Dawe, Gullo and 
Loxton (2004) therefore conducted a comprehensive review of this body of literature 
to further reduce this haziness and concluded that most factor analytic studies 
determine that impulsivity is a structure comprised of two distinct factors. The first 
of these factors can be described as rash impulsiveness, and reflects a tendency to act 
rashly and without consideration of consequences. This domain is derived from 
scales such as Eysenck's impulsivity scale, Cloninger's Novelty Seeking Scale, and 
Zuckerman's Sensation Seeking Scale. The second factor which is seen in the 
literature and which Dawe et al. (2004) identify in their review of the literature more 
closely resembles Gray's BAS conceptualisation. This can be referred to as 'reward 
sensitivity', and reflects individual variation in sensitivity to rewarding stimuli in the 
environment. Dawe et al. (2004) apply this model to substance abuse and propose 
that those individuals who are prone to abusing drugs have a more sensitive BAS, 
and are therefore more receptive to the rewarding effects of drugs and other stimuli. 
The authors also state that this model is also related to response disinhibition, which 
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reflects pre-existing individual differences in frontal cortex functioning which can be 
exacerbated by chronic drug use. Independently conducted confirmatory factor 
analysis supports the notion of these two components to impulsivity (Franken & 
Muris, 2006). 
Impulsivity and risk-taking remain an area of great interest to researchers 
because of the behaviours that can occur in this context, and which potentially have 
serious negative consequences. The link between impulsivity and various behaviours 
has been examined by a meta-analysis (n = 194) by Bogg and Roberts (2004). These 
authors examined the relationship between various facets of conscientiousness and 
health related behaviours, where conscientiousness is defined as "individual 
differences in the propensity to follow socially prescribed norms for impulse control, 
to be task- and goal-directed, to be planful, to delay gratification, and to follow 
norms and rules" (John & Srivastava, 1999, cited in Bogg & Roberts, 2004). 
Therefore, conscientiousness is inversely related to the construct of impulsivity. This 
research revealed that the facet of conscientiousness referred to as self-control (i.e. 
the propensity to inhibit impulsive thoughts, feelings, and behaviours) was 
negatively correlated to a variety of health related behaviours, including excessive 
alcohol use (meta-analysed r.-.29), drug use (r.-.24), risky driving (r.-.25), and 
risky sex (r.-.15). Therefore, it can be seen that rash impulsiveness is associated 
with a number of behaviours which have the propensity to result in negative health 
outcomes. Studies by Franken, Muris, and Georgieva (2006) and Johnson, Turner, 
and Iwata (2003) provide further support for the association between drug use and 
impulsivity, finding that people dependent on drugs had higher BAS scores than 
controls. Other research also supports the relationship between impulsivity and drug 
use (Conrod, Pihl, Stewart, & Dongier, 2000; Johnson et al., 2003). The relationship 
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between sexual risk taking and impulsive personality traits has also been confirmed 
by other research (Hoyle, Fejfar, & Miller, 2000; Mashegoane, Moalusi, Ngoepe, & 
Peltzer, 2002; Trobst, Herbst, Masters III, & Costa Jr, 2002). 
As well as being associated with the HP//AIDS risk behaviour of risky 
sexual practices, impulsivity has also been associated with needle sharing amongst 
IDU populations. This link was investigated in a study by Odum and colleagues 
(Odum, Madden, Badger, & Bickel, 2000) using a sample of opioid-dependent 
patients enrolled in an outpatient substance abuse treatment program. Using a 
titration procedure, the authors investigated the indifference points at various delays 
regarding their preference for obtaining hypothetical money and heroin outcomes, 
either immediately or after a delay. Participants were also asked to choose between 
whether they would share a needle to inject heroin immediately with a previously 
used needle, or wait one week to inject heroin with a sterile needle. The results of the 
study revealed that those participants who chose to use the non-sterile needle rejected 
the delayed money option (and therefore chose the immediate money outcome) more 
often than those participants who chose not to share needles, suggesting that the 
impulsive preferences were not simply specific to the context of heroin. The authors 
conclude that needle sharing may be a result of delayed consequences not being 
considered, or not having an impact on LDU current behaviour during decision-
making processes. Therefore, it appears that those 1DU with a propensity not to 
consider the consequences of their behaviour and who are therefore impulsive, are 
more likely to share needles. 
The association between impulsivity and needle sharing was also found in a 
study by Trobst and colleagues (Trobst et al., 2002). These authors found that those 
who were deemed at a high-risk for HP//AIDS due to their engagement in a variety 
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of sexual (e.g. sex with IDU, condom use) and substance use (e.g. sharing needles) 
risk behaviours were significantly more impulsive than those deemed to be at a low 
or medium risk. In this study, impulsivity was measured using the Impulsivity facet 
of Neuroticism in the Revised NEO Personality Inventory. The group of high-risk 
participants who exhibited impulsive personality traits were described by the authors 
as having particular difficulties with resisting cravings and urges. Brook et al. (1997) 
also found a relationship between what they termed poor emotional control and 
needle-sharing in sample of female 1DU. The authors define poor emotional control 
as impulsivity as measured by the Personality Research Form, as well as deviant 
sexual behaviour. 
It is clear from the literature that there is a link between substance abuse and 
the personality characteristic of impulsivity. To elucidate the reasons for this link, a 
field of research has been expanding in relation to the neurobiological correlates with 
impulsivity. From this perspective, researchers in this field propose that this 
association may be explained, at least partially, by neurobiological changes within 
the brain which can occur as the result of drug dependence and addiction. Robinson 
and Berridge (2003) state that addictive drugs affect the neural circuitry involved in 
pleasure, incentive motivation, and learning, and that these can in turn affect 
impulsivity. The reward system is said to include dopamine projections for the 
ventral tegmental area and substantia nigra to the nucleus accumbens (NAcc) and 
striatum, as well as glutamate inputs from the prefrontal cortex, amygdala and 
hippocampus. The reinforcing effect of drugs is thought to at least partially be 
explained by increases in mesolimbic dopamine release. Koob (2006) states that four 
neurotransmitters/neuromodulators play a critical role in the reinforcement of drugs, 
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those being the mesolimbic dopamine, opioid peptide, y-amiobutyric acid (GABA), 
and endocannabinoid systems. 
The role of the neurotransmitter serotonin has been found to be of pivotal 
importance in the development and behavioural expression of impulsivity. Animal 
studies have examined the role that serotonin plays in impulsivity by varying 
serotonergic neurotransmission as well as through lesions in brain sites where the 
neurotransmission of serotonin is abundant. Evenden (1999) notes that one of the 
most significant discoveries was made by Soubrie (1986) who found that when the 
neurotransmission of serotonin is reduced in animals, these animals exhibit difficulty 
in being able to adopt passive or waiting attitudes, thereby effectively exhibiting 
impulsive behaviour. Lesion studies such as that by Fletcher (1995) have also 
demonstrated that the reduction of serotonergic activity within the median raphe 
nuclei modulates behavioural inhibition. The role of serotonin in impulsivity has also 
received support from studies with human patients. For example, Linnoila, 
Virkkunen, George, and Higley (1993) found that in a sample of aggressive 
individuals, cerebro-spinal fluid (CSF) 5-hydroxindoleacetic acid (5-HIAA) was 
reduced only in those participants whose aggression was impulsive in nature. These, 
along with other existing research provide compelling evidence that serotonin forms 
at least part of the biological basis of impulsivity. 
A somewhat complementary position is one which highlights the role of the 
frontal lobes in impulsive behaviour. The involvement of the frontal lobes is essential 
for controlling impulses and inhibiting socially unacceptable behaviour, and when 
damage to this area occurs, impulsive behaviour is typically seen. For example, 
Miller (1992) conducted a series of studies in patients who had undergone a frontal 
lobectomy and found that patients exhibited impulsive behaviour in the form of 
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making a guess of what an object or a missing word was based on little information. 
While this is so, the patients were able to judge their chances of success as well as 
controls, however they exhibited a poorer ability to withhold making a guess until 
they had more information. Further research using monkeys found that damage to the 
frontal cortex, or more specifically the vetromedial frontal cortex, results in a 
reduced ability to modify behaviour in the face of changed reinforcement patterns 
when this area is lesioned (Roskilde, 1979). Robbins (1996) contends that, with 
damage, behaviour occurs not as a result of reasoned consideration, but due to 
previously conditioned responses. These responses, however, may not be appropriate 
for the given situation and can therefore be inappropriate, and resemble impulsive 
behaviour. It should be noted that the frontal lobes receive substantial dopaminergic 
and serotonergic inputs. 
Within the substance abuse literature, supporters of the position that changes 
within the frontal lobes are important in understanding impulsivity, argue that as a 
result of continued and prolonged drug use, damage to the frontal lobes occur, 
leading to a reduced ability to regulate and inhibit impulses. Yiicel, Lubman, 
Solowij, and Brewer (2007) conducted a review of existing literature covering the 
neurobiological and neuropsychological correlates of long-term drug addiction. The 
authors report that a clear conclusion can be drawn; that across the drug classes, 
extensive neurological deficits can be seen in those who engage in long-term 
substance use. Primary among these deficits is impairment to executive function and 
inhibitory control; however deficits were also apparent in areas of working memory 
and decision making. These deficits were in many cases apparent through both 
neuroimaging technology and as a result of neuropsychological testing. For example, 
research into heavy and long-term alcohol drinkers found that among other 
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neuropsychological impairments, deficits were found within the domain of executive 
functions (problem solving, response inhibition, decision-making, and judgement). 
Structural magnetic resonance imaging (MRI) studies have found structural neuronal 
injury and volume loss in areas of the frontal lobe, temporal lobe, and cerebellum 
(Mann et al., 2001; Pfefferbaum, Sullivan, Mathalon, & Lim, 1997). This type of 
damage is consistent with results seen in neuropsychological testing amongst this 
population. Similar results have been seen in other drug classes, including opiates, 
cannabis, inhalants, and MDMA, with areas affected including the frontal, temporal, 
parietal, basal ganglia, and cerebellar brain systems. In particular, Yiicel and 
colleagues report that the ventromedial prefrontal cortex (vm-PFC) and the dorsal 
subregion of the anterior cingulated cortex (d-ACC) have been identified as playing 
critical roles in inhibitory control. 
The difficulty for researchers in this field, however, is in extricating whether 
these neuropsychological deficits are solely due to drug use or are a complex 
interplay between a number of factors. Yiicel and colleagues (Yiicel & Lubman, 
2007; Yucel et al., 2007) explain that such factors can include a pre-existing 
vulnerability to impulsivity (e.g. genetic polymorphisms, personality characteristics, 
behavioural disorders), drug use patterns (e.g. duration of use, type of drug use, 
frequency), exposure to head injury, and so on, and these all have the ability to 
contribute to impulsive behaviour. While at this time the question about whether 
these effects can occur solely due to drug use, or due to pre-existing factors, or a 
combination, is unknown. However, Yiicel and Lubman (2007) state that what we 
can conclusively say is that those who exhibit these neurological dysfunctions are 
"likely to be an increased risk for making decisions that are impulsive, focussed on 
short-term gains, and lack inhibitory control"(p. 37). The association between 
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impulsivity and neurobiological changes, particularly within the prefrontal cortex 
and frontostriatal system, is therefore quite apparent. 
Yet another theoretical approach is one which essentially combines the 
abovementioned theories. This model hypothesises that there is a synergistic effect 
between heightened sensitivity to the rewarding stimuli through sensitisation of the 
mesolimbic dopamine system and the amygdala, combined with an inability to 
consciously inhibit impulsive behaviour, which may be the result of prefrontal 
dysfunction (Jentsch & Taylor, 1999). This position therefore draws on research 
suggesting that chronic drug use results in an augmentation of dopamine release 
within the reward system, but more specifically, the nucleus accumbens. This leads 
to sensitisation such that there is an increase in approach behaviour and responding 
in the presence of a conditioned reinforcer (eg. drug cues). Jentsch and Taylor (1999) 
also explain that the role of the amygdala is also an important one in elucidating the 
cause of impulsivity and drug addiction. The authors contend that neuroadaptations 
within this structure as a result of chronic drug use augment the associations made 
between stimuli and reward (eg. drugs, syringe, contextual factors), and these factors 
then lead to an increase in impulsive and drug-seeking behaviour. These factors, 
coupled with prefrontal dysfunction, mean that behaviour occurs in the context of 
increased disinhibition and recidivism to drug taking. 
As this brief review of literature into the neurobiology of impulsivity and 
addiction has indicated, understanding precisely what factors are at play 
neurobiologically to result in impulsive behaviour is by no means straight forward or 
clear cut. What is apparent, however, is that there are a number of areas which do 
play a role. As outlined above, this includes various neurotransmitter systems (such 
as serotonin, GABA, and dopamine), neurobiological changes in the frontal lobes 
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and NAcc, modulation of stress systems, and genetic factors. Following a 
comprehensive review of the literature within each field of research, Evenden (1999) 
concludes that across fields, researchers generally agree that impulsivity is 
constructed of a number of factors which operate independently as a result of 
different biological processes. In addition, these biological processes are likely to be 
more complex than simply one type of neurotransmitter, or one area of the brain and 
involve interactions between systems as well as between biological and social 
factors. The above review indicates support for this position. Regardless, the 
implications of this for the study of BBV transmission risk are that, while impulsivity 
may be influenced by pre-existing differences (such as organic or genetic reductions 
in dopaminergic function), neurological insult (such as prefrontal cortex lesions), or 
drug use (acute changes in dopaminergic or serotonergic function as a result of the 
use of certain drugs or long-term plastic changes resulting from chromic 
administration), all of which are germane to the experience of an 1DU. As such, 
assessment of levels of impulsivity and related constructs such as responsibility are 
clearly relevant to the prediction of injecting risk behaviours. 
Pharmacological effects of drug use 
It is now widely accepted that particular illicit and pharmaceutical substances 
can affect the consumers' cognitive function such that impairment to decision 
making and judgement is seen. This can result in the greater likelihood of engaging 
in behaviours typically conceived of as risky, such as needle sharing, unprotected 
sexual intercourse, driving a vehicle while under the influence, and other such 
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behaviours. The observation of these effects has been noted in both laboratory based 
experiments as well as in field studies and naturalistic environments. 
The pharmacological effect of benzodiazepines on neuropsychological and 
cognitive functioning has been extensively examined within the literature. Results of 
these studies indicate a clear impairment of functioning as a result of benzodiazepine 
use. Further, this impairment has been found to be of a dose-dependent nature, such 
that riskier behaviour is seen in accordance with higher doses. Lane and colleagues 
have conducted a number of laboratory studies demonstrating this effect. Using a 
hypothetical gambling task, the researchers found dose-related effects after 
administration of alprazolam (Lane, Tcheremissine, Lieving, Nouvion, & Cherek, 
2005) and also flunitrazepam (Lane, Cherek, & Nouvion, 2008). At higher doses, 
participants demonstrated increases in the selection of the risky option, and in the 
case of flunitrazepam, high doses also changed decision-making processes which 
were related to changes in learning and memory. After administering a 
neuropsychological assessment battery to participants who had been administered 
diazepam, Deakin, Aitken, Dowson, Robbins, and Sahakian (2004) found that 
compared to controls, those in the experimental group exhibited impairments in their 
performance on tests of planning and reaction time, and also make more risky 
choices on a risk taking task. In more descriptive studies and those involving rpu 
populations, benzodiazepine use has been associated with higher levels of BBV risk-
taking such as sharing injecting equipment more frequently and with a greater 
number of people (Darke, Hall, Ross, & Wodak, 1992; Darke, Ross, Cohen, Hando, 
& Hall, 1995; Darke, Swift, Hall, & Ross, 1993; Fry & Bruno, 2002; Klee, Faugier, 
Hayes, Boulton, & Morris, 1990a; Metzger et al., 1991). Klee, Faugier, Hayes, 
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Boulton and Morris (1990a) also found an effect of benzodiazepine use and 
increased sexual risk behaviour. 
Much research has been conducted regarding the biological processes which 
underlie the association between benzodiazepine consumption and impulsivity. There 
is now ample evidence that this drug modulates the GABA-A receptor complex, 
particularly those present within the prefrontal cortex and also within the limbic 
regions. The activation of the GABA receptors as a result of benzodiazepine use may 
produce pharmacological effects such as disinhibition when given at intoxicating 
doses. Research indicates that this disinhibition occurs as a result of changes in 
memory and learning about past gains and losses, which in turn means that there is a 
reduced ability to take this into account and make decisions appropriately to 
expected outcomes (Lane et al., 2008; Lane, Tcheremissine et al., 2005). Klee, 
Faugier, Hayes, Boulton and Morris (1990a) also state the effect that 
benzodiazepines have on memory may mean that 1DU have difficulty in recalling 
which users have shared equipment. The hypothesis that benzodiazepines act on 
GABA receptor sites, which in turn affects decision making and other cognitive 
processes has been supported both by neuroimaging studies as well as through 
neuropsychological assessments of executive and cognitive function. It appears that 
the effect that these drugs have on areas of the prefrontal cortex, particularly the 
orbitofrontal and dorsolateral regions, are vitally important in producing disinhibition 
(Deakin et al., 2004). 
While a large amount of research has focussed on the effect of 
benzodiazepine use on risk-taking, a number of other studies demonstrate that other 
drug classes can also have a similar impact. The effect of alcohol is known 
commonly to affect an individual's judgement and perception, such that consumers 
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may engage in behaviours riskier in nature than they would if sober. Indeed, research 
by Burian, Liguori, and Robinson (2002) found that in a simulated driving task, 
alcohol significantly increased risk-taking when in a high risk situation. Lane, 
Cherek, Pietras and Tscheremissine (2004) demonstrated in a laboratory setting that 
alcohol produced dose-related effects whereby riskier options were chosen on a 
gambling task at increased doses of alcohol. Alcohol has also been demonstrated to 
affect risky driving practices, and this study also demonstrated that heroin and 
cannabis also influenced risky driving (Darke, Kelly, & Ross, 2004). With regard to 
alcohol, Lane, Cherek, Pietras, and Tcheremissine (2004) propose that risk taking 
may be associated with changes in dopamine circuits within the midbrain, as well as 
changes in the GABAa receptor complex. George, Rogers and Duka (2005) propose 
that serotonin may also play a pivotal role. 
The impact that 3,4-methylenedioxymethamphetamine (MDMA) or ecstasy 
has on risk-taking has also been the subject of research, and demonstrates that this 
drug also can affect one's judgement and decision making abilities. Though the 
effects cannot be as clearly demonstrated in laboratory studies due to obvious ethical 
limitations, survey research with illicit drug consumers provides supporting evidence 
of such a relationship. This research suggests that while ecstasy may not compel all 
users to engage in sexual activity while intoxicated, those who do are more likely to 
engage in sexual risk-taking behaviours such as having multiple partners and 
engaging in sex without a condom (McElrath, 2005). It has also been reported that 
high users of ecstasy take more sexual risks than low users (Theall, Elifson, & Sterk, 
2006). This is also supported by Butler and Montgomery (2004) who reported that 
high users of ecstasy had higher levels of impulsivity, venturesomeness, and novelty 
seeking behaviour than non-drug users, and engaged in more risk taking when 
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compared with non-drug users, cannabis, and less frequent ecstasy users. A recent 
meta-analysis found that, as well as having neurocognitive deficits in the area of 
executive functioning, abstinent ecstasy users also demonstrated deficits in functions 
of attention and concentration, as well as verbal and nonverbal learning and memory 
(Kalechstein, De La Garza, Mahoney, Fantegrossi, & Newton, 2007). Although 
substantial literature exists supporting the role of ecstasy in impulsivity, other 
experimental research has found no such effect. For instance, Roiser, Rogers, and 
Sahakian (2007) examined participants' behavioural responses to a gambling task, 
and found no differences in terms of impulsivity between participants with ecstasy 
use, polydrug use, and drug naïve controls. As this indicates, there is some 
discrepancy amongst findings in relation to ecstasy use and impulsivity, however 
certainly these findings suggest a role of ecstasy in impulsivity. 
Neurobiologically, the increase in impulsive behaviour seen in participants 
who use ecstasy is hypothesised to be due to the modulation and depletion of 
serotonin within the brain. Animal studies indicate that low serotonin levels results in 
an increase in impulsive behaviour (Bizot, le Bihan, Peuch, Hamon, & Thiebot, 
1999; Wogar, Bradshaw, & Szabadi, 1993), and higher levels of serotonin decrease 
impulsive choices (Bizot et al., 1999; Poulos, Parker, & Le, 1996). Research with 
human participants which manipulates central serotonergic levels by dietary 
tryptophan depletion and loading provides support for hypothesis that the 
relationship between serotonin levels and impulsivity also exists in humans. For 
instance, Schweighofer, Bertin, Shishida, Okamoto, and Tanak (2008) utilised this 
research paradigm and conclude that low-serotonin levels causes impulsivity, as 
evidenced by a higher level of reward choices than for control serotonin levels. 
Therefore, the literature supports the theory that serotonin levels are closely linked 
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with impulsive behaviour, and in particular that low levels of serotonin are associated 
with an increase in impulsivity. Coexisting research into the relationship between 
MDMA and serotonin reveals that while the acute action of MDMA is to flood the 
synapses with serotonin (thereby producing effects such as euphoria, a sense of well-
being, and happiness), research using animals (Evenden, 1999; Reneman et al., 2002) 
and human participants (Morgan, 1998; Ramaekers & Kuypers, 2006; Sevy et al., 
2006) indicates that the long-term consequence of MDMA consumption is a 
depletion of serotonin levels. This depletion of serotonin that is seen as a result of 
ecstasy use is hypothesised by such authors as Butler and Montgomery (2004) to lead 
to greater impulsivity and risk taking. 
Other drug classes such as stimulants (e.g. cocaine) and opioids (e.g. heroin) 
have been implicated in research examining risk-taking. Obviously again, research 
into this area cannot be done in a laboratory setting and so rely on survey information 
or similar methodologies. Brand and his colleagues chose to examine the hypothesis 
that opioids impact risk-taking by using a sample of opiate dependent patients, 
requiring the participants to undertake a gambling task as an operationalisation of 
risky behaviour (Brand, Roth-Bauer, Driessen, & Markowitsch, 2008). Those 
patients who were opiate dependent tended to choose the risky alternatives more 
frequently than the control group, the authors explaining that this demonstrates 
abnormalities in decision-making which may also extend to dysfunctional behaviour 
in their daily lives. A study by Somlai, Kelly, McAuliffe, Ksobiech, and Hackl 
(2003) reveals that the injection of cocaine or crack was a significant predictor of 
sexual risk behaviour, again suggesting that the pharmacological effect of cocaine 
can impact risk-taking. Research by Stout and colleagues (Stout, Busemeyer, Lin, 
Grant, & Bonson, 2004) also supports the view that cocaine can influence risk- 
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taking. By using a gambling task paradigm (Iowa Gambling Task), cocaine users 
maintained responding to high-risk options despite negative consequences, which is a 
pattern of behaviour not present in controls. 
There has also been some preliminary evidence of the effect of cannabis on 
risk-taking. Again, in a laboratory setting, Lane and colleagues (Lane, Cherek, 
Tcheremissine, Lieving, & Pietras, 2005) administered varying doses of cannabis to 
participants as well as placebo cigarettes to the control group. Participants were 
required to undertake a risk-taking task. At the highest cannabis dose, participants 
chose the risky response option significantly more than other groups. The authors 
also note that the sensitivity to reinforcing and aversive outcomes was altered, which 
may be the reason for more risky options being chosen. Similar findings have been 
found from studies demonstrating that those participants in the cannabis condition 
exhibited increased risk-taking behaviours compared to drug-naive controls when 
undertaking a gambling task (Lane, Yecham, & Busemeyer, 2006; Whitlow et al., 
2004). Lane and colleagues hypothesise that the changes in decision making seen in 
studies such as the ones cited above where cannabis has been consumed may occur 
as a result of altered sensitivity to consequences due to changes within the 
mesolimbic prefrontal cortical network (Lane, Cherek et al., 2005). 
It is clear from the results of the above studies that the pharmacological effect 
of the drug results in neuropsychological changes, including altered judgement, 
planning, decision-making, and disruption to memory processes. The precise 
mechanisms at play which result in these changes are hypothesised by many 
researchers. Within the neuropsychology field it is now well accepted that the frontal 
lobes play a pivotal role in the regulation of behaviour. Termed executive functions, 
these include a number of cognitive abilities including planning, divided-attention, 
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decision-making, the ability to monitor and change behaviour as needed, and to 
initiate or stop behaviours as is appropriate to the situation etc. As cited above, the 
literature review presented by Yiicel et al. (2007) provides a clear conclusion that the 
long-term exposure of drugs results in neurological deficits, including deficits to the 
executive functions. Therefore, there is now compelling evidence that the frontal 
lobes are affected neurochemically as the result of the use of particular drugs. Much 
research is also being conducted as to the precise mechanisms that are at play in drug 
abusers that results in the more risky decisions being made in research paradigms 
such as those that utilise the Iowa Gambling Task (IGT). This research supports the 
notion that risky decisions in this context (i.e. choosing disadvantageous decks) is the 
result of a motivational bias for immediate gains and a 'myopia' for distant 
consequences, and greater attention to wins than losses (Stout, Rock, Campbell, 
Busemeyer, & Finn, 2005; Yechiam, Busemeyer, Stout, & Bechara, 2005). Even in 
conditions where participants are given feedback as to what result they would have 
had if they had made other (safer) choices on the IGT, drug abusers still made more 
risky choices (Yechiam, Stout, Busemeyer, Rock, & Finn, 2005). Again, these 
authors postulate that this result is due to these participants being drawn to 
potentially large outcomes even though it is a risky choice. Yechiam et al. (2005) 
state that this result supports the theory that signals of reward carry more weight than 
signals of risk because of drug users' stronger appetitive processes and weaker 
disinhibitory control. Yechiam et al.'s (2005) position here parallels that of Dawe 
and Loxton's (2004) model (previously outlined) which posits that impulsive 
behaviour seen in drug users is the result of two components; a 'reward sensitivity' 
(a heightened sensitivity to rewarding stimuli which resembles Gray's BAS 
conceptualisation) and 'response disinhibition' (a tendency to disregard risk or 
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consider future consequences). Concurrent research also indicates that drug abusers 
have a reduced awareness of errors leading to less advantageous choices (Garavan & 
Stout, 2005). 
While the above studies highlight the behavioural and neurochemical changes 
which occur during intoxication with substances, there is also research examining the 
long-term effects of drug use. For instance, in the study conducted by Brand, Roth-
Bauer, Driessen, and Markowitsch (2008) mentioned above, the participants 
completed the experimental protocol only after having completed detoxification from 
opiate dependence. Mean days of abstinence was 14.38 days, however risk taking 
was observed amongst these participants at a significantly higher level than controls. 
A meta-analysis of studies examining the long-term cognitive effects of prolonged 
benzodiazepine use following discontinuation was carried out by Barker and 
colleagues (Barker, Greenwood, Jackson, & Crowe, 2004). The authors found 
generalized cognitive deficits when compared with controls, including deficits in 
sensory processing, speed of processing, problem solving, attention and 
concentration, working memory, and general intelligence. These effects were present 
in a sample of long-term benzodiazepine users (mean 108 months) who had 
withdrawn from this medication for a mean of 42 months. Similarly, Stewart (2005) 
reports cognitive dysfunction in patients who were treated over a long period with 
benzodiazepines, and while improvement was seen upon discontinuation, these 
patients did not return to levels of functioning that matched controls. These 
publications are amongst a growing number demonstrating support for the notion that 
benzodiazepines and other drug classes can have prolonged impacts on cognitive 
functioning. As outlined above, the association with long-term ecstasy use and 
impulsivity is also one which is becoming recognised. 
Psychological Distress 
The presence of psychopathology and the impact that this has to blood borne 
virus risk transmission has been examined by a number of researchers. This 
combined research has consistently found that psychological distress plays a key role 
in impacting blood borne virus risk behaviours, in terms of both risky practices in 
injecting drugs and also risky sexual practices. One such study which clearly 
demonstrates these findings is by Darke, Ross, Cohen, Hando and Hall (1995). Using 
a sample of frequent amphetamine users, these authors found that psychological 
distress was an independent predictor of needle sharing, and that with each extra 
point obtained on the General Health Questionnaire (where higher points indicate 
increased psychological distress), the odds of the injector having recently shared 
needles rose by 8%. A number of other studies also find a significant relationship 
between general levels of psychiatric distress and needle sharing, particularly among 
[DU enrolled in methadone maintenance treatment programs (e.g. Brook et al., 1997; 
Darke, Swift, Ross, & Hall, 1994; Kleinman et al., 1994; Metzger et al., 1991; 
Woody, Metzger, Navaline, McLellan, & O'Brien, 1997). Adding to the above 
research, Disney et al. (2006) found that psychiatric comorbidity increases HIV risk. 
In this study, participants who were diagnosed as having antisocial personality 
disorder as well as an Axis 1 disorder exhibited greater substance use disorders and 
higher HIV risk than participants who were diagnosed as having one or no 
psychiatric disorder. As well as there being a relationship between emotional 
distress and sharing needles, Trobst, Herbst, Masters and Costa (2002) found a link 
between emotional distress and HIV/AIDS sexual risk behaviours. 
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A recurrent theme which is present among research into psychiatric 
symptoms and blood borne virus risk behaviours is that of Antisocial Personality 
Disorder (APD). This disorder is characterised by impulsive behaviour, a lack of 
responsibility, a careless disregard for others, and extensive criminal activity. Rates 
of APD amongst substance abusing populations are high, both in studies conducted 
in North America as well as in Australia. These rates range from 31% to 71%, 
however most report a prevalence of APD in the vicinity of 40% (Brooner, Bigelow, 
Strain, & Schmidt, 1990; Brooner, Greenfield, Schmidt, & Bigelow, 1993; Compton, 
Cottler, Shillington, & Price, 1995; Darke, Swift, & Hall, 1994; Darke, Williamson, 
Ross, Teesson, & Lynskey, 2004; Disney et al., 2006; Gill, Nolimal, & Crowley, 
1992; Kelley & Petry, 2000). It must be noted however, that a diagnosis of APD is 
not synonymous with psychopathy. In a study by Darke, Kaye, and Finlay-Jones, 
only 11% of the sample who met diagnostic criteria for APD also met criteria for 
psychopathy using the Revised Psychopathy Checklist developed by Hare (1980). 
Gerstley and colleagues (Gerstley, Alterman, McLellan, & Woody, 1990) argue that 
a diagnosis of APD is over-inclusive amongst the 1DU population because the mere 
use of an illicit substance generates similar behaviours and features characteristic of 
APD as a result of using expensive and illicit drugs. For instance, the authors state 
that behavioural problems such as irresponsibility, impulsivity, and criminality can 
occur as a result of drug use. These behaviours can be considered antisocial, however 
may be borne out of the substance use itself, rather than being caused by an 
antisocial personality feature. The study by Darke, Kaye, and Finlay-Jones (1998) 
provides support for this position. 
Despite this, many studies examine those substance users who qualify for a 
diagnosis of APD (as opposed to psychopathy). These studies have consistently 
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found that this population is at a higher risk of blood borne virus infections due to a 
greater likelihood of these people engaging in risky drug use and sexual practices 
compared to non-APD drug users. For example, Kelley and Petry (2000) found that 
those participants with APD had higher rates of injecting drug use, lower rates of 
needle-cleaning and greater numbers of sexual partners when compared with non-
APD participants. Similar findings have been reported by a number of other authors 
(eg. Brooner et al., 1990; Compton et al., 1995; Gill et al., 1992). Kelley and Petry 
(2000) also found that the relationship between blood borne virus risk behaviours 
and the presence of APD exists despite there being no difference in APD versus non-
APD participants' knowledge of HIV and risks for transmission. Not surprisingly, 
research also confirms that those with APD have higher odds of infection with HIV 
than non-APD drug abusers, and this has been found to be the case even after 
controlling for ethnicity, gender, and treatment status (Brooner et al., 1993). This 
reinforces the link between impulsivity and BBV transmission risk. 
Other psychiatric conditions such as mood and anxiety disorders have also 
been implicated in engagement in BBV risk behaviours. For instance, Johnson, Yep, 
Brems, Theno and Fisher (2002) found that in a sample of 513 street drug users, 
those participants who reported sharing needles and injecting equipment had higher 
levels of depression than those participants defined as non-sharers, however the 
authors do not state whether this effect is independent of frequency of injecting. 
Similarly, Mandell and colleagues (Mandell, Kim, Latkin, & Suh, 1999) found that 
in a community sample of 1DU, those which higher depressive symptoms had higher 
levels of needle sharing, both after cleaning it with bleach and without cleaning it, 
and this effect remained significant even after adjusting for demographic 
characteristics, life events, drug use patterns, and social and drug networks. Other 
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research provides further support for the association between symptoms of 
depression and needle sharing (eg. Hawkins, Hawkins, Latkin, & Chowdury, 1998; 
Strathdee et al., 1997), and over and above this, Stein and colleagues demonstrate 
that this relationship is related to severity, such that the greater the depression 
severity, the greater is the frequency of injection risk behaviour (Stein, Solomon, 
Herman, Anderson, & Miller, 2003), consistent with the Darke et al (1995) study 
using the GHQ. Research by Murphy et al. (2001) also supports a link between 
depression and BBV sexual risk behaviours in a sample of HIV infected adolescents, 
and found that the odds of participants having had unprotected sex at last intercourse 
increased by 50% if depression symptoms were present as opposed to participants 
who were not depressed. There is also some evidence of other mood disorders such 
as dysthymia being associated with needle sharing (Abbott, Weller, & Walker, 
1994). 
Though more limited in number, a few studies also examine the particular 
relationship that anxiety has on BBV risk. The results of these studies suggest that 
the presence of anxiety is also emerging as a further factor which significantly 
impacts whether an LDU will engage in risky behaviours. In a recent study, Reyes et 
al. (2007) investigated the effect of severe anxiety symptomatology and HIV risk 
behaviour in a sample of 557 LDU. The authors report that participants with severe 
anxiety symptoms were more likely to share needles, cotton, and rinse water, to pool 
money to buy drugs, than those who do not have severe symptoms of anxiety. These 
participants were also more likely to engage in backloading, which has been 
identified as a risk factor for BBV transmission (Jose et al., 1993). Jose et al. (1993) 
explain that backloading is a process where 1DU use their syringes to mix drugs and 
give measured shares to other IDU by squirting the drug solution into the syringes of 
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other 1DU. Participants with severe anxiety in Reyes et al.'s (2007) study were also 
more likely to practice risky sexual behaviours, such as unprotected vaginal or oral 
sex. Lundren, Amodeo, and Chassler (2005) also found a relationship between 
anxiety and needle sharing. 
The literature is clear in demonstrating the link between BBV risk behaviours 
in those who have increased levels of psychological distress, either generally or as a 
diagnosis of anxiety, depression or APD. Although many researchers do not 
comment on the possible reasons behind this association, several authors have 
postulated why this association exists. The relationship between APD and BBV risk 
behaviours is thought by several authors to be simply an expression of the underlying 
characteristics of the disorder. These characteristics include irresponsible and 
reckless behaviour, poor impulse control, and low harm avoidance, and therefore the 
relationship with needle sharing is not surprising (Brooner et al., 1993; Compton et 
al., 1995). Kelley and Petry (2000) found in their study that participants with APD 
were more likely to use cocaine and heroin than non-APD clients and argue that 
because these drugs are more often used intravenously, the increase in needle risk 
behaviours amongst this population may be due to prolonged and more frequent use 
of these drug classes. 
With regard to more general psychological distress, Kleinman (1994) notes 
that high levels of psychiatric distress acts as a barrier between the cognitive 
knowledge of the risks associated with needle sharing and making behavioural 
change to reduce these risks. It appears then that the depressed mood is the more 
powerful of the two, and results in more careless behaviour, perhaps due to a reduced 
sense of self-worth or hopelessness. It may also reflect a sense of low self-esteem 
which reduces the IDUs confidence in their ability to reject offers from others to 
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share. Mandell, Kim, Laticin and Suh (1999) believe that when in a depressed mood, 
some rpu may try to overcome this by injecting with a group of people. This 
increases injecting risk, however also provides social interaction and support which 
can assist to alleviate the depression. Stein, Solomon, Herman, Anderson and Miller 
(2003) offer several other reasons for the association between depression and 
increased injection risk behaviour. Firstly, they postulate that those with depression 
have less confidence in giving careful thought to the consequences of life decisions, 
thereby leading to reduced participation in preventative behaviours. Secondly, 
depression is known to affect cognitive functions such as concentration and attention, 
and this may promote greater carelessness in drug use activities. Thirdly, a poorer 
ability to cope with stressful life events may lead to heightened levels of needle 
sharing. Metzger et al. (1991) suggests that the presence of high levels of depression 
and anxiety lead to poorer treatment outcome and relapse, and therefore a reduced 
effectiveness of treatment may explain the relationship between psychological 
distress and BBV risk. Specifically in relation to anxiety, Reyes et al. (2007) 
contends that the presence of anxiety symptomatology such as poor confidence in 
own abilities to prepare drug solutions, use condoms, and prepare for injection and 
sexual episodes, may lead to a greater engagement in BBV risk behaviours. 
Conclusion 
It is clear from above review of the literature that the transmission of blood-
borne viruses remains a significant problem worldwide. While preventative and 
educational efforts have resulted in the reduction of transmission rates of some 
blood-borne viruses such as HIV, the incidence of HCV transmission remains 
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staggering. The reason for the difficulty in slowing down the transmission of the 
virus is partly due to the highly transmittable nature of the disease, in that it has a 
higher viral infectivity content that HIV (Gerberding, 1995). Additionally, however 
there appears to be some complacence amongst at-risk populations. Primary among 
those at risk of becoming infected with BBV are IDU, and research has revealed that 
having knowledge about HIV transmission amongst this population is not enough, as 
it does not equate to behavioural change (Metzger et al., 1991). It is clear then, that 
something else is at play which results in some rDU putting themselves at increased 
risk while others do what they can to minimize that risk. Because there is no vaccine 
available to protect against HCV and the rates of transmission are so high, it is 
important to identify which factors are involved in its transmission if prevention is to 
take place. 
As the review of the literature above indicates, there have been a number of 
factors which have been consistently shown to put rDU populations at an increased 
risk of BBV transmission. Some demographic variables such as being of female 
gender, being younger in age, and having a longer duration of injecting history are 
generally found to be significant contributors to BBV risk. However, some of these 
may be secondary characteristics of another variable (for example, being injected by 
others, which is more common among females than males) and others may be 
collinear (for example, age and duration of injecting career). The personality 
characteristic of impulsivity is also a predictor, as is the presence of psychopathology 
such as depression, anxiety, and antisocial personality disorder, and general 
psychological distress. The pharmacological effect that substances have on risk 
taking is also very much a predictor of engaging in BBV risk behaviours. A summary 
of the variables and their relationship to BBV risk is given in figure 1 below. 
Figure 1. Variables hypothesised to predict BBV transmission risk 
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APD 
Despite the fact that these factors have all been shown independently to be 
significant predictors, there have been no studies specifically examining the 
combined and relative effects that these variables have. While the literature suggests 
that all of the above mentioned factors are important, it is not clear which of these 
variables are most important for understanding risk behaviour. Some authors do state 
the importance of further research being conducted to increase our understanding of 
risk behaviour in this context. For example, Darke, Swift, Hall and Ross (1993) note 
the relationship between psychological dysfunction, benzodiazepine use, and 
injecting risk taking, and argue that this is an area which requires further research. 
Similarly, Staiger, Kambouropoulos and Dawe (2007) contend that personality 
variables need to be considered in substance misuse treatment programs, particularly 
anxiety and impulsivity related traits. Darke, Swift, Ross and Hall (1994) highlight 
the importance of understanding and treating psychopathology to encourage the 
reduction of substance use and BBV risk behaviours. 
The implications of doing such research would potentially be very significant. 
By determining which variables are most important in predicting BBV risk 
behaviours, [DU can be screened to identify those most at risk. For instance, if the 
research reveals that significant predictive factors are female gender, younger age, 
and benzodiazepine use, then those IDU who fit these criteria would indicate 
elevated risk for engaging in BBV risk behaviours. This population can then be 
prioritised for interventions to reduce this risk and also be administered interventions 
which are specifically designed for this group. Identification of this subgroup using 
information gleaned from such research would therefore enable harm reduction 
resources to be used in the most effective way possible, where harm reduction efforts 
are targeted to the most vulnerable of IDU. 
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Ecological validity for such 'a project comes from intervention projects 
demonstrating that a targeted approach can have real and significant results in 
reducing harmful behaviours. Conrod, Castellanos, and Mackie (2008) recently 
conducted a randomised control trial with teenagers to determine whether targeted 
interventions could prevent the development of harmful binge drinking patterns. 
Participants had an intervention program delivered to them if they exhibited 
personality factors deemed to be risky for the development of unhealthy drinking 
trends, and were followed up six and twelve months post-intervention. Results 
revealed that the intervention was particularly efficacious, with the growth of binge 
drinking being delayed on average by six months. The intervention was mostly 
effective for those participants who had elevated sensation-seeking personality traits. 
Such a study demonstrates that interventions conducted in those deemed to be at 
elevated risk can indeed be successful in assisting to prevent the development of 
harmful behaviours. 
A recent harm reduction project conducted in Tasmania has shown that 
individually targeted brief intervention sessions with LDU can be successful. This 
project was conducted with LDU and provided participants with education about the 
prevention of harms associated with injecting drug use. The results indicated 
sustained reductions in risky injection practices (Hallam, 2006). The disadvantage to 
such interventions however, is that they are relatively expensive when compared to 
alternative education options for this population, such as information pamphlets. 
Therefore, having knowledge that can enable guidance in the development of 
screening options, thereby allowing intervention to those most at risk, can provide 
valuable information in the fight against BBV transmission as well as provide an 
attractive intervention option for funding bodies. 
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Empirical Study 
Predictors of Injecting Risk Behaviours in a sample of Injecting Drug Users 
112 
Empirical Study Abstract 
Incidence of blood-borne viruses such as Hepatitis B, Hepatitis C, and HIV have 
begun to rise in recent years, with Hepatitis C now being the most communicable 
disease in Australia. Spread by blood-to-blood contact, it is now recognised that by 
far the majority of new cases of blood-borne viruses are transmitted during the 
process of injecting illicit drugs, through behaviours such as the sharing of injecting 
equipment. Previous studies have identified a number of factors that independently 
predict the risk of injecting drug users (rpm engaging in these risk behaviours. 
These factors include demographic, drug use and injection variables, psychological 
distress factors (i.e. anxiety and depression), and impulsivity factors, however to date 
no research has comprehensively examined these risk factors in a combined sense in 
order to establish which IDU are at a heightened risk for engaging in risky injection 
episodes. The current study sought to address this, and utilised a multivariate 
regression modelling approach with a sample of 269 regular 1DU in Tasmania to 
examine the contribution of the above factors to the prediction of the engagement in 
various injecting risk behaviours. The study details factors which emerged as 
significant predictors to transmission through needle and syringe contamination, 
other equipment contamination, contamination from injecting others, exposure from 
being injected by others, needlestick contamination, as well as overall risk. While the 
factors which significantly contribute to risk in the various aspects of transmission 
behaviours vary, the factors of unstable accommodation status, amphetamine use, 
alcohol use, less occasions of self-injection, higher symptoms of anxiety, and a desire 
to seek out novel stimulation emerged as the most significant contributors to overall 
risk. Of these, elevated anxiety symptoms and reduced episodes of self-injection 
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were clearly the most important factors as identified in a multivariate model for 
overall risk of engaging in blood-borne virus risk behaviours. This finding suggests 
that while there is value in delivering blood-borne virus transmission intervention 
efforts to all 1DU, particular attention and emphasis should be paid to those Du 
exhibiting the above risk factors. Specific strategies for intervention is discussed in 
the below report. 
Blood-borne viruses 
Blood-borne viruses (B BY) are those which are spread via blood-to-blood 
contact, the most common of which are the hepatitis B virus (HBV), hepatitis C virus 
(HCV) and the human immunodeficiency virus (HIV). While a vaccine is available 
to control the impact and spread of HBV, there is no such measure available to assist 
with limiting the transmission of HIV and HCV. Chronic infection with these viruses 
leads to devastating consequences. In the case of HIV, progression of this virus may 
lead to the development of acquired immunodeficiency syndrome (AIDS), a 
syndrome which lowers the immune system and thereby leaves one vulnerable to 
contracting illnesses which are then fatal. With regard to HCV, the health outcomes 
of chronic infection are the development of cirrhosis of the liver, hepatocellular 
carcinoma, and liver failure. As well as the physical costs that infection with these 
viruses brings, there a number of psychological and socioeconomic factors that can 
impact on one's experience of the virus. These include the breakdown of 
relationships, difficulty in sustaining paid employment, feelings of fear, anxiety, 
depression, and stigmatisation by the general community as well as healthcare 
professionals (Community Affairs References Committee, 2004; Parliament of 
NSW, 1998). 
There are a number of routes which have been recognised as methods by 
which the transmission of BBVs can occur. These include vertical transmission 
(mother-to-child), needle-stick injuries, tattooing, piercing, acupuncture and sexual 
contact where blood-to-blood contact is present. Prior to 1990, recipients of blood 
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products in Australia were also at risk of BBV transmission as screening for the 
presence of HCV antibodies was not available at this time. 
While any of the above methods can transmit BBV, by far the majority of 
new cases of BBVs are transmitted during the process of injecting illicit drugs. 
During this procedure, there are many opportunities for blood-to-blood contact to 
occur, and it has been estimated that just over 80% of prevalent HCV cases are 
transmitted this way (Dore et al., 1999; Ministerial Advisory Committee on AIDS, 
2006). It has been identified that a large contributing factor to these high rates is the 
practice of sharing or re-using injecting equipment (by either lending to or borrowing 
from other IDU) that can occur within IDU populations. It is now well recognised 
that the sharing of any injecting paraphernalia, be it needles, syringes, swabs, water 
vials, tourniquets, spoons etc., carry with it a risk of transmitting BBVs (Crofts et al., 
1999; Hagan et al., 2001; MacDonald & Wodak, 2003; Maher et al., 2006; Thorpe et 
al., 2002). 
HCV has now become the most common communicable disease in Australia 
(Dore et al., 2003) and at the end of 2005 there were over 264,000 people living with 
HCV antibodies in Australia (Ministerial Advisory Committee on AIDS, 2006). 
Reports document a 45% increase in new HCV infections in Australia between 1997 
and 2001, and estimate that the prevalence of HCV is set to triple by 2020 unless 
changes are implemented to curb the rising rates of transmission (Law et al., 2003). 
Among the injecting drug user (IDU) population, prevalence of HCV is in the range 
of 50 to 70% (Law et al., 2003), with an increase in new cases estimated to be at 15% 
per year (Crofts et al., 1997). In recent years, incident diagnoses of HIV have also 
began to rise, with the National Centre in HIV Epidemiology and Clinical Research 
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(2006b) reporting a increase in rates by 41% between 2000 and 2005. Clearly, the 
spread of these viruses has become an important issue both in Australia and globally. 
In response to the increasing rates of HIV which occurred in the 1980s, a 
number of campaigns were introduced in Australia and worldwide to reduce the 
spread of the virus. This included education to the 'at risk' IDU population, including 
education about safe injecting practices, as well as improved access to clean injecting 
equipment. These interventions were considered to be successful, in that HIV 
incidence rates and rates of sharing equipment were reduced. However, while these 
campaigns were successful in curbing rates of HIV transmission, HCV incidences 
did not enjoy the same success. The greater difficulty in controlling the spread of 
HCV is attributed to the fact that this virus is more efficiently transmitted than HIV, 
such that extremely small volumes of blood can still transmit the virus (Gerberding, 
1995). High background prevalence rates also hamper efforts to reduce virus 
transmission (Crofts et al., 1999) . 
It is clear that while interventions have assisted in the reduction of BBV 
transmission rates, there remains much work to be done to curb the soaring rates of 
HCV and control the recent rise of new cases of HIV. Currently, many interventions 
are provided to all liDU due to this population being recognised as a primary risk-
group, however, knowledge is required as to what specific factors lend one MU to 
engage in BBV risk behaviours such as needle-sharing while another IDU may not, 
in order to best target interventions, given limited resources. 
Risk Factors 
A number of studies have been conducted to examine whether specific factors 
impact on the sharing of injecting equipment and HCV transmission. While some 
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studies find significant effects, a review of the literature clearly reveals that an IDU's 
ethnicity (e.g. Dwyer et al., 2002; Garfein et al., 1996), level of formal education 
(e.g. Chang et al., 1998; Maher et al., 2006; Thomas et al., 1995) and sexual 
orientation (e.g. Diaz et al., 2001; Garfein et al., 1998; Hagan et al., 1999) is not 
consistently associated either with the transmission of HCV or with the sharing of 
injecting equipment. Research also suggests that the type of treatment and whether 
one is engaged in treatment services does not consistently impact on these risks (e.g. 
Maher et al., 2006; Van Beek et al., 1998). Similarly, whether one has stable or 
unstable housing appears unrelated to risk of HCV transmission and equipment 
sharing (e.g. Hagan et al., 2001; Thomas et al., 1995; Villano et al., 1997). 
While the factors outlined above appear not to predict the sharing of injecting 
equipment or HCV transmission, other factors do seem to influence an IDUs risk of 
these outcomes. The clear majority of studies which examine the presence of prison 
history as a factor reveal this is significant in predicting both the risk of HCV 
transmission as well as predicting the sharing of injecting equipment (e.g. Crofts et 
al., 1993; Maher et al., 2004; Van Beek et al., 1998). Although results are somewhat 
discrepant between studies, a trend also exists suggesting that female lDU are at a 
greater risk for the transmission of HCV (e.g. MacDonald et al., 2000; Maher et al., 
2006; Maher et al., 2007) in addition to being more likely to share injecting 
equipment (Dwyer et al., 1994; Montgomery et al., 2002). Varied findings are also 
apparent in terms of whether the IDUs drug choice is a significant predictor, however 
taken as a whole the literature suggests that regular stimulant users are at a 
marginally increased risk when compared with opiate users (e.g. Crofts et al., 1994; 
Maher et al., 2006; Van Beek et al., 1994). Those IDU who inject on a daily or more 
frequent basis are also generally found to be at a greater risk for HCV transmission 
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than those who inject on a less frequent basis (e.g. Dwyer et al., 2002; MacDonald et 
al., 2000; Villano et al., 1997). This likely reflects the cumulative risk that each 
injection episode brings. In addition to the above factors that appear to be assocated 
with BBV transmission risk, Injecting in a public location such as street-based 
injecting has also been associated with an increase in BBV transmission (Maher et 
al., 1998; Strathdee et al., 2001 ), presumably due to a pressure to inject quickly so as 
not to be seen by the public, therefore taking less care in adhereing to safe injecting 
practices. Being injected by others and injecting others has also been associated with 
increased BBV transmission (Hahn et al., 2002) due to there being more 
opportunities for second-person contamination (Stoove & Fry, 2006). 
Age of the IDU and duration of injecting drug use are two variables which 
are consistently found to be significant, whereby the older the LDU is, and the longer 
the duration of IDU use, the greater the likelihood of having contracted HCV (e.g. 
Chang et al., 1998; Chetwynd et al., 1995; Diaz et al., 2001; Hagan et al., 2001; 
MacDonald et al., 2000). Incidence studies reveal that the greatest risk for HCV 
transmission is in the initial years of injecting and younger age, and younger IDU are 
also found to be more likely to share needles and injecting paraphernalia (Crofts et 
al., 1995; Hagan et al., 1999; Van Beek et al., 1998). Together, these studies indicate 
that the most risky time for BBV transmission to occur is during the initial years of 
injecting, when the 1DU is likely to be younger, and perhaps taking more risks with 
injecting (such as sharing equipment). However, the older the LDU and the longer the 
years of injecting, the greater is the likelihood that the rpu has contracted HCV, 
presumably as a function of cumulative exposure. 
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Impulsivity 
A further factor which has been identified within the literature as impacting 
on BBV risk behaviours is that of impulsivity. Impulsivity is typically conceived of 
as a personality trait where behaviours involve rashness, a lack of foresight or 
planning, and a lack of reflection and deliberation (Dawe & Loxton, 2004). Dawe, 
Gullo, and Loxton (2004) conducted a comprehensive literature review into the field 
of impulsivity, and concluded that impulsivity generally consists of two factors; 'rash 
impulsiveness' where one tends to act rashly and without consideration as to 
consequences, and 'reward sensitivity' which reflects individual variation in 
sensitivity to rewarding stimuli in the environment. This conceptualisation is largely 
consistent with Arnett's model of impulsivity, which refers to two components being 
the novelty of stimulation (seeking out novel sensations), and the intensity of 
stimulation (seeking out sensations which are intense in experience) (Arnett, 1994). 
In relation to the IDU population, one would expect that an LDU high in impulsivity 
would be more likely to take risks in terms of sharing equipment for the sake of 
immediate outcomes rather than considering the potential consequences of such 
behaviour when compared with an individual with lower impulsivity characteristics. 
In line with this, research indicates that this construct is related to a number 
of negative health outcomes, including excessive alcohol use, drug use, risky driving, 
and risky sex (Bogg & Roberts, 2004; Conrod et al., 2000; Hoyle et al., 2000). The 
relationship between impulsivity and needle-sharing has also been directly examined, 
finding that these variables are indeed significantly related. For instance, Trobst and 
colleagues (Trobst et al., 2002) found that those IDU who were deemed at a high risk 
for HIV due to their engagement in a variety of sexual (e.g. unprotected sex) and 
substance use (e.g. sharing needles) risk behaviours were significantly more 
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impulsive than those deemed to be low and medium risk. Odum and colleagues 
(Odum et al., 2000) propose that those 1DU who choose to share injecting equipment 
do so because delayed consequences of this behaviour (e.g. contracting HCV) is not 
considered during the decision making process, leading LDU to choose the immediate 
reward (i.e. administering the drug in a risky manner). 
Psychological Distress 
The relationship between the presence of psychopathology and BBV risk 
behaviours amongst the IDU population has been examined by a number of 
researchers, the results of which consistently indicate that these are indeed related. 
This relationship is perhaps most startlingly demonstrated by a study conducted by 
Darke, Ross, Cohen, Hando and Hall (1995) who found that, in a sample of regular 
amphetamine users, psychological distress was an independent predictor of needle 
sharing, and that with each extra point obtained on the General Health Questionnaire 
(where more points indicates higher distress), the odds of the injector having recently 
shared needles rose by a notable factor of 8%. Such a relationship between 
psychological distress and needle sharing is reported in a number of other studies 
(Brook et al., 1997; Darke, Swift, & Hall, 1994; Kleinman et al., 1994; Metzger et 
al., 1991; Woody et al., 1997). 
The presence of mood and anxiety disorders has also been found to 
significantly impact on whether an IDU will engage in risky behaviours. Several 
studies demonstrate that those IDU with higher depressive symptoms reported higher 
levels of needle-sharing (Johnson et al., 2002; Mandell et al., 1999). Stein, Solomon, 
Herman, Anderson and Miller (2003) reports that this relationship is related to 
severity, such that the greater the depression severity, the greater the frequency of 
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injection risk behaviour. Similarly, emerging research indicates that the presence of 
anxiety disorders is a significant factor in contributing to BBV risk behaviours. 
Reyes et al. (2007) found that [DU with severe anxiety symptoms were more likely 
to share needles, cotton, and rinse water, pool money to buy drugs, and engage in 
backloading when compared with those who do not report severe symptoms of 
anxiety. 
The reason for the association between the presence of psychopathology and 
risk for BBV transmission has been hypothesised by a number of researchers. 
Theories include that psychological distress acts as a barrier between the knowledge 
of risk factors for BBV transmission and making behavioural change to reduce these 
risks, perhaps due to a reduced sense of self-worth and hopelessness, and also 
perhaps due to having less confidence in one's ability to give careful thought as to 
one's decisions (Kleinman et al., 1994; Stein et al., 2003). Also, it is hypothesised 
that cognitive deficits associated with depression such as reduced concentration and 
attention may result in carelessness in drug use activities (Stein et al., 2003). 
Pharmacological Effects of Drug Use 
The pharmacological effects of several illicit and pharmaceutical substances 
are now well recognised as impacting on cognitive functions, particularly those 
involved in decision making, which can lead to poor choices such as having 
unprotected sexual intercourse, sharing injecting equipment, and driving while under 
the influence. 
Primary amongst the drugs shown to impact decision making processes are 
the benzodiazepines. Laboratory studies clearly indicate that impairment in decision 
making occurs as a result of benzodiazepine use. Lane and colleagues demonstrated 
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this by asking participants to complete a hypothetical gambling task, and found dose-
related effects whereby at higher doses participants chose risky options more often 
(Lane et al., 2008; Lane, Tcheremissine et al., 2005). In descriptive studies of IDU, 
benzodiazepine use has been found to be related to more frequent sharing of injecting 
equipment and sharing with a greater number of people (Darke et al., 1992; Darke et 
al., 1993; Fry & Bruno, 2002; Klee et al., 1990a; Metzger et al., 1991). 
While much research exists demonstrating the impact that benzodiazepines 
have on risk-taking behaviours and decision-making processes, other drug classes 
have also been shown to have similar effects. Alcohol and cannabis have been shown 
to affect decision making processes in laboratory settings, whereby participants in 
the experimental groups chose riskier options in a hypothetical gambling task than 
control participants (Lane et al., 2004; Lane, Cherek et al., 2005). Descriptive studies 
examining the impact of opiates, stimulants, and MDMA report that these substances 
are also associated with risk-taking behaviours such as unprotected sexual 
intercourse, and choosing risky options in gambling tasks (Brand et al., 2008; 
McElrath, 2005; Somlai et al., 2003; Theall et al., 2006). 
Neurobiologically, it is hypothesised that alterations in the functioning of the 
frontal lobes are responsible for impairments in the processes of decision making, 
judgement, and planning which result in risky choices being made. The precise 
mechanisms at play to result in such risk-taking is still under contention amongst 
researchers, however modulation of various neurotransmitter systems such as 
dopamine, serotonin, and the GAB A-A receptor complex is thought to play a role, at 
sites including the prefrontal cortex, limbic system, and the midbrain. For instance, 
in the case of benzodiazepines, research indicates that the GABA-A receptor 
complex within the prefrontal cortex and limbic regions is modulated with 
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benzodiazepine use, which results in the pharmacological effect of disinhibition and 
impulsive behaviour. These behavioural changes are indicated to result from 
alterations in the ability to recall what was learned about past gains and losses, 
meaning that an individual's ability to take this information into account when 
informing decisions is compromised (Lane et al., 2008; Lane, Tcheremissine et al., 
2005). 
While such neurochemical changes are noted after the acute administration of 
the drug, research also reveals that disinhibition and impulsive choices can occur 
following the cessation of drug use. Yticel, Lubman, Solowij, and Brewer (2007) 
conducted a review of existing literature covering the neurobiological and 
neuropsychological correlates of long-term drug addiction and concluded that across 
the drug classes, extensive neurological deficits can be seen in those who engage in 
long-term substance use. Primary among these deficits are impairments to executive 
function and inhibitory control; however deficits were also apparent in areas of 
working memory and decision making. Specifically, Barker, Greenwood, Jackson 
and Crowe (2004) examined the long-term cognitive effects of benzodiazepine use 
and that that this resulted in deficits in sensory processing, speed of processing, 
problem solving, attention and concentration, working memory, and general 
intelligence, even after discontinuation of the drug. 
Similarly, residual changes to cognition following long term MDMA use has 
also been found to occur such that damage is seen in the neural circuits that are 
activated during the acute administration of the drug (e.g. the hippocampus in 
MDMA users). During the process of developing dependence to a drug following the 
chronic administration of the drug, changes in neural circuits and functioning also 
occurs. 
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As the above review indicates, both acute and long-term use of the drug 
classes noted above can result in a number of neurobiological changes leading to 
impaired decision-making processes. A poor ability to make appropriate decisions 
can then result in behaviours associated with increased risk, such as injecting in 
conditions that are associated with a greater risk for BBV transmission (e.g. sharing 
equipment, being injected by others). 
Rationale for Current Study 
As is evident from the research cited above, there have been many studies 
conducted to determine the risk factors for BBV transmission and the sharing of 
injecting equipment. The impetus to find out which individuals are at a heightened 
risk of contracting BBVs is due to the need to target interventions at the most 
vulnerable group, thereby delivering interventions at the most efficient and effective 
way possible. In Australia, interventions are generally being provided to all 
accessible IDU, regardless of their propensity to take risks in relation to sharing 
injecting equipment. However it is apparent from existing research that some 
characteristics, such as the presence of certain demographic factors, an impulsive 
personality, psychological distress, and the use of particular substances can place an 
1DU at a greater risk for engaging in such behaviours as sharing equipment that can 
lead to contracting and transmitting BBVs. While these factors have been shown to 
independently impact on risk for BBV transmission, what is ideally required is an 
understanding as to the combined and relative effects that these variables have and 
which of these are the most important for understanding this risk behaviour. 
By determining which variables are the most important in predicting BBV 
risk behaviours, it may be possible to screen 1DU to identify those most at risk and 
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this subgroup can then be prioritised for more in depth interventions. In this way, the 
intervention can be delivered in the most efficient manner possible, thereby having 
the greatest impact on reducing the spread of BBVs such as HCV. The current study 
therefore aims to bridge this gap, by determining the relative impact of each of the 
risk factors outlined above, thereby determining which factors have the greatest 
impact on BBV risk behaviours. 
Hypotheses 
Based on the findings of previous literature summarised above, we would 
anticipate that higher levels of psychological distress (anxiety and depression) and 
impulsivity will be significant predictors of risky injection practices in a sample of 
regular IDU. Similarly, it is expected that benzodiazepine, amphetamine (including 
prescription stimulants), cannabis, MDMA, alcohol and opiate use would be 
positively associated with BBV risk behaviours. It is also hypothesised that the 
demographic variables of females, older age, longer duration of drug use, daily 
injecting, IDU with prison history, and stimulant users will be significant predictors 
of BBV risk behaviours. Further, it is hypothesised that lower levels of self-injection 
and having last injected in a public location would be associated with engagement in 
BBV risk behaviours. 
It is hypothesised that higher levels of cocaine and LSD use would not 
produce significant relationships with BBV risk behaviours, and similarly, it is 
expected that the IDUs primary spoken language, level of education, sexual 
orientation, treatment status, and accommodation status will not predict BBV risk. 
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Method 
Participants 
Participants of the 2006 and 2007 Elicit Drug Reporting System (DRS) in 
Tasmania formed the sample of the current study. The 1DRS is a national drug 
market monitoring system commissioned by the Australian Government Department 
of Health and Aging which gathers information as to emerging drug trends. 
Eligibility criteria for participation in the [DRS and the current study were that the 
individual must have been injecting substances at least once monthly for the past six 
months, had resided in Tasmania for the past twelve months or more, and were 18 
years or older. Participants were recruited through advertisements distributed through 
Needle and Syringe Program (NSP) outlets, pharmacies (through promotional 
material included with injection equipment) or health services, and snowball methods 
(word of mouth by friends or associates). Participants were screened for their 
eligibility by referring agencies and interviewers. Of the 285 participants who 
completed the study, 16 cases were excluded from analyses due to incomplete data 
on the dependent variable measure (BBV-TRAQ-SV). Thus, 269 participants were 
included in the current study, and the demographic characteristics of this remaining 
cohort can be found in Table 1. 
Table 1. 
Demographic Characteristics of the IDU Cohort 
Demographic 	 n=269  
Sex (%) 	 Male 63.2 
Female 36.8  
Age (mean years) 	 31.8 (SD 8.0) 
Grade at school completed (mean years) 	 10.0 (SD 1.4) 
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Post-school qualifications (%) 
None 	 56.9 
Trade/Technical 	37.2 
University/College 	5.9 
Employment (%) 
Unemployed 	72.9 
Full time/part time 	13.7 
Other 	 13.4 
Stable 91.4 
Unstable 	 8.6 
 
Accommodation (%) 
 
Treatment in past 6 months (%) 
None 	 45.0 
Pharmacotherapy 	48.0 
Other 	 7.0 
Duration of injection (mean years) 	 12.5 (SD 7.3) 
Frequency of injection last month (%) 
Less than daily 	67.3 
Daily 	 32.7 
Last location of injection 
Private 	 72.9 
Public 27.1 
Drugs used in last 6 months 
Pharmaceutical 	88.8 
opioids 
Methamphetamine 	84.0 
Benzodiazepines 79.6 
Cannabis 	 89.2 
Materials and Instruments 
IDRS Interview Schedule. The 2006 and 2007 IDRS interview schedules were 
administered to participants in the 2006 and 2007 cohorts, respectively. This is a 
standardised tool, and is similar to that used in previous research (Topp et al., 2001). 
The interview gathers information on demographics; drug use; price, availability, 
purity, and use of various drugs including heroin, cocaine, methamphetamine, 
cannabis, opioids, and benzodiazepines. In addition to this, the interview also 
contains sections on crime, risk-taking (including needle sharing), health, and general 
drug trends. Full details of these studies and the interview schedules are available in 
the 2006 and 2007 National IDRS reports (Black et al., 2008; O'Brien et al., 2007). 
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Arnett Inventory of Sensation Seeking (AISS). The AISS (Arnett, 1994) was 
used as a measure of impulsivity in the current study. This instrument was developed 
in response to Zuckerman's conceptualisation of sensation seeking, and focuses on 
novelty and intensity as the two components of this concept. The Novelty subscale 
includes items relating to the seeking of novel stimulation and the willingness to take 
risks to obtain this stimulation (e.g. I would like to travel to places that are strange 
and far away), while the Intensity scale contains items which reflect the level of 
stimulus intensity (e.g. When I listen to music, I like it to be loud). The AISS consists 
of 20 items, with two subscales of 10 items each measuring Intensity and Novelty. 
Items were all presented with a Likert scale response option where participants 
indicated how much they agreed with the item statement (1 = describes me very well, 
2 = describes me somewhat, 3 = does not describe me very well, 4 = does not 
describe me at all). 
At the time of publication, the AISS was found to have internal reliability of 
Cronbach a = .70 for the entire scale, .64 for the Intensity subscale, and .50 for the 
Novelty subscale (Arnett, 1994). Similar coefficients were found by Zarevski, 
Marusic, Zolotic, Bunjevac, and Vukosav (1998) who reported .58 for the Intensity 
scale, and .53 for the Novelty scale. Using data from the current study, Cronbach 
alpha was found to be .63 for the total scale, .51 for the Intensity subscale, and .51 
for the Novelty subscale. The AISS has been criticised for having unsatisfactory 
internal reliability for the subscales and the total scale (e.g. Roth & Herzberg, 2004). 
The AISS is considered to have good construct validity (Arnett, 1994; Powell, 
Hardoon, Derevensky, & Gupta, 1999). Roth and Herzberg (2004) confirm the 
hypothesised two-factor structure of the AISS (novelty vs. intensity of stimulation) 
by factor analysis. 
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They also report satisfying convergent validity when correlated with the 
NEO-Five Factor Inventory (NEO-FFI), as the Novelty scale was most highly 
correlated with the NEO-FFI scale 'Openness to Experience' and 'Extraversion' 
while the Intensity subscale was most highly correlated (negatively) with the NE0- 
FFI scale 'Agreeableness'. The authors also report good discriminant validity, as 
indicated by considerably low correlations with the remaining NEO-FFI scales 
('Conscientiousness' and `Neuroticism'). 
Kessler Psychological Distress Scale (K10). This 10- item scale was used in 
the current study as a non-specific measure of psychological distress. This scale asks 
participants to rate their experience of negative emotional states in the 4 weeks prior 
to the assessment (e.g. Did you feel tired out for no good reason?). There are five 
response options for each question, ranging from 'none of the time' to 'all of the 
time'. Scores range from 10 to 50, with higher scores indicating high levels of 
psychological distress. 
The K10 is a widely used instrument, often used in health settings and in 
public health surveys as a screening tool for the possible presence of psychological 
conditions. Sensitivity and specificity data as well as other measures of validity 
indicate that the instrument can be used appropriately to screen for the presence of 
psychological conditions in the community (Andrews & Slade, 2001). For instance, 
analyses by Andrews and Slade (2001) indicates that of those who score above 30 
points on the K10, 82.6% meet DSM-IV criteria for an anxiety, affective, or 
substance use disorder. The scale has undergone rigorous psychometric testing and 
found to have both strong reliability and validity (Kessler et al., 2002). The 
psychometric properties of the scale has been examined within an injecting drug user 
population in Australia, and found to have both high levels of internal consistency 
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(Cronbach's a = .84) as well as concurrent validity (accuracy of predicting the 
presence of a DSM-IV affective disorder was 76.7% using a cut-off score of 27) 
(Hides et al., 2007). Cronbach alpha using the data from the current study was found 
to be .91. Overall, this instrument has strong psychometric properties and has proven 
appropriate for use with an Australian [DU population. 
Confirmatory factory analyses research by Brooks, Beard and Steel (2006) 
into the factorial composition of the K10 reveals that this instrument consists of 4 
factors and a 2-factor second-order factor structure. The second-order factors have 
been identified as representing Depression and Anxiety and these categorical 
divisions were utilised for the current study. Using the current data set, internal 
consistencies for each of the subscales was acceptable; with Cronbach's a of .79 for 
the anxiety subscale, and .91 for the depression subscale. 
Blood-borne Virus Transmission Risk Assessment Questionnaire (Short 
Version) (BBV- TRAQ -SV). This 15-item questionnaire was designed for use with 
IDU populations and examines the risk of BBV transmission which occurs during the 
injection process (Stoove & Fry, 2006; see Appendix A). It was used in the current 
study as a measure of such risk by enquiring how frequently participants engage in 
particular risk behaviours in the month preceding assessment. Three areas of possible 
transmission risk are examined by the questionnaire; those being contamination by 
the sharing of needles and syringes, the sharing of other equipment used in the 
process of injection (e.g. filters, water, spoons), and second person contamination as 
a result of another person's involvement in the preparation and injecting process. The 
questionnaire takes approximately 6 — 8 minutes to administer and yields scores for 
each category ranging from 0 (no times) to 5 (more than 10 times in the past month). 
Scores are weighted depending on the presence of protective factors, such as 
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disinfection of injecting equipment. For details of complete scoring procedures, 
please refer to Stoove and Fry (2006). 
Dwyer et al. (2002) undertook psychometric evaluation of the BBV-TRAQ-
SV, reporting that three independent factors were identified by principal components 
analysis; confirming the three subscales outlined above. Modest internal 
consistencies were found for these subscales (needle and syringe contamination a = 
0.60, other injecting equipment contamination a = .81, second person contamination 
a = .61). Independent psychometric analysis was conducted by Bruno, de Graaff, and 
Ante! (2007) which found internal consistencies for the 15-items (Total BBV-
TRAQ-SV score) to be acceptable at a = .81. Poor to good internal consistencies 
were reported for the subscales (needle and syringe contamination a = 0.52, other 
injecting equipment contamination a = .70, second person contamination a = .82). 
For the current study, coefficient alphas were found to be .68 for the total scale, .45 
for the needle and syringe contamination scale, .58 for the other equipment 
contamination scale, and .82 for the second person contamination scale. 
BAS Scales. Carver and White's (1994) Behavioural Activation System 
(BAS) scales were used as a measure of impulsivity in the form of behavioural 
activation (i.e. responsiveness to something desired). It is a 13-item scale which asks 
participants to rate their agreement with each statement using 4 point scale, ranging 
from 1 ('very true for me') to 4 ('very false for me'). The items yield scores for three 
subscales; BAS Drive (items reflect the persistent pursuit of desired goals e.g. When 
I want something, I usually go all-out to get it), BAS Fun Seeking (items reflect a 
desire for new rewards and a willingness to approach a potentially rewarding event 
on the spur of the moment e.g. / will often do things for no other reason than that 
they might be fun), and BAS Reward Responsiveness (items reflect positive 
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responses to the occurrence or anticipation of reward e.g. When I get something I 
want, I feel excited and energized). For complete details of the scale and scoring 
please refer to Carver and White (1994). Carver and White also developed an 
accompanying scale, entitled Behavioural Inhibition System, the items of which 
reflect reactions to the anticipation of punishment. Together, these scales are referred 
to as the BIS/BAS scales. 
The BAS scales have been subjected to rigorous psychometric examination 
and the results of these analyses have been consistently positive. Carver and White's 
(1994) original conceptualisation of the scales consisting of four structures 
(behavioural inhibition, reward responsiveness, drive, and fun seeking) has been 
supported by a number of independent studies (e.g. Campbell-Sills, Liverant, & 
Brown, 2004; Heubeck, Wilkinson, & Cologon, 1998; Jorm et al., 1998; Leone, 
Perugini, Bagozzi, Pierro, & Mannetti, 2001) using both exploratory and 
confirmatory factor analyses. Test-retest reliability over an 8-week period has been 
found to range from .59 (BAS Reward Responsiveness) to .69 ( BAS Fun Seeking) 
for the scales (Carver & White, 1994). Internal reliabilities for the scales have been 
acceptable, with Carver and White (1994) reporting coefficients from .66 (BAS Fun 
Seeking) to .76 (BAS Drive) and Campbell-Sills et al. (2004) reporting a range from 
.73 (BIS) to .82 (BAS Drive). For the current study, moderate coefficient alphas were 
found (BAS total = .83, BAS Drive = .77, BAS Fun Seeking = .72, BAS Reward = 
.66). 
Validation studies have also been positive, with a number of studies reporting 
good convergent and discriminant validity. The scales have been found to be related 
to, but distinguishable from, alternative measures of similar traits (Campbell-Sills et 
al., 2004; Carver & White, 1994). For instance, the scales have been found to 
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correlate positively with similar traits (BIS with neuroticism and negative affectivity, 
BAS with positive affectivity and extraversion) (Campbell-Sills et al., 2004; Carver 
& White, 1994; Heubeck et al., 1998; Jorm et al., 1998). The construct validity of the 
scales is also supported by research findings that the BIS scale is successful in 
predicting the level of nervousness in response to an impending punishment, and the 
BAS scale is successful in predicting happiness in response to an impending reward 
(Carver & White, 1994). Concurrent validity analyses have also been positive, 
finding that the BIS/BAS scales are reflective of temperamental traits rather than 
transient states (Campbell-Sills et al., 2004). 
Procedure 
Following screening to determine eligibility, participants were given an 
information sheet further detailing the content of the interview to assist in informed 
decision making regarding their involvement. Potential participants were informed 
that information given was treated as strictly confidential, that their participation was 
entirely voluntary, and that they were free to withdraw at any time or decline to 
answer any questions. 
Those who agreed to be involved in the study signed a consent form, and then 
completed the interview protocol face-to-face with the interviewer in a place that was 
convenient to them, including the premises of health services, NSPs, or private 
homes when requested by the participant. Ethics approval was granted by the 
Tasmanian Social Sciences Human Research Ethics Committee. Following the 
completion of the interview, participants were reimbursed AUD$30 for their time 
and other expenses. 
Data Manipulations and Data Handling 
To prepare data for analyses, a number of data manipulations and recoding of 
variables was conducted. Accommodation status was operationalised such that stable 
accommodation refers to having one's own house (including renting), or residing in 
their parents or family's house, while unstable accommodation included living in a 
boarding house/hostel, a shelter/refuge, or being of no fixed address/homeless. 
Education was defined as number of years of education and ranged between 0 and 12 
years. Treatment status was defined as whether the participant was undertaking 
treatment at the time of the interview or not undertaking any treatment. Frequency of 
injecting was divided into three categories; being weekly or less, more than weekly 
but less than daily, and daily or more frequent injecting. Duration of injecting and 
• age was not categorised, and remained as a scale variables in all analyses. Prison 
history was defined as whether the participant had ever been imprisoned (not 
inclusive of remand without sentence). Ethnicity was operationalised to two 
categories;. 'English' or 'other' as the main language spoken at home however was 
removed from analyses due to a lack of variability in the data (only one participant 
responded that their primary language spoken at home was not English). Sexual 
orientation was also deleted from analyses due to a high number of missing cases. 
All drug use variables refer to the number of days used in the 6 months prior to 
interview (maximum = 180). 
Variables with missing data were handled using listwise deletion within 
subsections, leaving a total of 269 participants for demographic and drug use 
variables, 228 participants for the AISS data, 258 participants for K10, and 249 
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participants for the BAS variables. Missing data was estimated for the variable 'in 
the last month did you always self- inject' using median substitution, such that the 
median of 0 (which was recorded for n=220 of the 264 complete cases) was used for 
5 cases. Multivariate analyses were conducted using full listwise deletion in all cases 
(n=218). 
Data was analysed using univariate and multiple linear regression in a latent 
variable context and was undertaken using MPlus (Muthen & Muthen, 2009) in order 
to identify variables that were significantly related to each factor of the BBV-TRAQ-
SV. Additionally, in order to produce a more easily interpreted prediction, a 
categorical outcome variable was produced, being the presence of any BBV 
transmission risk (a score on the BBVTRAQ >0), and significant predictors of this 
categorical variable were identified using univariate and multivariate logistic 
regression models. For all analyses, the Mean and Variance-Adjusted Weighted 
Least Squares (WLSMV) estimator was used as simulation studies have 
demonstrated that this estimator provides robust estimates of model coefficients for 
continuous and ordered categorical data even if data are not multivariately normally 
distributed (Muthen & Muthen, 2009). 
Results 
BBV-TRAQ-SV 
Just under half of the sample (n = 121, 45.0%) received a score of 0 on the 
BBV-TRAQ-SV indicating that no BBV transmission risk behaviours were present 
in the month prior to questionnaire completion (Figure 1). Means and standard 
deviations for BBV-TRAQ-SV total scale, Needle and Syringe Contamination, Other 
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Injecting Equipment Contamination, and Second Person Contamination subscales are 
presented in Table 2. 
140 
120 
100 
80 
E 60 40 
20 
0 \CI rf? (50 ,b,0 530 530 AO ,b0 5b0 c:30 	43 1,0 630 c30 	qp op QC, 	\c" 
\\ 0;\ 	43■ co\ 	,z;\ 	.‘;'• 	\'• \'• \:• 	 „s:• „:"1, 
 
BBV-TRAO-SV Score 
Figure 1. Distribution of responses to the BBV-TRAQ-SV. 
Table 2 
Means, Standard Deviations, Number of Participants who Scored 0 (no risk), and 
Possible Score Range for BBV-TRAQ-SV Subscales (N = 269) 
SD 	0% (n) 	Range 
Total 	 11.53 	19.07 	45.0 (121) 0-215 
Needle and Syringe Contamination 	3.53 	7.65 	70.6 (190) 0-100 
Other Injecting Equipment Sharing 	5.76 	12.78 	73.2 (197) 0-85 
Second Person Contamination 	2.25 	4.83 	68.0 (183) 0-30 
Measurement Models 
Measurement models were conducted by fitting one factor congeneric models 
to the BBV-TRAQ-SV scale. Items were treated as ordered categories and the 
WLSMV estimator was used rather than ordinary least squares, as stimulation studies 
have demonstrated that this is more robust for ordered categorical and non-
multivariate normal datasets (Muthen & Muthen, 2009). 
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Firstly, confirmatory factor analyses were conducted for the original 
published model of the full BBV-TRAQ-SV scale and subscales. Results for the fit 
statistics of Chi-square, Root Mean Square Error of Approximation (RMSEA), and 
Tucker-Lewis index (TLI) all fall outside of an acceptable range, demonstrating that 
none of these models provided a good fit to the data (Table 3). It is noted that the 
Needle/Syringe Contamination, Other Equipment Contamination, and Second Person 
Contamination factors are fall in the range of acceptable fit indices by the 
Comparative Fit Index (CFI; >0.9: Tabachnick & FideII, 2001). However, in the 
context of the unacceptable values for all remaining fit indices, none of these 
measurement models could be accepted as providing good fit to the data. 
Table 3 
Fit Statistics for Published Model 
Factor Chi-square test of 
model fit 
CFI TLI RMSEA 
Full scale (items 1-15) 178.38, p<0.001 0.83 0.84 0.17 
Needle/syringe contamination 
(items 1-4)* 
6.99, p=0.03 0.96 0.885 0.096 
Other equipment contamination 
(items 5-9) 
14.93, p=0.0019 0.961 0.935 0.122 
Second person contamination 
(items 10-15) 
55.29, p<0.001 0.958 0.937 0.218 
*Items 1-4 produce non-positive definite matrix; analysis conducted treating items as 
continuous due to absent scores in some categories 
Previous research by Bruno, de Graaf, and Antel (2007) conducted an 
exploratory factor analysis and identified an alternative five factor model of the 
BBV-TRAQ-SV; being Needle and Syringe Contamination, Other Injecting 
Equipment Contamination, Exposure from Assisting Others to Inject, Exposure from 
being Assisted to Inject, and Needlestick exposure. This factor analysis identified 
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that the psychometric properties of the subscales are improved by separating Second 
Person Contamination to exposure from being injected by others and injecting others, 
and that the item assessing needlestick exposure is largely unrelated to the subscale it 
was originally allocated to (Needle and Syringe Contamination). 
Table 4 below presents the results of a confirmatory factor analysis which 
assessed the extent to which the proposed scales highlighted above fit the data. The 
Needle and Syringe Contamination factor comprises items assessing injection with 
another person's used syringe, injection with a needle/syringe after another person 
has already injected some of its contents, re-using a needle/syringe taken out of a 
shared disposal/sharps container, and wiping of own injection site with an object 
which had been used by another. The Other Equipment Contamination factor 
comprises items assessing injection with a drug filtered through another person's 
filter, injection with a drug prepared in another person's used spoon or mixing 
container, and injection with a drug that had come into contact with another person's 
used needle/syringe. The Contamination after Injecting Others consists of one item 
only, being injection with a drug that had been prepared immediately after 'assisting' 
another person with their injection. The Contamination from Being Injected' factor 
comprised items assessing injection with a drug that was prepared by another person 
who had already injected or assisted in someone else's injection, injection by another 
person who had already injected or assisted in someone else's injection, and another 
person touched your injection site. The Contamination from Needlestick factor 
consisted of one item, which assessed the receiving of an accidental needle-
stick/prick from another person's used needle/syringe. As can be seen in Table 4, the 
fit statistics for these models uniformly fall within the acceptable ranges and this 
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model of the BBV-TRAQ-SV structure is clearly more appropriate than the initial 
published structure (Table 3). 
Table 4 
Fit Statistics for the Alternative Model (N=269) 
Factor 	Chi-square test CFI 	TLI 	RMSEA 
of model fit  
Needle/syringe 	1.27, p=0.52 	1.00 	1.02 	<0.001 
contamination 
(Items 1,2,4,9) 
Other 	 161.13, 	1.00 	1.00 	<0.001 
equipment 	p=0.97* 
contamination 
(Items 5,6,8) 
Contamination 	- 	 - 	 _ 
after injecting 
others (Item 10) 
Contamination 	139.82, 	1.00 	1.00 	<0.001 
from being 	p=0.99* 
injected 
(Items 11,12,15) 
Contamination 	- 	 - 
from 
needlestick 
(Item 3) 
Note: Item 7 produced non-positive definite matrices due to high multicollinearity with other variables 
and was therefore excluded; items 13 and 14 had zero variance in this sample so were not able to 
contribute to these analyses. Single items are not appropriate for confirmatory factor analytic 
modelling. *Chi-square from analyses using the robust maximum likelihood estimator (MLR) due to 
convergence problems in WLSMV analyses 
Factor loadings for each of the subscales are listed below in tables 5, 6, and 7, 
respectively. Each of the items was noted to be statistically significant. 
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Table 5 
Factor Loadings for Items Comprising Needle/Syringe Contamination Factor 
Item 	Item Content 	 Factor 
Number loading 
1 	Injection with another person's used needle/syringe 	0.92 
2 Injection with a needle/syringe after another person had 	0.82 
already injected some of its contents 
4 	Re-use of a needle/syringe taken out of a shared 	 0.53 
disposal/sharps container 
9 	Wiping own injection site with an object (e.g, swab, tissue, 	0.64 
hanky, towel etc) which had been used by another person 
Table 6 
Factor Loadings for Items Comprising Other Equipment Contamination Factor 
Item 	Item Content 	 Factor 
loading 
5 
	
Injection of a drug that was filtered through another 	0.52 
person's filter 
6 
	
Injection of a drug that was prepared in another person's 	0.99 
used spoon or mixing container 
8 
	
Injection of a drug which had come into contact with 	0.58 
another person's used needle/syringe  
Table 7 
Factor Loadings for Items Comprising Contamination From Being Injected Factor 
Item 	Item Content 	 Factor 
loading 
11 
	
Injection of a drug that was prepared by another person who 0.87 
had already injected or assisted someone else's injection 
12 
	
Injection by another person who had already injected or 	0.99 
assisted in someone else's injection 
15 
	
Injection site touched by another person (e.g., to feel for a 	0.92 
vein, to wipe away blood, or to stop bleeding) 
Linear Regression Analyses 
Using this alternative model of the BBV-TRAQ-SV, univariate linear 
regression analyses were conducted, within a latent variable context (where scale 
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variables are involved in the analyses, the latent structure of this scale was 
incorporated in the analysis rather than a subscale, hence reducing measurement 
error) to determine which variables predict BBV transmission risk as identified on 
the BBV-TRAQ-SV. This was conducted separately for each of the identified 
factors, and also for a categorical model which assessed whether the participant had 
any risk on the BBV transmission risk as measured by the BBV-TRAQ-SV. Note 
that the variable of the number of days of tobacco use was not able to be analysed as 
either continuous or categorical data due to distributional problems (almost all cases 
were daily use, with near-zero variance) and as such is not included in the analyses 
below. Similarly, the 'intensity' construct of the Arnett Inventory of Sensation 
Seeking was also unable to be calculated either by treating items as ordinal or 
continuous due to violations of data assumptions, and therefore is not included in the 
analyses. 
Variables identified in the univariate analyses to be significant or to approach 
significance (p <0.10) were included in a multivariate linear regression analysis for 
each factor. All these analyses were conducted with full listwise deletion, leaving a 
remaining sample of 218 participants. Details as to the results of the univariate and 
multivariate linear regression analyses for each factor and overall risk is presented 
below. 
Factor 1: Needle and Syringe Contamination 
As can be seen in Table 8, a number of variables were found to significantly 
predict the factor of Needle and Syringe Contamination, although were uniformly of 
relatively small magnitude (explaining <10% of variance in this factor) . Stable 
accommodation, the number of days of benzodiazepine injection in the last six 
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months, depression and anxiety as measured by the K10, and the number of days 
used prescription stimulants in the last six months were all positively related to 
Needle/Syringe Contamination. Significant inverse relationships were found between 
the Needle/Syringe Contamination factor and the 'drive' and 'fun-seeking' concepts 
of the Behavioural Activation Scale. A number of variables were also identified as 
approaching significance (p < 0.1); being a positive relationship between always self-
injecting in the previous month, the 'Novelty' construct of the AISS scale, and the 
'reward responsiveness' construct of the Behavioural Activation Scale. The 
'Intensity' construct from the AISS scale was not included in univariate analyses due 
to a failure of the model to be produced as a result of data violations of the 
assumptions for analysis. 
Table 8 
Univariate Linear Regression Analyses for Factor 1: Needle and Syringe 
Contamination 
95% CI of B  
Variable 	B 	P 	R2 	Lower 	Upper 
bound 	bound 
Demographic Variables 
Sex (M=1) 0.025 0.908 0.000 -0.541 0.591 
Age 0.002 0.866 0.000 -0.034 0.039 
Duration of IV 
use 
0.013 0.332 0.011 -0.022 0.048 
IV frequency 0.093 0.574 0.004 -0.333 0.519 
Stable 
accommodation 
0.710 0.007** 0.065 0.035 1.385 
(Unstable = 1) 
Prison history 
(prison = 1) 
0.231 0.276 0.014 -0.315 0.778 
Years of 
education 
0.028 0.674 0.002 -0.145 0.202 
Treatment (1=in 
treatment) 
0.005 0.979 0.000 -0.504 0.514 
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Pharmacological Effects of Drug Use (number of days used in past six months) and 
Injection Variables 
IV 
benzodiazepines 
0.008 0.035* 0.048 -0.002 0.017 
Benzodiazepines 0.002 0.386 0.021 -0.003 0.007 
Amphetamines 0.001 0.726 0.001 -0.004 0.006 
Cannabis -0.002 0.680 0.017 -0.011 0.008 
Prescription 
stimulants 
0.008 0.018* 0.046 -0.001 0.018 
Cocaine -0.002 0.975 0.000 -0.186 0.182 
LSD 0.031 0.429 0.008 -0.070 0.132 
MDMA 0.009 0.547 0.003 -0.028 0.045 
Alcohol 0.001 0.780 0.001 -0.005 0.006 
Any opiate 0.000 0.851 0.001 -0.005 0.006 
Public injection 
last time 
0.178 0.452 0.007 -0.433 0.790 
(1 =public) 
Self injection 0.193 0.057(*) 0.037 -0.068 0.453 
Psychological Distress Variables : Kessler 10 
Anxiety 0.326 0.012** 0.065 -0.659 0.007 
Depression 0.461 0.001*** 0.075 -0.813 -0.110 
Impulsivity Variables 
AISS Novelty 0.329 0.081(*) 0.025 -0.156 0.814 
AISS Intensity _ - - 
A 
BAS Drive -0.294 0.048* 0.044 -0.676 0.088 
BAS Reward 0.221 0.076(*) 0.021 -0.100 0.542 
Responsiveness 
BAS Fun -0.268 0.004** 0.038 -0.511 -0.025 
Seeking 
Note: (*) p <0.10, * p <0.05, ** p <0.01 ***p< 0.001, A Model unable to be 
produced due to violations of data assumptions. 
Table 9 details the multivariate model for the Needle/Syringe Contamination 
factor, incorporating all variables identified as p<0.10 in the univariate analyses. 
Together, these variables accounted for 31.7% of variance in the latent model of this 
factor. While each of these predictors when considered individually was a 
statistically significant predictor of Needle/Syringe Contamination, when these are 
considered together, the strongest (or, most important) predictors were the construct 
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of 'fun-seeking' on the Behavioural Activation Scale, which was inversely related to 
Needle/Syringe Contamination (B = -0.796, p = 0.048) and the frequency of use of 
pharmaceutical stimulants, which was positively related to Needle/Syringe 
Contamination (B = 0.008, p = 0.070). 
Table 9 
Multivariate Model for Factor 1: Needle and Syringe Contamination 
95% CI of B 
Variable B P Lower 	Upper 
bound bound 
K10 Anxiety 0.035 0.876 -0.618 0.548 
K10 Depression 0.267 0.291 -0.917 0.384 
BAS Drive 0.086 0.796 -0.769 0.941 
BAS Fun-seeking -0.796 0.048* -1.832 0.241 
BAS Reward 0.776 0.107 
Responsiveness -0.465 2.017 
AISS Novelty 0.221 0.683 -1.169 1.61 
Stable accommodation 0.463 0.112 -0.288 1.215 
Days used IV 0.008 0.222 
Benzodiazepines -0.008 0.023 
Pharmaceutical 0.008 0.070(*) 
stimulants days -0.003 0.02 
Self inject 	 0.015 0.929 -0.424 0.454 
Note: (*) p < 0.10, * p < 0.05 
Factor 2: Other Equipment Contamination 
Univariate analyses for the factor of Other Equipment Contamination 
revealed that the number of days used alcohol in the last six months, anxiety and 
depression as assessed by the K10, and always having self-injected in the last month 
was positively and significantly predicted risk of Other Equipment Contamination on 
the BBV-TRAQ-SV, with individual predictors explaining up to 14% of the variance 
in the factor. Two predictors were identified as approaching significance in 
predicting other equipment contamination risk, and these were a negative 
p Variable 	B 
95% CI of B  
R2 	Lower 	Upper 
bound 	bound 
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relationship with sex (males being less risky on this variable than females), and a 
positive relationship with the number of days used benzodiazepines in the last six 
months (refer to Table 10). 
Table 10 
Univariate Linear Regression Analyses for Factor 2: Other Equipment 
Contamination 
Demographic Variables 
Sex (M=1) -0.239 0.052* 0.047 -0.555 0.077 
Age 0.001 0.933 0.000 -0.017 0.018 
Duration of IV 
use 
-0.001 0.835 0.000 -0.018 0.015 
IV frequency 0.059 0.510 0.005 -0.172 0.290 
Stable 
accommodation 
0.217 0.165 0.021 -0.185 0.618 
(Unstable = 1) 
Prison history 
(prison = 1) 
-0.147 0.270 0.015 -0.490 0.196 
Years of 
education 
(continuous) * 
0.023 0.452 0.004 -0.055 0.100 
Treatment (1=in 
treatment) * 
-0.085 0.398 0.007 -0.345 0.175 
Pharmacological Effects of Drug Use 
Injection Variables 
(number of days used in past six months) and 
IV 
benzodiazepines 
0.003 0.163 0.019 -0.002 0.008 
Benzodiazepines 0.003 0.078(*) 0.175 -0.001 0.008 
Amphetamines 0.001 0.275 0.010 -0.002 0.004 
Cannabis* 0.000 0.900 0.000 -0.002 0.002 
Prescription 
stimulants * 
0.003 0.193 0.023 -0.003 0.010 
Cocaine 0.012 0.547 0.005 -0.040 0.064 
LSD 0.014 0.432 0.006 -0.032 0.059 
MDMA 0.004 0.575 - 0.003 -0.015 0.024 
Alcohol 0.002 0.030* 0.041 0.000 0.005 
Any opiate 0.000 0.853 0.000 -0.002 0.002 
Public injection 0.003 0.984 0.000 -0.332 0.620 
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last time 
(1=public) 
Self injection 0.229 0.000*** 0.139 0.062 0.396 
Psychological Distress Variables : Kessler 10 
Anxiety 0.291 0.002** 0.116 -0.538 -0.043 
Depression 0.245 0.027* 0.077 -0.530 0.040 
Impulsivity Variables 
AISS Novelty 0.139 0.256 0.012 -0.176 0.453 
AISS Intensity A - 
BAS Drive -0.052 0.587 0.004 -0.296 0.193 
BAS Reward 0.086 0.302 0.012 -0.129 0.301 
Responsiveness ° 
BAS Fun- -0.172 0.154 0.037 -0.483 0.139 
Seeking 
Note: (*) p <0.10, * p <0.05, ** p <0.01 ***p< 0.001, A Model unable to be 
produced due to data violations of assumptions, °Regression model would not 
converge due to data distributional issues. 
In a multivariate analysis (Table 11), the factors identified as significant or 
approaching significance together accounted for 32.5% of the variance in the latent 
model of the Other Equipment Contamination factor. When the variables entered in 
the univariate analyses are examined in this context, the significant predictor of self-
injection was identified (B = 0.260, p < 0.001), along with the number of days of 
alcohol used in the last six months being positively related to the factor (B = 0.003, p 
= 0.052), and anxiety as measured by K10 being positively related (B = 0.188, p = 
0.086) to other equipment contamination although not significantly so (p < 0.10). 
Therefore, the variables of anxiety, self-injection, and number of days of alcohol use 
were identified as the most important variables in predicting risk of BBV 
transmission through contamination with other injecting equipment. 
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Table 11 
Multivariate Model for Factor 2: Other Equipment Contamination 
95% CI of B 
Variable B P Lower Upper 
bound bound 
K10 Anxiety 0.188 0.086(*) -0.470 0.094 
KIO Depression -0.138 0.298 -0.203 0.478 
Sex -0.134 0.378 -0.525 0.257 
Days used 
benzodiazepines 0.002 0.122 -0.001 0.005 
Days used 
alcohol 0.003 0.052(*) -0.001 0.006 
Self-injection 0.260 0.000*** 0.070 0.450 
Note: (*) p <0.10, ***p< 0.001 
Factor 3: Contamination From Injecting Others 
Sex (males being more at risk than females) and the number of days used 
alcohol in the previous six months were found to be positively related to the 
Contamination from Injecting Others factor when subjected to univariate linear 
regression analyses, although both predictors explained less than 10% of the variance 
in this factor. The 'reward responsiveness' construct of the Behavioural Activation 
Scale was noted to approach significance levels in univariate analyses and was 
positively related to the factor (see Table 12). 
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Table 12 
Univariate Linear Regression Analyses for Factor 3: Contamination From Injecting 
Others 
95% CI of B  
Variable 	B 	p for B 	R2 for 	95% CI of 95% CI of 
value latent 	B (Low) 	B (High) 
variable 
Demographics Variables 
Sex (M=1) 0.450 0.027* 0.045 -0.076 0.975 
Age -0.004 0.756 0.001 -0.036 0.028 
Duration of IV 
use 
0.000 0.979 0.000 -0.034 0.034 
Frequency of IV 
use 
0.070 0.640 0.002 -0.315 0.454 
Stable 
accommodation 
-0.051 0.850 0.000 -0.752 0.649 
(Unstable = 1) 
Prison history 
(prison = 1) 
0.001 0.996 0.000 -0.519 0.521 
Years of 
education 
(continuous) 
-0.009 0.898 0.000 -0.183 0.166 
Treatment (1=in 
treatment) 
-0.137 0.452 0.005 -0.607 0.333 
Pharmacological Effects of Drug Use (number of days used in past six months) and 
Injection Variables 
IV 
benzodiazepines 
0.002 0.609 0.002 -0.007 0.011 
Benzodiazepines -0.001 0.481 0.005 -0.004 0.002 
Amphetamines 0.001 0.652 0.002 -0.004 0.006 
Cannabis 0.001 0.263 0.011 -0.002 0.005 
Prescription 
stimulants 
0.004 0.238 0.007 -0.004 0.012 
Cocaine -0.106 0.463 0.092 -0.480 0.267 
LSD -0.013 0.828 0.001 -0.166 0.140 
MDMA 0.015 0.222 0.010 -0.017 0.048 
Alcohol 0.006 0.000*** 0.067 0.002 0.010 
Any opiate -0.001 0.596 0.002 -0.004 0.003 
Pharmaceutical 
opiate 
0.001 0.690 0.002 -0.004 0.005 
Public injection 
last time 
-0.097 0.678 0.002 -0.697 0.503 
(1 =public) 
Self injection -0.012 0.912 0.000 -0.294 0.270 
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Psychological Distress Variables: Kessler 10 
Anxiety 0.031 0.808 0.001 -0.365 0.302 
Depression 0.062 0.671 0.002 -0.441 0.316 
Impulsivity Variables 
AISS Novelty -0.079 0.741 0.001 -0.691 0.534 
AISS Intensity A - - - - 
BAS Drive 0.007 0.965 0.000 -0.257 0.266 
BAS Reward 0.319 0.057(*) 0.037 -0.113 0.750 
Responsiveness 
BAS Fun 0.074 0.645 0.002 -0.341 0.490 
Seeking 
Note: (*) p <0.10, * p <0.05, ***p< 0.001, A Model unable to be produced due to 
data violations of data assumptions. 
The multivariate model, comprising all variables identified as statistically 
significant (p<0.01) in univariate analyses (Table 13) accounted for 16.6% of 
variance in the Contamination from Injecting Others factor. The most important 
variables in predicting the factors were found to be sex (males more at risk than 
females: B = 0.611, p = 0.012), and the number of days of alcohol use in the 
preceding six months (B = 0.007, p < 0.001). These variables were both positively 
and significantly related to the Contamination from Injecting Others factor. 
Table 13 
Multivariate Model for Factor 3: Contamination From Injecting Others 
95% CI of B 
Variable B P Lower 	Upper 
bound 	bound 
BAS Reward 
responsiveness 0.250 0.188 -0.239 	0.738 
Sex 0.611 0.012* -0.013 	1.235 
Alcohol days used 0.007 0.000*** 0.002 	0.012 
Note: * p <0.05, ***p< 0.001 
P Variable 	B 
95% CI of B  
R2 	Lower 	Upper 
bound 	bound 
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Factor 4: Exposure From Being Injected 
Univariate analyses for the factor of Exposure from Being Injected revealed 
that duration of IV use, and the number of days of any opiate use in the preceding six 
months was inversely and significantly related to the factor. The variables of stable 
accommodation, always having self-injected in the preceding month, anxiety as 
measured by the K10, and the 'novelty' construct of the AISS was positively and 
significantly associated with the exposure from being injected factor. A number of 
variables were also identified as approaching statistical significance in predicting the 
factors; namely age, and sex (females more at risk than males) were inversely 
associated, while the number of days of MDMA use and alcohol use in the previous 
six months, depression as measured by the K10, and having injected in a public 
location at the last injection time were positively associated with the factor Exposure 
from Being Injected (see Table 14). 
Table 14 
Univariate Linear Regression Analyses for Factor 4: Exposure from Being Injected 
by Others 
Demographic Variables 
Sex (M=1) -0.292 0.085(*) 0.026 -0.730 0.145 
Age -0.018 0.086(*) 0.026 -0.044 0.009 
Duration of IV 
use 
-0.028 0.030* 0.054 -0.062 0.005 
IV frequency -0.160 0.249 0.014 -0.518 0.198 
Stable 
accommodation 
0.708 0.001** 0.076 0.178 1.239 
(Unstable = 1) 
Prison history 
(prison = 1) 
-0.301 0.112 0.025 -0.788 0.187 
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Years of 
education 
(continuous) 
0.015 0.761 0.001 -0.112 0.142 
Treatment (1=in 
treatment) 
-0.066 0.689 0.001 -0.494 0.361 
Pharmacological Effects of Drug Use (number of days used in past six months) and 
Injection Variables 
IV -0.003 0.726 0.007 -0.023 0.017 
Benzodiazepines 
Benzodiazepines -0.001 0.388 0.012 -0.005 0.003 
Amphetamines 0.002 0.355 0.008 -0.003 0.006 
Cannabis 0.001 0.209 0.016 -0.002 0.005 
Prescription 
stimulants 
0.002 0.586 0.002 -0.007 0.010 
Cocaine 0.006 0.858 0.000 -0.079 0.091 
LSD 0.000 0.994 0.000 -0.117 0.118 
MDMA 0.019 0.065(*) 0.020 -0.008 0.047 
Alcohol 0.003 0.070(*) 0.024 -0.001 0.007 
Any opiate -0.003 0.019* 0.053 -0.006 0.000 
Pharmaceutical 
opiate 
-0.002 0.143 0.026 -0.006 0.002 
Public injection 
last time 
0.315 0.075(*) 0.026 -0.141 0.772 
(1 =public) 
Self injectiong 0.517 0.000*** 0.260 0.349 0.685 
Psychological Distress Variables: Kessler 10 
Anxiety 0.227 0.044* 0.036 -0.517 0.063 
Depression 0.236 0.061(*) 0.033 -0.561 0.089 
Impulsivity Variables 
AISS Novelty 0.402 0.009** 0.054 0.006 0.798 
AISS Intensity A - 
BAS Drive 0.101 0.490 0.005 -0.275 0.476 
BAS Reward 0.037 0.722 0.001 -0.229 0.303 
Responsiveness 
BAS Fun- -0.116 0.365 0.007 -0.447 0.214 
Seeking 
Note: (*) p <0.10, * p <0.05, ** p <0.01 ***p< 0.001, A Model unable to be 
produced due to data violations of data assumptions, # Regression model would not 
converge due to data distributional issues. 
Table 15 details the multivariate model for the Exposure from Being Injected 
by Others factor, and together accounted for 49.6% of the variance in the latent 
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variable. The most important predictors were not always self-injecting in the month 
prior to data collection (B = 0.529, p < 0.001) which was positively related to the 
factor, as well as anxiety as measured by the K10 which was noted to have an inverse 
relationship to exposure from being injected by others (B = -0.484, p = 0.001). 
Depression as measured by the K10 was also identified as a strong predictor for this 
factor (B = 0.397, p < 0.001). However, it is noted that due to this factor assessing 
only exposure from being injected by others, this excludes those participants who 
always inject themselves, such that if one does not allow anyone else to assist with 
injecting, then they are at no risk of exposure to BBV from injection by others. 
Table 15 
Multivariate Model for Factor 4: Exposure from Being Injected by Others 
95% CI of B 
Variable Lower 
bound 
Upper 
bound 
K10 Anxiety -0.484 0.001*** 0.105 0.863 
K10 Depression 0.397 0.011* -0.799 0.006 
AISS Novelty -0.124 0.369 -0.479 0.231 
Age 0.000 1.000 -0.049 0.049 
Sex -0.136 0.535 -0.698 0.427 
Duration of IV use -0.002 0.950 -0.072 0.068 
Stability of 
accommodation 0.428 0.103 -0.248 1.104 
Days used ecstasy 0.010 0.410 -0.021 0.041 
Days used alcohol 0.003 0.174 -0.003 0.010 
Days used any opiate 0.000 0.848 -0.005 0.005 
Public injection last time 
injected 0.340 0.193 -0.333 1.012 
Self-injection 0.529 0.000*** 0.312 0.747 
Note: * p < 0.05, ***p< 0.001 
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Factor 5: Needlestick Contamination 
Table 16 below identifies the results of univariate linear regression analyses 
in the prediction of BBV transmission through the Needlestick Contamination factor. 
These analyses revealed that depression and anxiety as measured by the K10 were 
significant predictors, and were positively related to the factor of Needlestick 
Contamination, individually explaining up to 20% of the variance in this factor. 
Having had the last injection occurring in a public place was noted to approach 
statistical significance, and was also positively related to the factor. Similarly, the 
variable of IV use frequency was also found to approach significance, and was 
positively related to the Needlestick Contamination factor. 
Table 16 
Univariate Linear Regression Analyses for Factor 5: Needlestick Contamination 
95% CI of B 
Variable B P R2 Lower 
bound 
Upper 
bound 
Demographic Variables 
Sex (M=1) -0.168 0.532 0.007 -0.860 0.524 
Age -0.005 0.813 0.002 -0.065 0.054 
Duration of IV 
use 
0.014 0.584 0.010 -0.050 0.078 
Frequency of IV 
use 
0.379 0.076(*) 0.056 -0.171 0.929 
Stable 
accommodation 
0.058 0.916 0.000 -1.361 1.476 
(Unstable = 1) 
Prison history 
(prison = 1) 
0.000 1.000 0.000 -0.856 0.856 
Years of 
education 
(continuous) 
0.038 0.632 0.003 -0.167 0.243 
Treatment (1=in 
treatment) 
-0.191 0.464 0.009 -0.865 0.483 
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Pharmacological Effects of Drug Use (number of days used in past six months) and 
Injection Variables 
IV 0.007 0.112 0.037 -0.005 0.019 
Benzodiazepines 
Benzodiazepines 0.002 0.382 0.014 -0.003 0.006 
Amphetamines -0.001 0.668 0.004 -0.008 0.006 
Cannabis 0.000 0.764 0.001 -0.005 0.004 
Prescription 
stimulants 
0.002 0.654 0.003 -0.010 0.015 
Cocaine 0.005 0.923 0.000 -0.136 0.147 
LSD 0.005 0.960 0.000 -0.247 0.257 
MDMA 0.011 0.668 0.005 -0.054 0.075 
Alcohol 0.000 0.921 0.000 -0.008 0.008 
Any opiate 0.002 0.296 0.022 -0.003 0.007 
Public injection 
last time 
-0.764 0.082(*) 0.104 -1.893 0.366 
(1 =public) 
Self injection 0.150 0.360 0.018 -0.273 0.573 
Psychological Distress Variables: Kessler 10 
Anxiety 0.613 0.000*** 0.198 -1.021 -0.204 
Depression 0.602 0.000*** 0.163 -1.014 -0.190 
Impulsivity Variables 
AISS Novelty 	0.032 0.916 0.000 -0.754 0.818 
AISS Intensity A - - - - 
BAS Drive -0.110 0.630 0.005 -0.698 0.478 
BAS Reward -0.002 0.994 0.000 -0.810 0.805 
Responsiveness 
BAS Fun -0.254 0.135 0.026 -0.692 0.184 
Seeking 
Note: (*) p <0.10, ***p< 0.001, A Model unable to be produced due to data 
violations of data assumptions, it Regression model would not converge due to data 
distributional issues. 
Variables found to be significant or approach significance in the univariate 
analyses were entered in the multivariate model and together accounted for 21.8% of 
variance in the Needlestick Contamination factor (see Table 17). While each of the 
predictors entered into the multivariate analyses were significant predictors 
individually to the overall factor of Needlestick Contamination, the most important 
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predictor when the variables were considered together was the variable of anxiety as 
assessed by the K10. This variable was found to be a statistically significant 
predictor, and was positively related to the factor of Needlestick Contamination (B = 
0.763, p = 0.002). 
Table 17 
Multivariate Model for Factor 5: Needlestick Contamination 
 
95% CI of B  
Lower 	Upper 
bound bound 
 
Variable 
 
KIO Anxiety 	0.763 	0.002** 	-1.39 	-0.136 
K10 Depression 	-0.301 0.228 -0.342 0.944 
Frequency of IV use 	0.341 	0.322 	-0.547 	1.229 
Public Injection last 
time injected 	-3.249 	0.992 	-867.152 	860.654 
Note: ** p <0.01 
Prediction of Any Risk 
Table 18 below indicates the extent to which each variable predicts whether a 
person had any risk of BBV transmission as measured by the BBV-TRAQ-SV 
instrument. Univariate analyses revealed that the number of days of alcohol use in 
the preceding six months, not always having self-injected in the previous month, and 
the 'novelty' construct of the Arnett Inventory of Sensation Seeking each were found 
to independently and significantly predict overall BBV transmission risk, and were 
all positively related to the factor. Depression as measured by the K10 instrument 
was also found to be a significant predictor of risk, and this was also a positive 
relationship. The factors of stable accommodation and the number of days of 
amphetamines used in the previous six months were noted to approach statistical 
significance, and are recognised as important predictors of risk of BBV transmission. 
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Both these variables were positively related to the factor meaning that unstable 
accommodation and more frequent use of amphetamines are associated with a greater 
likelihood of engaging in BBV transmission risk behaviours. 
Table 18 
Univariate Linear Regression Analyses for the Prediction of Any Risk on the BBV-
TRAQ-SV. 
  
95% CI of B  
R2 	Lower 	Upper 
bound 	bound 
 
Variable 	B p 
 
Demographic Variables 
Sex (M=1) -0.184 0.249 0.008 -0.595 0.227 
Age -0.011 0.268 0.007 -0.035 0.014 
Duration of IV 
use 
-0.016 0.135 0.013 -0.044 0.012 
Frequency of IV 
use 
-0.153 0.198 0.010 -0.459 0.153 
Stable 
accommodation 
0.408 0.073(*) 0.020 -0.178 0.994 
(Unstable = 1) 
Prison history 
(prison = 1) 
-0.117 0.481 0.003 -0.544 0.310 
Years of 
education 
(continuous) 
0.031 0.579 0.002 -0.112 0.173 
Treatment (1=in 
treatment) 
-0.054 0.726 0.001 -0.451 0.343 
Pharmacological Effects of Drug Use (number of days used in past six months) and 
Injection Variables 
IV 0.004 0.224 0.009 -0.004 0.011 
Benzodiazepines 
Benzodiazepines 0.001 0.278 0.007 -0.002 0.004 
Amphetamines 0.003 0.055(*) 0.024 -0.001 0.007 
Cannabis 0.000 0.972 0.000 -0.003 0.003 
Prescription 
stimulants 
0.005 0.236 0.012 -0.006 0.015 
Cocaine 0.050 0.219 0.022 -0.055 0.155 
LSD -0.014 0.622 0.002 -0.084 0.057 
MDMA 0.025 0.117 0.024 -0.016 0.065 
Alcohol 0.003 0.048* 0.024 -0.001 0.008 
Any opiate -0.001 0.259 0.007 -0.004 0.002 
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Public injection 
last time 
0.183 0.291 0.007 -0.263 0.630 
(1 =public) 
Self injection 0.400 0.000*** 0.116 0.131 0.669 
Psychological Distress Variables: Kessler 10 
Anxiety 0.310 0.004** 0.052 -0.583 -0.036 
Depression 0.202 0.87 0.019 -0.507 0.102 
Impulsivity Variables 
AISS Novelty 0.391 0.045* 0.036 -0.111 0.894 
AISS Intensity A - - - - - 
BAS Drive 0.174 0.203 0.012 -0.178 0.526 
BAS Reward 0.094 0.539 0.003 -0.301 0.489 
Responsiveness 
BAS Fun -0.093 0.513 0.004 -0.460 0.274 
Seeking 
Note: (*) p <0.10, * p <0.05, ** p <0.01 ***p< 0.001, A Model unable to be 
produced due to data violations of data assumptions. 
Finally, to assess the overall risk of BBV transmission risk as assessed by the 
BBV-TRAQ-SV, a multivariate model was created using the variables of K10 
anxiety, AISS novelty, stability of accommodation, days used amphetamines, days 
used alcohol, and self-injection. Together, these variables explain 21.4% of 
variability and the most important predictors were found to be anxiety as assessed by 
the K10 (B = 0.204, p = 0.073), which was positively related to transmission risk, 
and not always having self-injected in the previous month (B = 0.418, p < 0.001), 
which was positively related to the overall factor (see Table 19). 
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Table 19 
Multivariate Model for the Prediction of Any Risk on the BBV-TRAQ -SV. 
95% CI of B 
Variable B P Lower Upper 
bound bound 
K10 Anxiety 0.204 0.073(*) -0.496 0.089 
AISS Novelty 0.254 0.229 -0.290 0.797 
Stability of 
accommodation 0.142 0.626 -0.607 0.890 
Days used 
amphetamines 0.003 0.147 -0.002 0.007 
Days used alcohol 0.003 0.134 -0.002 0.009 
Self-injection 0.418 0.000*** 0.123 0.714 
Note: (*) p <0.10, ***p< 0.001 
Discussion 
The current study aimed to determine which variables are the most important 
in predicting BBV risk behaviours in a sample of injecting drug users. Based on 
variables identified in previous research as potentially predictive of BBV risk the 
variables investigated in the current study included demographic, drug use and 
injection variables, depression and anxiety, and impulsivity domains. Unstable 
accommodation, amphetamine use, alcohol use, less occasions of self-injection, 
higher symptoms of anxiety (K10), and a high tendency to seek out novel stimulation 
(AISS Novelty) emerged as relevant predictors of the overall risk of engaging in 
behaviours risky for the transmission of BBVs, however these were not consistent in 
regard to exposure to risk from contamination or needles or other injecting 
equipment, or contamination from other aspects of the injecting process (i.e. 
needlestick contamination, exposure from being injected by another person, exposure 
from injecting another person). Following are details of each variable examined and 
their contribution to BBV risk. 
159 
Demographic Variables 
It was hypothesised that the female sex will be associated with BBV risk 
behaviours (MacDonald et al., 2000; Maher et al., 2006; Maher et al., 2007). While 
female sex was not associated with increased risk of exposure on an overall 
composite measure of risk, the current study demonstrated that females in this 
sample were more at risk in specific aspects of the injection process: in particular, 
through the contamination of 'other' injecting equipment (e.g. spoons, water, 
tourniquets) as well as through exposure from being injected by others. The 
association between female gender and risk of contamination through being injected 
by another person is consistent with findings from Evans et al. (2003) who report that 
in their study of gender differences in injecting in San Francisco, females were more 
likely to be injected by others and therefore were exposed to more episodes of 
potential BBV transmission opportunities. The association between female gender 
and increased risk of contamination through 'other' injecting equipment is of 
significance, however it is noted that the sharing of peripheral injecting equipment 
such as waters, tourniquets, and cottons carries with it a relatively lower risk than 
contamination from shared needles and syringes (De, Roy, Boivin, Cox, & 
Morissette, 2008). In keeping with these significant variables, the results indicate that 
being female reduces the risk of contamination when assisting others to inject, as this 
behaviour was more common among males. Sex was found not to be a significant 
predictor for the factors of needle/syringe contamination or needlestick 
contamination. Therefore, female sex in the current context appears to be associated 
with some elements of BBV transmission risk, however is not a strong predictor of 
overall risk and does not support the literature (e.g. MacDonald et al., 2000; Maher et 
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al., 2006; Maher et al., 2007) which report that females are at a greater risk for the 
transmission of HCV and for sharing injecting equipment. 
Previous research indicates that in general, older age is associated with an 
increase in BBV transmission risk behaviours (e.g. Chang et al., 1998; Chetwynd et 
al., 1995; Diaz etal., 2001; Hagan et al., 2001; MacDonald et al., 2000) however the 
results of the current study identified no relationship between age and overall BBV 
transmission risk. Age was found not to be predictive of contamination through 
needles and syringes, other injecting equipment, through injecting others, or through 
needlestick exposure. By contrast, it was identified that as one's age increases, the 
risk of BBV exposure from being injected decreases, as risk associated with injection 
by others was more common among younger IDU. Therefore, the results suggest that 
the hypothesis that older age is associated with an increase in BBV risk is 
unsupported due to there being no overall association identified between age and 
BBV risk, and only one significant association with one aspect of BBV risk being 
identified (namely, risk from injection by others which is higher amongst younger 
mu). Similarly, the hypothesis that longer duration of IV use would be associated 
with an increased risk of engaging in risky behaviours for BBV transmission was not 
supported, as the results of the current study indicate that the longer one has been 
injecting for the exposure to BBV as a result of being injected by others decreases. 
Additionally, this variable was found not to be predictive of overall risk of BBV 
transmission behaviours, nor any of the alternate factors (contamination through 
needles and syringes, other injecting equipment, through injecting others, and 
through needlestick episodes). Taken together, these results suggest a trend (not 
significantly so) such that younger rpu and those who are newer initiates are those 
that are at an increased risk of poor injecting practices. This is consistent with the 
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literature which examines BBV incidence rates (i.e. Crofts et al., 1995; Hagan et al., 
1999; Van Beek et al., 1998) and suggests that those who are less experienced are 
more risky in their injection practices, perhaps due to lack of understanding of the 
BBV transmission risks associated with injecting, including when being injected by 
others. Therefore, these results suggest that this group of [DU, specifically those who 
are younger and who have less injecting experience, should be targeted for BBV 
interventions. This, however, is identified as a potentially challenging group to 
target, due to this group being new initiates and therefore less accessible for 
interventions. As such, intervention efforts may be best targeted to those LDU with 
more experience who are initiating others to injecting practices. By focussing on this 
group, education regarding BBV transmission risks can be provided, with the aim of 
creating a flow-on effect to new initiates. 
The frequency of injecting was hypothesised to be a significant predictor for 
BBV risk, particularly, that those who inject on a daily basis will be at greater risk 
than those who inject less frequently. The results indicate that this hypothesis was 
supported in relation to contamination by an accidental needlestick/prick with 
another person's used syringe, but not in relation to any of the other BBV factors 
(needle/syringe and other equipment contamination, contamination from injecting 
others and being injected by others), and similarly was also not predictive of overall 
risk of BBV transmission behaviours. This hypothesis therefore, was only partially 
supported and generally runs contrary to the significant body of research (e.g. Dwyer 
et al., 2002; MacDonald et al., 2000; Villano et al., 1997) which report that the more 
frequently someone injects, the more at risk they are of BBV transmission, 
supposedly due to cumulative exposure and more opportunities for BBV 
transmission to occur and for risky injection episodes. The reason for this variable 
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not being supported by the current study may be due to the relatively heavy injectors 
that comprise this sample. To be eligible for participation in the current study, TDU 
were required to have injected on a minimum of a monthly basis for the previous six 
months, and therefore reflect a population of regular IDUs, who often inject on a 
more frequent basis than once per month. This restricted recruiting means that this 
study identifies risk only in relation to a defined sample who inject on a very regular 
basis. The result that needlestick exposure is significantly predicted by frequency of 
injecting is a logical result, given that it reflects a population who are quite enmeshed 
in injecting behaviour, and are therefore in more contact with needles and are around 
people who are injecting. Therefore, there are increased opportunities for accidental 
needlestick injuries. This result suggests that intervention strategies should focus on 
practical methods to reduce needlestick pricks, such as cleaning up injecting areas 
regularly, and in particular prior to injecting substances. 
It was hypothesised that stability of accommodation would not be predictive 
of BBV risk behaviours (Hagan et al., 2001; Thomas et al., 1995; Villano et al., 
1997), however this hypothesis was not supported. Unstable housing was found to be 
predictive of the overall risk of BBV behaviours and therefore indicates that those 
who are in unstable housing were at an elevated risk for contracting BBV. Unstable 
housing was also found to be predictive of elevated contamination opportunities 
though needle and syringe sharing as well as exposure opportunities through being 
injected by another person. Logically, this result makes sense in that one would 
assume that stable housing would allow a safer injecting environment, while unstable 
housing may require the [DU to inject in an environment which necessitates hurried 
injecting and which is less sterile (e.g. street based injecting, or injecting in another 
person's private house which may result in less control of the injecting environment). 
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For instance, Southgate et al. (2003) report that when an [DU is injecting in street 
environments, a pressure exists to inject quickly so as not to be seen by the police, 
members of the public, and other users therefore potentially leading to more injecting 
risks being taken. 
The hypothesis that 1DU with a prison history will increase one's risk of 
engaging in BBV risk behaviours (Crofts et al., 1993; Maher et al., 2004; Van Beek 
et al., 1998) was not supported. This variable was not a statistically significant 
predictor of any aspect of BBV transmission risk. It should be noted that this study 
assesses 1DU who are not currently in prison and assesses their current engagement 
in risk behaviours. Therefore, due to these IDU being in the community rather than 
in prison where there is limited access to sterile injecting equipment, this sample 
theoretically has access to sterile injecting equipment and may be less likely to 
engage in risky injecting. 
Level of education and treatment status were hypothesised to not be 
significant predictors of BBV risk, and indeed this was the case for the current study. 
Neither of these variables were found to be predictive of any of the five factors, nor 
the overall BBV-TRAQ-SV scale, thereby supporting previous findings that whether 
one is in treatment or not, or whether one has a greater number of years of formal 
education does not impact on the likelihood of taking risks when injecting. 
Pharmacological Effects of Drug Use Variables 
Previous literature has identified that a number of drug classes have been 
implicated in increasing one's risk for engaging in BBV risk behaviours, and as such 
it was hypothesised that benzodiazepine, amphetamine (including prescription 
stimulants), cannabis, MDMA, alcohol and opiate use would be positively associated 
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with BBV risk behaviours while cocaine and LSD would not produce significant 
relationships with BBV risk behaviours. Indeed, benzodiazepine use by intravenous 
means was positively associated with risk behaviours through sharing of needles and 
syringes, and benzodiazepine use generally was associated with the engagement in 
risk behaviours with other injecting equipment (e.g. sharing spoons, swabs etc). 
While this was so, benzodiazepine use was not associated with any of the other BBV 
risk factors, nor related to overall risk. Therefore, benzodiazepine use has a clear 
association with the engagement in some elements of risky injection practices 
however this association is not strong enough to be a predictor for overall risk. This 
finding provides additional support to previous research which finds that IDU who 
use benzodiazepines tend to be at a greater risk for sharing injecting equipment (e.g. 
Darke et al., 1992; Darke et al., 1993; Metzger et al., 1991), and is likely a reflection 
of the production of disinhibition and impulsivity by the drug (Yikel et al., 2007), 
which in turn affects decision making processes. 
Conversely, amphetamine use was found to be a relatively strong predictor of 
risk of engaging in BBV transmission behaviours. This variable was found to be 
predictive of overall risk, such that more frequent use of amphetamines resulted in a 
higher likelihood in BBV risk and therefore supported the hypothesis. While this is 
so, amphetamine use was not associated with elevated risk on specific aspects of 
injecting including needle and syringe contamination, other equipment 
contamination, contamination from injecting others and being injected by others. In 
addition to frequency of amphetamine use predicting overall risk, more frequent use 
of prescription stimulants was also found to be predictive of BBV risk behaviours, 
however only in relation to needle and syringe sharing behaviours. 
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The hypothesis that cannabis use would be predictive of BBV risk behaviours 
was not supported, with the results of the current study indicating that higher 
frequency of cannabis use did not contribute to increased risk of BBV contamination 
by any method. This findings runs contrary to previous research (e.g. Lane, Cherek et 
al., 2005) which indicates a relationship between cannabis and risk-taking, however 
it is noted that in the research by Lane and colleagues (Lane, Cherek et al., 2005) this 
was based on acute administration of cannabis and was not related to a specific 1DU 
population. A failure to identify a relationship between cannabis use and BBV risk 
behaviours may also be reflected by the fact that the study population has a generally 
high level of cannabis use. It was identified that 54.3% of participants reported a 
daily use of cannabis, and this restricted range in cannabis frequency of use may 
have compromised the ability to detect a relationship between cannabis use and BBV 
risk behaviours if indeed one exists. 
Consistent with the hypotheses, the frequency of cocaine use and LSD use 
was found not to be predictive of any form of engagement in BBV transmission risk 
behaviours therefore suggesting that LSD and cocaine do not affect cognitive 
processes in the same way or to such an extent as other drug classes in relation to 
decision making and risk taking. This may be partially sample-dependent as there 
was a relatively low frequency of use of either of these drugs in the current sample 
(10% and 17% respectively reported any recent use of cocaine or hallucinogens), 
consistent with the availability of these drugs in the study context (de Graaff & 
Bruno, 2007; de Graaff & Bruno, 2008). As such, this finding may not generalise to 
contexts where cocaine availability is high. 
MDMA use was hypothesised to be predictive of BBV risk behaviours, and 
this was partially supported by the finding that more regular use of MDMA was 
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associated with an increase in risk of being exposed to BBV through being injected 
by another person. This finding suggests that those 1DU who are less regular 
injectors, and therefore those who are more often injected by others, also tend to be 
users of MDMA. This is supported by a significant inverse relationship between 
frequency of ecstasy use and duration of injecting in this sample (r=-0.21, p<0.001). 
While MDMA use was found to be related to risk of BBV transmission through 
being injected by others, the results also indicate that MDMA use was not associated 
with elevated risk of needle/syringe contamination, other equipment contamination, 
contamination through accidental needlestick injuries, or overall risk of engaging in 
BBV risk behaviours. Therefore, this result appears to generally run contrary to 
previous findings which note a relationship between MDMA use and risk-taking. 
However it is noted that previous studies report a relationship between MDMA and 
behaviours such as unprotected sexual intercourse (McElrath, 2005; Theall et al., 
2006) and is not specific to risks taken through the process of injecting drugs. 
Moreover, the current study sampled an uncommon population of MDMA 
consumers, those that also inject (White et al., 2006) and as such, these individuals 
may be distinct from those participating in laboratory studies of risk-taking and/or 
exposed to multiple other pertinent pharmacological effects of substances (from, for 
example, amphetamines) which may obscure the specific effects of MDMA. 
Alcohol was hypothesised to be predictive of BBV risk behaviours, and this 
hypothesis was indeed supported. The results indicate that alcohol was related to a 
general overall risk of engaging in BBV risk behaviours, and has therefore been 
identified as an important factor in determining those at increased risk for being more 
careless in the injecting process. This result may be due to acute effects, whereby 
injection episodes occur while under the influence of alcohol and coordination and 
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decision making processes are affected, or it also may be reflective of more 
generalised cognitive changes due to chronic use which affects decision making and 
in turn, engagement in risky behaviours. Given this finding, it is apparent that NSP 
workers should be aware that alcohol is a key predictor for BBV transmission risk 
and those who report frequent alcohol use will be IDU who may benefit from 
targeted interventions. In addition to alcohol being identified as a predictor for 
overall BBV risk, the results of the current study also indicate that the more 
frequently alcohol is consumed, the more likely one is to engage in behaviours that 
can lead to BBV contamination through injecting equipment such as spoons, waters, 
swabs, or tourniquets as well as through second-person situations such as when 
injecting others or being injected by others. Notably, there was no relationship 
between frequency of injection and frequency of alcohol use in this sample (r.0.01, 
p=0.87). Together, these findings indicates that experimental findings that alcohol is 
related to risky decision making (Lane et al., 2004) are likely to be able to be applied 
to the IDU population in relation to risk taking during injecting episodes. 
More frequent opiate use was hypothesised to be a significant predictor for 
one's risk of engaging in BBV transmission risk behaviours however this hypothesis 
was not supported. No significant relationships were found between this variable and 
the factors of BBV transmission risk, aside from a significant, but inverse, 
relationship between exposure as a result of being injected by others, such that less 
frequent opiate use is associated with a greater risk of more careless practices when 
being injected by another person. This unexpected inverse relationship may indicate 
that those who regularly inject opiates are people who commonly inject themselves, 
and therefore, by definition, they won't be injected by others. Correlational analysis 
supports this, with a relationship between increased frequency of opioid use and self- 
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injection apparent (r=0.16, p=0.008), as well as between increased frequency of 
opioid use and a longer duration of injecting (1..0.23, p<0.001). The overall result of 
opiate use on BBV risk behaviours is obviously contrary to the hypothesis and 
suggests that in this context, the pharmacological effects of opiates do not impact on 
elevated risky injection practices (or that the increased injection experience of these 
participants has over-ridden any specific pharmacological affect of the drug in 
injection risk behaviour). This finding is consistent with recent laboratory based 
research which found that prescription opioids did not affect performance on a 
variety of measures of impulsivity after acute administration (Zacny & De Wit, 
2009). 
Injection Variables 
It was hypothesised that having last injected in a public place would be 
associated with greater risks in the process of injection perhaps due to being more 
hurried to avoid detection by the public and police, as well as perhaps being due to 
difficulties in setting up a clean environment for injection preparation. This variable 
was not related to overall risk of BBV transmission behaviours. Similarly, having 
had the previous injection episode occur in a public location was not significantly 
related to contamination by needles and syringes as well as other injecting 
equipment, or contamination from injecting others. This variable approached 
statistical significance in being related to exposure when being injected by others, 
however was inversely associated with the variable of needlestick contamination, 
indicating that having the last injecting episode occur in public actually results in less 
likelihood of receiving an accidental needlestick from another person's used syringe. 
Therefore, the hypothesis that injecting in a public location results in greater BBV 
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transmission risk behaviours cannot be said to have been supported by the current 
study. It is noted however, that risk of contamination from being injected by another 
person was associated with unstable accommodation as well as approaching 
significance with last having injected in a public place (and that there was a 
significant association between last injecting in public and unstable accommodation, 
1=0.14, p=0.025). The relationship with these two variables suggests that being 
injected in public place and by another person may be a particularly risky scenario 
for opportunities for BBV transmission. 
The variable of self-injection was hypothesised to be related to BBV 
transmission behaviours, specifically that the less one self-injects (and therefore is 
assisted to inject or is injected by someone else) then the greater the risk of 
contracting a BBV due to greater opportunities for transmission to occur. Indeed, this 
hypothesis was supported, with the results indicating that the less one self-injects the 
greater the risk of overall BBV transmission behaviours, as well as risk of needle and 
syringe contamination, contamination through other injecting equipment, and 
exposure from being injected by others. Therefore, having another person involved in 
the injection process is clearly a risk for transmission of BBVs and suggests that 
intervention efforts should focus on those 1DU who don't always self inject. In 
addition, educating those IDU who inject others is an alternative method which is 
likely to prove effective also, by using this population to educate their peers on safer 
injecting practices. By contrast, it is noted that this variable did not predict 
contamination from needlestick. Also, this variable did not predict contamination 
from injecting others although this finding is logical given that if an IDU does not 
inject themselves, then they would be unlikely to inject others, and those who self-
inject are not all going to also inject others. 
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Psychological Distress Variables 
Based on the results of previous literature, it was hypothesised that increased 
levels of psychological distress would be related to the engagement in BBV risk 
behaviours during the injection process. The results revealed that both the anxiety 
and depression subscales of the K10 positively related to overall risk on the BBV-
TRAQ-SV, as well as to the needle/syringe and other injecting equipment 
contamination factors, as well as exposure from being injected by others, and 
needlestick contamination factors. Consistent with previous literature (Johnson et al., 
2002; Mandell et al., 1999; Reyes et al., 2007; Stein et al., 2003), these results 
support the notion that psychological distress predicts the likelihood that an IDU will 
engage in behaviours known to be associated with BBV transmission. This supports 
suggestions that psychological distress is a barrier between cognitive knowledge of 
injecting risks and behavioural change to reduce these risks (Kleinman et al., 1994; 
Stein et al., 2003). This supports the importance of treatment provision to reduce 
psychological distress among this population, as this will likely also have beneficial 
effects on reducing BBV transmission risk behaviour. 
Impulsivity Variables 
It was hypothesised that higher levels of reported impulsivity would be 
significantly associated with engagement in BBV risk behaviours. The results reveal 
that the 'novelty' of stimulation aspect of impulsivity (analogous to the 'reward 
sensitivity' factor) was associated with some aspects of engaging in BBV risk 
behaviours thereby partially supporting the hypothesis. Specifically, higher levels of 
'novelty' impulsivity were associated with a higher risk of BBV risk behaviours, 
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specifically in regard to exposure through the process of being injected. Therefore, it 
would appear that the novelty (i.e. seeking out events that are novel for the purpose 
of experiencing the stimulation of a new event) of the stimulus is a relavent aspect of 
impulsivity when predicting those who are more likely to engage in BBV risk 
injecting behaviours. There was no relationship apparent between AISS novelty and 
years of injection career (r=0.10, p=0.13), frequency of injection (r=0.11, p=0.12) or 
injection by others (r=0.11, p=0.10). This suggests that this relationship is not simply 
relevant to new initiates (who may be less skilled in injection and more likely to be 
injected by others). This finding is therefore only partially consistent with Dawe and 
Loxton's (2004) model of impulsiveness who argue that novelty, or reward 
sensitivity, plays a role in cue-induced cravings and motivation to use drugs while 
rash-spontaneous impulsivity influences actual drug-taking behaviour and the 
difficulty to discontinue use even when negative consequences of drug use is 
recognised. The above findings suggest that novelty not only plays a role for new 
initiates to use drugs (as is suggested by the theoretical model), but for all IDUs and 
therefore suggests a role of novelty for ongoing use. The reasons for novelty also 
being important for ongoing injecting drug use is not easily explained by the two-
factor model of impulsivity as presented by Dawe and Loxton (2004). 
Impulsivity as measured by the BAS revealed that the 'drive' factor of 
impulsivity in this context was inversely related to risk, such that the lower one's 
'drive' to persistently pursue desired goals, the higher the risk of engaging in needle 
and syringe contamination behaviours. The 'reward responsiveness' element of BAS 
which reflects positive responses to the occurrence or anticipation of rewards was 
positively related to needle and syringe contamination and contamination through 
injecting others, indicating that higher levels of reward responsiveness are associated 
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with a higher likelihood of engaging in behaviours likely to result in contamination 
through these methods. A significant negative relationship was also noted between 
the BAS concept of `fun seeking', such that those who have a greater desire for new 
rewards and who have a willingness to seek these rewards on the spur of the moment 
have a lower risk of engaging in unsafe injecting practices with needles and syringes 
(e.g. reusing needles), a finding that runs contrary to the hypothesis. No other 
contamination routes were found to be significantly related to the BAS element of 
'fun seeking'. Together, these demonstrate a complex association between facets of 
impulsiveness and risk behaviours. This is consistent with the increasing awareness 
of the complexity of impulsiveness as a construct (e.g. Dawe & Loxton, 2004; 
Evenden, 1999) and that simple, global, assessments of 'impulsiveness' may not 
prove fruitful for prediction of BBV transmission risk behaviours. As the magnitude 
of the relationships between facets of impulsiveness and BBV risk scores was 
statistically significant, but small magnitude (5% of shared variance or less), the 
more substantial associations with psychological distress, self injection and other 
demographic and drug use variables would be more practically relevant in prediction 
of BBV risk behaviours in a primary health setting. 
Summary of Most Important Predictors of BBV Risk Behaviours 
While some variables were noted to be positive predictors of some aspects of 
BBV risk behaviours, the variables most predictive of overall risk for engaging in 
behaviours known to be associated with BBV transmission were unstable 
accommodation, amphetamine use, alcohol use, fewer occasions of self-injection, 
higher symptoms of anxiety (K10), and individuals with a desire to seek out novel 
stimulation (AISS Novelty). Of these variables, the most important predictors are 
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increased anxiety symptoms and reduced episodes of self-injection (others involved 
in the injection process). Odds ratios suggest that those who do not always self inject 
are approximately four times more likely to engage in BBV risk behaviours, and 
those that have high levels of anxiety are approximately 1.2 times more likely (20% 
more likely) to engage in BBV risk behaviours than other regular injecting drug 
consumers in this sample. Those IDU that have these characteristics are therefore 
those who are at the greatest risk for engaging in behaviours known to increase risk 
of contamination while injecting, and therefore are those who are at the greatest risk 
of contracting BBVs and experiencing the health and psychosocial sequelae of this. 
Implications of Research 
The identification of these factors being the most important for predicting the 
engagement in BBV risk behaviours is practically useful as there is now a clear 
indication as to which IDU are at an increased risk of contracting a BBV, and 
thereby also as to where prevention efforts will be best directed for maximum impact 
to reduce BBV transmission amongst this population. As previously mentioned, 
current interventions are distributed to all accessible 1DU regardless of their 
propensity to participate in risky episodes of injecting which carry more 
opportunities for the transmission of BBV. 
The results presented here demonstrate that health and outreach workers who 
are involved with the IDU population should target individuals with the 
characteristics of unstable accommodation, amphetamine use, alcohol use, less 
occasions of self-injection, higher symptoms of anxiety, and an elevated desire to 
seek out novel stimulation, as these have been demonstrated to be more strongly 
associated with aspects of BBV risk transmission behaviours. Once these IDU are 
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identified as belonging to a risk group for risky injection practices, more intensive 
interventions are able to be directed to those who are most likely to benefit from such 
intervention. 
In addition to the risk factors listed above, the results reviewed in the 
preceding paragraphs also indicate that one method for effectively delivering these 
interventions may be to target the peers of 1DU. The finding that new initiates (those 
who are younger and have less injecting experience) are at an increased risk for 
engaging in BBV risk behaviours, including being injected by others, brings with it a 
logistical challenge for reaching these populations who may not be as enmeshed in 
the culture of injecting drug use, and thus less accessible to intervention efforts (i.e. 
will not be visiting NSP centres frequently or at all). Therefore, focussing on 
providing education messages about safe injecting to those 1DU more available and 
experienced in injecting, and who are the individuals who assisting in, or injecting 
the new initiates, means that these education messages will be also provided to the 
population at most risk of practising unsafe injecting. 
In addition to providing at risk 1DU with education regarding methods of 
BBV transmission and possible health outcomes, health workers need also to 
regularly deliver messages of practical behaviours to reduce risk. This may involve 
encouraging self-injection where possible to reduce the risk of second person 
contamination, using clean and sterile needles and syringes, in addition to clean 
peripheral injecting equipment (e.g. spoons, swabs, waters, tourniquets), not touching 
other's injection sites, among other similar safety methods, including less commonly 
considered practical suggestions such as cleaning up injecting areas regularly and 
before injecting to reduce the risk of accidental needlestick. If such targeted 
prevention and education methods were effective, this would assist in reducing 
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overall incidence rates of BBV transmission amongst this population and associated 
health, economic, and social costs related to BBVs. 
Indeed, research investigating the effects of using peers for harm reduction in 
IDU populations has indicated that this is an effective strategy. For instance, 
Broadhead et al. (1998) compared the efficacy of harm reduction strategies delivered 
in a traditional provider-client model (delivered by professional outreach workers) 
and peer-driven intervention. Peers were given guidance and structured incentives 
(small monetary rewards) to deliver the intervention. Results revealed that the peer-
driven intervention outperformed the traditional intervention in terms of the number 
of IDUs recruited, the ethnic and geographic representativeness of the recruits, and 
the effectiveness of the BBV prevention education. The authors note that in addition 
to these benefits, the strategy was a more cost-effective method of intervention. 
Similarly, Latkin and colleages (Latkin, 1998; Latkin, Mandell, Vlahov, 
Oziemkowska, & Celentano, 1996) found that training peer leaders was effective in 
promoting safe injecting messages amongst IDU social networks, finding that when 
compared with controls, those involved in networks reported less needle sharing and 
sharing of cookers. The efficacy of using peer methods in addition to simple 
education methods is supported by research indicating that education alone is not a 
significant factor in reducing HIV risk behaviours, and that peer-directed 
interventions are required for successful outcomes (Madray & Van Hu1st, 2000). 
Other research by Norman et al. (2008) also supports the use of peer-driven models 
in facilitating HCV treatment, and research by Gaston, Best, Manning, & Day (2009) 
indicates that these methods can also assist in facilitating the appropriate response to 
overdose in others. Taken together, these results suggest that using peers as educators 
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and role models is an effective strategy to effect change in IDUs, and would present 
as a feasible method to access new initiates to safer injecting drug use. 
While the current study has demonstrated clear variables which affect risk-
taking in injecting, it is worth noting that the variance explained by the multivariate 
models is moderate, and there remains much variance not accounted for by the 
variables analysed in the current study. This therefore suggest that while particular 
emphasis should be paid to those IDU fitting criteria known to be associated with a 
greater likelihood of engaging in BBV risk behaviours while injecting, intervention 
efforts should continue to be provided to all accessible LDU as it is apparent that 
there are further risk factors that are unknown at this time as well as situational 
complexities which are not able to be modelled statistically. 
Methodological Considerations 
It should be noted that while the current research is invaluable in identifying 
those LDU at greatest risk for engaging in risky injection episodes there are some 
methodological aspects which do require consideration. The first of these is that this 
study has been conducted with an LDU population which is specific to Tasmania and 
therefore these results may not be extrapolated to other populations around Australia 
or internationally. For instance, in relation to Australian IDU populations, it is known 
that the Tasmanian IDU differs from the other states in regards to patterns of drug 
use. Tasmania typically has lower heroin and cocaine use than other states, and 
higher use of morphine, and currently has the highest use of benzodiazepines in 
Australia (Stafford et al., 2009). The current study also only examines IDU 
populations in larger cities in Tasmania, and the results cannot be necessarily 
extrapolated to those in rural areas. 
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The second point which bears consideration in relation to the current study is 
that the data obtained by the Tasmanian IDU population is of a self-report nature, 
and is therefore subject to difficulties in verification that the data obtained is an 
accurate report of drug use and risks pertaining to this. Self-report data can be 
affected by one's ability to accurately recall information (Del Boca & Noll, 2000), 
which in this population may be additionally affected by cortical damage due to drug 
use itself (Del Boca & Noll, 2000). Furthermore, self-report data may be affected by 
respondent characteristics, such as personality characteristics, social desirability and 
need for approval, cognitive impairment/function, attitudes and beliefs, 
psychological state (e.g. anxiety, depression), physical condition (e.g. fatigue, 
intoxication, withdrawal), and motivation to participate (Del Boca & Noll, 2000). 
While the difficulties associated with using self-report data should be noted, 
it should also be considered that studies of this nature are bound to use this method 
of data collection only, as alternative methods (e.g. experimental designs which 
under laboratory conditions administer placebos or drug substances to participants, or 
observe injecting episodes) have obvious ethical constraints due to the illicit nature 
of these drugs and therefore are impractical to use. While these factors should be 
noted, research by Darke (1998) has examined the reliability and validity of self-
reported drug use and HIV risk-taking among injecting drug users and used external 
validation procedures (biomarkers and collateral interviews) to determine reliability 
and validity of this data type amongst this population. Darke concludes that while 
inconsistencies do occur, self-report data amongst this population is sufficiently valid 
for research purposes and for gaining a relatively accurate understanding of drug use 
and risk-behaviours. To further maximise the validity of the data provided in the 
current study, all interviewers were trained to interview with this population and are 
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instructed on how best to verify information to maximise the possibility that 
responses are accurate. 
Conclusions 
The results of the current study have provided valuable information to assist 
in the reduction of the spread of BBV such as HCV, HBV, and HIV in Australia and 
potentially overseas. The research has utilised strong methodological processes with 
a large sample of Tasmanian 1DU to reveal those 1DU who are most likely to engage 
in behaviours such as the sharing of needles/syringes and injection equipment and 
other risky injecting behaviours that have an elevated risk of facilitating the 
transmission of BBVs. Those IDU at greatest risk have now been identified as those 
who have less occasions of self-injecting, greater symptoms of anxiety, are in 
unstable accommodation, have more frequent levels of amphetamine and alcohol 
use, or a propensity to seek out new situations for novel stimulation. The most 
important of these variables has been revealed to be reduced anxiety and less 
occasions of self-injecting. The incidence rates of BBVs in Australia and worldwide, 
particularly HCV incidence rates are astounding and are known to be primarily 
transmitted by injecting practices amongst the IDU population. Having this 
additional knowledge as to those IDU who are at increased risk for contributing to 
these high incidence rates will enable prevention efforts to be targeted to these 
individuals, hopefully assisting in reducing the overall spread of these viruses 
amongst the EDU population. 
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Appendix A: BBV -TRAQ-SV 
Section A — Needle & Syringe Contamination 
la 	In the last month, how many times have you injected with another person's 
used needle/syringe? 
	
No times 	Once 	Twice 	3-5 times 	6-10 times 	More than 10 
4, times 
(Go to 
question 2) 
lb 
	
On those occasions, how often did you rinse it with a combination of full- 
strength bleach and water (i.e, the 2x2x2' method) before you used it? 
Never 	 Rarely 	Sometimes 	Often 	Every time 
2 	In the last month, how many times have you injected with a needle/syringe after 
another person has already injected some of its contents? 
No times 	Once 	Twice 	3-5 times 	6-10 times 	More than 10 
rim. 
2a* How many different people have used a needle before you in the last month? 
None 	One person 	Two People 	3-5 People 	6-10 People More than 10 
44 people 
(Go to 
question 3) 
2b* 	Who were these people? (can pick more than one) 
Regular sex 	Casual sex 	Close friends 	Acquaintance Other (specify): 
partner 	partner 
3 	In the last month, how many times have you received an accidental 
needle-stick/prick from another person's used needle/syringe? 
No times 	Once 	Twice 	3-5 times 	6-10 times 	More than 10 
timac 
4a In the last month, how many times have you re-used a needle/syringe taken out 
of a shared disposal/sharps container? 
No times 
	
Once 
	
Twice 	3-5 times 	6-10 times 	More than 10 
40 
	 times 
(Go to 
question 5) 
4b 	On those occasions, how often did you rinse it only with full-strength 
bleach before you re-used it? 
Never 
	
Rarely 	Sometimes 
	
Often 
	
Every time 
Section B — Other Injecting Equipment Sharing 
5 	In the last month, how many times have you injected a drug that was 
filtered through another person's filter? 
No times 	Once 	Twice 	3-5 times 	6-10 times 	More than 10 
times 
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6a In the last month, how many times have you injected a drug that was 
prepared in another person's used spoon or mixing container? 
	
No times 	Once 	Twice 	3-5 times 	6-10 times 	More than 10 
4, times 
(Go to 
question 7) 
6b 	On those occasions, how often did you clean the spoon or mixing 
container before using it? 
Never 	 Rarely 	Sometimes 	Often 	Every time 
7 	In the last month, how many times have you injected a drug prepared 
with water which had been used by another person? 
No times 	Once 	Twice 	3-5 times 	6-10 times 	More than 10 
times 
8 	In the last month, how many times have you injected a drug which had 
come into contact with another person's used needle/syringe? 
No times 	Once 	Twice 	3-5 times 	6-10 times 	More than 10 
times 
9 	In the last month, how many times have you wiped your own injection 
site with an object (e.g, swab, tissue, hanky, towel etc) which had been 
used by another person? 
No times 	Once 	Twice 	3-5 times 	6-10 times 	More than 10 
times 
9i* 	In the last month, how many times have you used another person's 
tourniquet? 
No times 	Once 
	
Twice 	3-5 times 	6-10 times 	More than 10 
times 
Section C — Second Person Contamination 
Ca In the last month, how many times has someone used a needle after you 
have used it? 
No times 	Once 	Twice 	3-5 times 	6-10 times 	More than 10 
times 
In the last month, how many times have you injected a drug that you 
prepared immediately after 'assisting' another person with their injection 
(e.g, injecting them, holding their arm, handling used needle/syringe; 
touching their injection site to feel for a vein, to wipe blood away, or to 
stop bleeding)? 
10 
a 
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No times 	Once 
	
Twice 	3-5 times 	6-10 times 	More than 10 
40 times 
(Go to 
question 11) 
10 	On those occasions, how often did you wash your hands before 
preparing your mix? 
Never 	 Rarely 	Sometimes 	Often 	Every time 
11 
a In the last month, how many times have you injected a drug that was prepared by another person who had already injected or assisted 
someone else's injection? 
	
No times 	Once 
	
Twice 	3-5 times 	6-10 times 	More than 10 
44 times 
(Go to 
question 12) 
11 	On those occasions, how often did the person preparing the mix 
wash their hands before preparing the mix? 
Never 	 Rarely 	Sometimes 	Often 	Every time 
12 In the last month, how many times have you been injected by another 
a 	person who had already injected or assisted in someone else's injection? 
No times 	Once 	Twice 	3-5 times 	6-10 times 	More than 10 
times (Go to 
question 13) 
12 	On those occasions, how often did the person injecting you wash 
their hands before injecting you? 
Never 
	
Rarely 	Sometimes 	Often 	Every time 
13 In the last month, how many times have you injected with a 
a 	needle/syringe which had been handled or touched by another person 
who had already injected? 
No times 	Once 	Twice 	3-5 times 	6-10 times 	More than 10 
(Go to times 
question 14) 
13 	On those occasions, how often did they wash their hands prior to 
handling the needle/syringe that you used? 
Never 	 Rarely 	Sometimes 	Often 	Every time 
14 In the last month, how many times have you touched your own injection 
a 	site (e.g, to feel for a vein, to wipe away blood, or to stop bleeding) soon 
after 'assisting' another person with their injection (e.g, injecting them, 
holding their arm, handling their use needle/syringe; touching their 
injection site to feel for a vein, to wipe away blood, or to stop bleeding)? 
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No times 	Once 	Twice 	3-5 times 	6-10 times 	More than 10 
times 
14 	On those occasions, how often did you wash your hands before 
touching your own injection site? 
Never 	 Rarely 	Sometimes 	Often 	Every time 
15 In the last month, how many times has another person touched your 
a 	injection site (e.g, to feel for a vein, to wipe away blood, or to stop 
bleeding)? 
No times 	Once 	Twice 	3-5 times 	6-10 times 	More than 10 
40 times 
(completed 
survey) 
15 	On those occasions, how often did the person wash their hands 
before they touched your injection site? 
Never 	 Rarely 	Sometimes 	Often 	Every time 
